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Anxiety disorders form a group of psychiatric disorders which are 
characterised by excessive psychological and physical anxiety responses 
to different subjectively threatening situations. In nature, the emotions 
of fear and anxiety are not pathological in many situations. Fear is what 
we experience when confronted with an acute threatening situation, like 
encountering a dangerous predator. Anxiety refers to a fear-like response 
in anticipation of a non-acute impending threatening situation. For example, 
anxiety can develop if we wander in an isolated, dangerous place in which 
predators or natural dangers might be looming around the corner. If we are 
presented with acute threats a fear response is an adaptive way of dealing 
with it as it prepares us for quick, decisive action. 
Psychological anxiety responses include worrying, restlessness, 
concentration difficulties, irritability and sleep disturbances. Physical 
anxiety responses include increased respiration rate, muscle tension, 
fatigue, increased cardiac activity with palpitations, blushing, sweating, 
tingling sensations, headaches, abdominal or thoracic pain, dizziness, 
trembling, shaking, nausea and shortness of breath. In anxiety disorders, fear 
or anxiety responses are excessive, persisting and exist in association with 
non-threatening cues and are thus considered pathological.1 Classification 
of different distinct anxiety disorders is based on the prevailing symptoms 
and on the provoking cues or situations. The most widely used classification 
manual is the Diagnostic and Statistical Manual, fifth edition (DSM-5).1 The 
DSM-5 recognizes seven main distinct anxiety disorders: (1) Separation 
Anxiety Disorder, (2) Selective Mutism, (3) Specific Phobia, (4) Generalized 
Anxiety Disorder (GAD), (5) Panic Disorder (PD), (6) Social Anxiety Disorder 
(SAD, formerly known as social phobia), and (7) Agoraphobia. The current 
thesis will focus on the latter four anxiety disorders as these are the most 
prevalent and disabling anxiety disorders and as these four were included in 
the large dataset that will be used in this thesis for data analysis.
GAD is characterised by chronic anxiety and being overly concerned over 
everyday matters, in which catastrophic outcomes are dreaded. PD is 
characterised by recurring panic attacks and subsequent development of 
anticipatory anxiety for suffering more panic attacks. SAD is characterised 
by fear and anxiety in social interactions over public embarrassment, 
humiliation, and excessive concerns over being socially incompetent. All 
excessive anxiety responses are often followed by further non-adaptive 
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behavioural changes. A lot of patients will start to avoid situations or places 
in which their anxiety responses were previously triggered. Someone with PD 
might start to avoid places in which panic attacks were triggered. Someone 
with SAD might start avoiding social gatherings or situations in which they 
feel vulnerable to being judged. Persons with agoraphobia avoid public 
places or situations from which there are no escape options (e.g. public 
transportation, cinemas, theatres etc.) because they fear fainting, death or 
loss of control. Agoraphobia used to be a specifier for PD, but is considered 
a separate anxiety disorder since the introduction of the Diagnostic and 
Statistical Manual, fifth edition (DSM-5). See table 1 for the classification 
criteria for GAD, PD, SAD and Agoraphobia according to the DSM-5.1
Table 1. Criteria for classification of four anxiety disorders according to the Diagnostic 
and Statistical Manual, fifth edition.
GAD SAD Agoraphobia PD
Key features Excessive anxiety and 
worry occurring more 
days than not about a 
number of events or 
activities.
The individual finds it 
difficult to control the 
worry.
Presence of three (or 
more) accompanying 
symptoms 
1.  Restlessness or 
feeling keyed up or 
on edge.
2.  Being easily fatigued.




5.  Muscle tension.
6.  Sleep disturbance 
Marked fear or anxiety 
about one or more social 
situations in which the 
individual is exposed 
to possible scrutiny by 
others.
Examples include social 
interactions (e.g., having 
a conversation, meeting 
unfamiliar people), being 
observed (e.g., eating or 
drinking), and performing 
in front of others (e.g., 
giving a speech).
A marked fear or anxiety 
about two (or more) of the 
following five situations:
1.  Using public 
transportation
2.  Being in open spaces
3.  Being in enclosed spaces 
4.  Standing in line or being 
in a crowd
5.  Being outside the home 
alone.
Recurrent unexpected panic 
attacks.
A panic attack is an abrupt 
surge of intense fear or 
intense discomfort that 
reaches a peak within 
minutes, and during which 
time four (or more) of the 
following symptoms occur:
1.  Palpitations, pounding 
heart, or accelerated heart 
rate.
2.  Sweating.
3.  Trembling or shaking.
4.  Sensations of shortness of 
breath or smothering.
5.  Feelings of choking.
6.  Chest pain or discomfort.
7.  Nausea or abdominal 
distress.
8.  Feeling dizzy, unsteady, 
light-headed, or faint.
9.  Chills or heat sensations.
10.  Paresthesias 
11.  Derealization or 
depersonalization.
12.  Fear of losing control or 
“going crazy.”
13.  Fear of dying.
Table continues
12
GAD SAD Agoraphobia PD
Secondary 
features
The individual fears or 
avoids these situations 
because of thoughts that 
escape might be difficult or 
help might not be available 
in the event of developing 
panic-like symptoms or 
other incapacitating or 
embarrassing symptoms.
At least one of the attacks has 
been followed by one or both 
of the following:
Persistent concern or worry 
about additional panic attacks 
or their consequences.
A significant maladaptive 
change in behaviour related to 
the attacks
Specifier Performance only: if 
the fear is restricted to 
speaking or performing 
in public.
Duration The fear, anxiety, or avoidance is persistent, typically lasting 6 months or more. Panic attacks and subsequent 
worry or avoidance 
behaviours were present for 
at least 1 month or more
Out-of-
proportion
The fear or anxiety is out of proportion to the actual 
threat posed by the social or agoraphobic situations and 
to the sociocultural context.
Consistency The social or agoraphobic situations almost always 
provoke fear or anxiety.
Avoidance The social or agoraphobic situations are avoided or 
endured with intense fear or anxiety, or require the 
presence of a companion. 
Distress/ 
impairment
The condition cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning.
Exclusion 
criteria
The disturbance is not attributable to the physiologic effects of a substance (e.g., a drug of abuse, a medication) 
or another medical condition (e.g., hyperthyroidism). If another medical condition is present, the fear, anxiety, or 
avoidance is clearly unrelated or is excessive.
The fear, anxiety, or avoidance disturbance is not better explained by another mental disorder 
Adapted from: the Diagnostic and Statistical Manual, 5 edition. 
Epidemiology
Excessive anxiety responses were already depicted in early historical texts on 
mental health. The earliest descriptions of excessive anxiety responses date 
back to Greek and Roman times.2 In his 1638 book “The Anatomy of Melancholy” 
Robert Burton – under the pseudonym Democritus Junior – poetically described 
individuals who seemingly suffer from an anxiety disorder:
Many lamentable effects this fear causeth in men, as to be red, pale, 
tremble, sweat, it makes sudden cold and heat to come over all the 
body, palpitation of the heart, syncope (…). Many men are so amazed 
and astonished with fear, they know not where they are, what they 
Table 1. Continued
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say, what they do, and that which is worst, it tortures them many 
days before with continual affrights and suspicion. It hinders most 
honourable attempts, and makes their hearts ache, sad and heavy. 3
Nowadays, anxiety disorders are the most prevalent psychiatric disorders. 
12-Month prevalence estimates for anxiety disorders (including specific 
phobia) in the general population range from 8.4-21.3%, whereas lifetime 
prevalence estimates range between 14.5-33.7%.4–7 The age of onset tends 
to be during the formative years of adolescence and young adulthood: the 
median age of onset for SAD is 13 years, for agoraphobia is 20 years, for 
PD is 24 years and for GAD is 31 years.8 Anxiety disorders are roughly twice 
as prevalent in females compared to males.9 Anxiety disorders are more 
likely to develop in persons with high levels of psychological vulnerability: 
prevalence of anxiety disorders was increased around twofold in persons 
with premorbid high levels of neuroticism or anxiety sensitivity.10,11 
Patients with anxiety disorders suffer from substantial disability as a 
result of anxiety responses and accompanying avoidance behaviours. 
Globally, anxiety disorders are the seventh leading cause of years lived 
with disability; i.e. years of life lived in less than ideal health.12 This makes 
the impact of anxiety disorders on global disability higher when compared 
with diabetes, migraine, asthma and ischemic heart disease. Critically, 
only a minority of patients with anxiety disorders seek professional help. In 
a large European general population study, only 20.6% of patients with an 
anxiety disorder reported ever receiving treatment.13 Furthermore, patients 
with anxiety disorders are prone to high levels of comorbidity. Comorbidity 
with other psychiatric disorders is present in 85% of patients with GAD, 
80% of patients with PD, 74% of patients with SAD and in 97% of patients 
with agoraphobia in the general population.14 Comorbidity of two or more 
anxiety disorders is common. Correlations between PD with agoraphobia 
and SAD with agoraphobia are especially high, with tetrachoric correlations 
of 0.64 and 0.68 respectively, indicating that these disorders very often co-
occur.14 Among other psychiatric disorders, depressive disorders are the 
most frequent comorbid disorders. The correlations with anxiety disorders 
range between 0.43 and 0.62 for major depressive disorder, between 0.44-
0.55 for dysthymia, between 0.43-0.49 for posttraumatic stress disorder 
(PTSD), between 0.38-0.51 for attention deficiency hyperactivity disorder 
(ADHD) and between 0.27-0.44 for any substance use disorder (SUD).14 
These correlations indicate that comorbidity with these disorders often 
occurs. The relative risk of having any chronic somatic disease such as 
hypertension, arthritis, asthma, ulcers, diabetes or cardiovascular diseases 
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is increased around two-fold for patients with anxiety disorders.15 This is 
especially problematic as levels of disability are even further increased 
when a person with a chronic somatic disease also has a comorbid anxiety 
disorder.16 Furthermore, economic costs associated with anxiety disorders 
are high. From scarcely available studies, it appears that in Europe yearly 
total additional costs associated with anxiety disorders range from €1,450 - 
€1,630 per patient.17 A substantial portion of disability and economic costs 
associated with anxiety disorders is due to reduced work performance. The 
yearly work loss associated with anxiety disorders is estimated to be 17.6 
days.18 On the whole, anxiety disorders are highly prevalent disorders that 
are clearly associated with poor health outcomes, increased disability and 
high societal impact. 
Pathophysiology
Genes
The aetiology of anxiety disorders is multicausal. First, there is strong 
evidence from twin studies that genetic factors underlie the development 
of anxiety disorders. The heritability estimates for GAD range between 
32-49%, for SAD range between 39-56%, for PD equals 48%, and for 
Agoraphobia equals 67%.19,20 This indicates that between one and two 
thirds of contributing factors in the aetiology of anxiety disorders are 
genetically defined. High levels of heritability exist in disorders in which 
genetic causes are associated with the development of this disorder at the 
population level. Many researchers devoted time and resources to unravel 
this genetic vulnerability by aiming to identify specific genes that contribute 
to the development of anxiety disorders. However, the candidate genes that 
were derived from this type of genetic research were only inconsistently 
associated with anxiety disorders and could not account for the high levels 
of heritability found in twin studies. This disparity between high heritability 
levels and low number of genes with a causal relationship to a disorder is 
termed the "missing heritability problem”. Newer genetic research focuses 
on genome wide association studies (GWAS), as these methods have less 
risks of yielding inconsistent results. As of now, large GWAS studies into 
anxiety disorders showed only a small number of genetic aberrations, in 
the form of single nucleotide polymorphisms (SNPs).21 These SNPs explain 
a mere 10% of the variance of the genetic vulnerability. In other words: 
90% of underlying genetic susceptibility genes are still unknown. However, 
current GWAS efforts are still relatively underpowered when taking the low 
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hazard ratio of potential SNPs into account. Hopefully, future meta-analyses 
of GWAS findings will succeed in identifying additional susceptibility genes 
that are relevant to anxiety disorder pathophysiology and will thereby close 
the gap of missing heritability. Furthermore, future GWAS studies might 
expand beyond the classic case-control design into a dimensional approach 
to take heterogeneity of the anxiety disorder sample into account. This 
heterogeneity is underscored by the significant overlap in GWAS findings 
between anxiety disorders and the psychological trait neuroticism.11 This 
highlights the possibility that a transdiagnostic approach into vulnerability 
factors for anxiety disorders instead of diagnostic entities such as anxiety 
disorder diagnoses could yield more meaningful genetic associations. The 
genetic contribution is in any case most likely polygenetic: not any single 
genetic factor determines all risk for development of anxiety disorders, but 
rather an interplay between many different genetic factors determines the 
risk. 
Additionally, there are strong indicators that gene-environment (GxE) 
interactions are relevant in development of anxiety disorders.22 In GxE 
interactions a genetic vulnerability for development of a disease will only 
lead to development of this disease when the individual encounters certain 
environmental stressors. In GxE interaction research, environmental 
stressors studied include stressful life events and childhood trauma. When 
these environmental stressors are encountered, a genetic vulnerability 
might lead to a higher tendency for anxiety responses. Furthermore, 
epigenetic processes likely contribute to the development of anxiety 
disorders. The term epigenetics is used to describe potentially heritable and 
functionally relevant modifications in gene expression without changes to 
the genetic code that are embedded within the DNA. These changes in gene 
expression can occur as a result of DNA-methylation. It is argued that certain 
environmental factors, such as childhood trauma or stressful life-events 
might evoke epigenetic changes.23 However, as there are few candidate 
genes found that are relevant in the development of anxiety disorders, the 
relevance of GxE interaction and epigenetics is still largely unknown.23 
Brain
The brain anatomy of patients with anxiety disorders shows differences in 
comparison with controls. For instance, patients with GAD have a larger grey 
matter volume in the amygdala.20,24,25 Structural differences in amygdala, 
hippocampus, parahippocampal gyri, and brainstem nuclei are present in 
PD.20,26 Brain anatomy findings in SAD were inconsistent.27 The functions 
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of the associated brain regions are all related to emotional responses or 
processes. Besides structural brain anatomy differences, functional neuronal 
differences are present in anxiety disorders. These functional differences 
represent aberrant activation patterns in brain regions as a response to 
external stimuli. Usually, in laboratory settings, anxiety provoking tasks are 
used when studying functional neuronal differences. When confronted with 
anxiety provoking stimuli, anxiety disorder patients show greater amygdala 
activation and disruptions in amygdala-based intrinsic functional networks. 
This specific aberrant pattern of activation was named the ‘fear circuit’ due 
to its relevance to fear and anxiety responses.24 Some other brain regions, 
such as the anterior cingulate cortex, the fusiform gyrus, the inferior frontal 
gyrus, the superior temporal gyrus, the globus pallidus and the insula also 
show different activation patterns in anxiety disorder patients.24,25 Finally, 
some neuronal differences in anxiety disorder patients were shown when 
using novel neuroimaging techniques, such as PET, SPECT and metabolic 
MRI.25 These findings are still too inconsistent and should be considered 
preliminary. 
Understanding neuroimaging differences in anxiety disorders are important 
as they could potentially provide a rationale for certain types of treatments. 
For instance, if a certain drug type would be able to mitigate the aberrant 
activation in the fear circuit in anxiety disorders that drug could prove 
effective in treatment of anxiety disorders. Also, neuroimaging findings 
might be indicative of certain subtypes or differences in clinical course. 
However, currently these neuroimaging findings cannot yet be translated 
into daily clinical practice.28
Neurochemistry
The cornerstone of anxiety disorders is the heightened emotional response 
after a subjectively threatening stimulus. Both the autonomic nervous 
system (ANS) and the hypothalamic-pituitary-adrenal axis (HPA-axis) are 
activated in this response.29 The response of the ANS consists of increased 
sympathetic activation and decreased parasympathetic activation. Both 
result in changes in various bodily functions: control of respiration, cardiac 
regulation (the cardiac control centre), vasomotor activity (the vasomotor 
centre), and certain reflex actions such as coughing, sneezing, swallowing 
and vomiting. Many of these autonomic effects are indeed present when 
patients experience anxiety responses. Furthermore, it seems that aberrant 
breathing patterns and reduced heart rate variability are present in PD 
patients even if they are not currently experiencing panic symptoms.26,30 
17
Chapter 1 - G
eneral introduction
These findings likely reflect ongoing changes in ANS activity in PD patients. 
These ongoing autonomic disruptions lead to lingering somatic anxiety 
phenomena and can reduce the threshold for triggering a full-blown panic 
attack. In this study the effects were adjusted for use of psychotropic 
medication that are known to influence the heart rate variability. However, 
there still is debate as of whether these changes are present as the largest 
single study into autonomic dysregulation in anxiety disorders did not show 
differences in resting state autonomic function between anxiety disorders 
and controls.31 
It is a longstanding theory that the HPA-axis is involved in anxiety disorders, 
as the main physiologic functions of the HPA-axis revolve around stress 
responses.26 Indeed, patients with anxiety disorders show overactivation 
of the HPA-axis.32,33 Higher HPA axis activation leads to increased levels of 
cortisol, the stress hormone, which triggers several somatic responses 
that can be anxiety provoking. This heightened stress response might lead 
to non-threatening situations being perceived as critically threatening by 
patients with anxiety disorders. Probably, heightened HPA-axis activity 
is the pathway between childhood trauma and development of anxiety 
disorders, as childhood trauma is a strong risk factor for both adult presence 
of psychiatric disorders and for increased HPA-axis activity at adulthood.34 
However, some studies show reduced levels of cortisol in presence of anxiety 
symptoms.35 Therefore, the direction of causality is unsure and the results 
from this field of research are still inconclusive.
Biochemistry
Different neurotransmitters are associated with anxiety disorders. Plasma 
levels of 5-hydroxytryptamine (serotonin, 5-HT) and gamma aminobutyric 
acid (GABA) activity were linked to GAD.25 These signalling hormones play a 
vital role in communication within and between different brain regions. Many 
anti-anxiety drugs target these neurotransmitter pathways. Besides altered 
plasma levels, PET studies are suggestive of changes in 5-HT and GABA 
neuronal circuitry involved in anxiety processing in anxiety disorders.25 Other 
research into biological markers for anxiety disorders shows inconsistent 
findings. For instance, some studies showed that anxiety disorders are linked 
to higher CRP-levels,36–38 while others found no association.39 Likewise, 
anxiety symptoms were also linked to both higher33 and lower cortisol,35 
as well as higher 35,37,40 and lower interleukin-6 (IL-6) measurements.36 
Furthermore, inconsistent findings were reported for associations with 
metabolic syndrome markers,41–45 tumour necrosis factor-α (TNF-α) 
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levels,37,40 and BDNF levels.46,47 In spite of decades of rigorous scientific work 
there are currently no clinical tests based on biological differences available 
for psychiatric disorders.28
Clinical course
Once anxiety disorders have developed, clinical course is heterogenous: 
while some patients fully recover, others develop chronic symptoms. A 
naturalistic 12-year study in a clinical sample showed that recovery rates 
during the 12-year period varied across diagnoses: 82% of PD patients 
recovered, while recovery occurred in only 58% of GAD patients, in 48% of 
PD patients who had agoraphobia, and 37% of SAD patients.48 
When left untreated, anxiety disorders might remit, but more likely symptoms 
will remain persistent. A study assessing one-year follow-up on anxiety 
disorder severity showed that symptomatology hardly changed in untreated 
samples.49 Unfortunately, many patients with anxiety disorders do not seek 
professional care. Around 80-90% of patients with anxiety disorders do not 
access professional care or delay accessing it.13,50 A delay of 15 years for 
seeking professional care is not at all out of the ordinary. Even in presence 
of evidence-based treatments, many patients do not fully remit. A 12-year 
naturalistic follow-up study in a clinical sample showed that probabilities of 
experiencing eight consecutive weeks of having no or mild anxiety symptoms 
were modest.48 Although it is clear that a substantial number of anxiety 
disorder patients do not benefit from different treatments, no clear definition 
for treatment resistance in anxiety disorders exists. 
Several individual risk factors for chronicity or suboptimal treatment results 
in anxiety disorders are known: higher baseline severity of anxiety symptoms, 
presence of comorbidity, higher levels of disability, longer previous 
duration of anxiety symptoms, younger age of onset, longer duration of 
untreated anxiety symptoms, and presence of childhood trauma.48,51–55 Also, 
sociodemographic and lifestyle factors such as lower education years, higher 
age, having no partner, having low levels of social support, smoking and 
nicotine dependency, having financial problems, and being unemployed or 
having a low income were associated with poor outcomes in anxiety disorder 
patients.48,49,55–58 Additionally, psychological traits such as high neuroticism, 
high anxiety sensitivity, high levels of worrying, low extraversion, and low 
levels of mastery are related to poor outcomes in anxiety disorders.51,55,59 
Although some individual risk factors are identified, due to the complex 
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interplay between these factors much is still unknown about how clinical 
course in anxiety disorders is defined. As a result, these risk factors cannot 
yet be implemented in clinical care or in clinical decision making.
Treatment 
Psychotherapy like cognitive behavioural therapy (CBT) is shown to be 
effective in treating anxiety disorders, with large effect sizes: Hedges g 
was 0.80 for CBT versus control conditions in GAD, 0.81 for CBT versus 
control conditions in PD, and 0.88 for CBT versus control conditions in 
SAD.62 In this meta-analysis of 31 studies, control conditions consisted of 
waiting lists (n=24), care as usual (n=4) and pill placebos (n=3). Generally, 
treatment results were largest when comparisons were made against 
waiting lists and were smaller, but still significant, when comparisons 
were made against care as usual or pill placebo. This comes as no surprise 
because a waiting list control condition only controls for natural course, 
pill placebo for natural course and nonspecific treatment effects and 
care as usual for natural course as well as nonspecific and specific effects 
treatment effects. Furthermore, pharmacotherapy is effective in treatments 
of anxiety disorders. Different classes of medication are used in anxiety 
disorders, e.g. selective serotonin reuptake inhibitor (SSRIs), serotonin-
noradrenaline reuptake inhibitors (SNRIs), benzodiazepines (BZDs), 
tricyclic antidepressants (TCAs), tetracyclic antidepressant, monoamine 
oxidase inhibitors (MAOIs), anticonvulsants and antipsychotics. Due to 
the likely involvement of serotonergic pathways in anxiety disorders, a 
preference for serotonergic agents exists. These include SSRI’s, as well as 
SNRIs, the TCAs clomipramine and imipramine and the MAOI phenelzine. All 
of these medication classes show a significant effect in anxiety disorders, 
with Cohen’s d pre- and posttreatment ranging from 1.83 for TCAs to 2.25 for 
SNRIs.63 These effect sizes indicate a very large beneficial effect of initiating 
a pharmacologic treatment regimen. In comparison with pill placebo, the 
effects of pharmacotherapy in anxiety disorders remain substantial, with 
effect sizes around 0.60 for SSRIs and 0.50 for SNRIs.64 Careful consideration 
is needed in treatment selection as pharmacotherapeutics have side-effects. 
SSRIs are considered first-line treatments in all anxiety disorders as these 
are usually tolerated best. 
Prognosis
The cornerstones of clinical practice in medicine consist of diagnosis, 
prognosis and treatment. The relevance of prognosis for clinicians was first 
recognized by Hippocrates, who believed that a valid prognosis should follow 
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from the physician’s assessment of an individual patient, using knowledge on 
pathophysiology and on factors that define the clinical course.65,66 However, 
the prognoses provided by physicians are not empirically validated. For 
instance, experienced radiology oncologists who specialized in lung 
cancer performed poorly when predicting two-year deaths, dysphagia and 
dyspnoea in lung cancer patients.67 Emergency Department physicians were 
reasonably able to predict new occurrences of asthma exacerbations in 
asthmatic patients.68 Psychiatrists were reasonably able to predict recurring 
suicidal behaviour in the next 6-months in patients they assessed for suicidal 
behaviour.69 They were, however, unable to predict 6-month incidence of 
suicide in the same patients. These examples illustrate the lack of accuracy 
in clinician opinion prognoses in medicine. Instead of clinician opinion 
prognoses, prediction models can be used to provide individual prognoses. 
In prediction models, the prognosis is based on statistical associations 
between individual patients and disease characteristics with outcomes.70 
There is ample evidence that statistical prediction methods can improve 
poor predictive properties of clinician opinion prognoses.66,69,71
Precision psychiatry
In spite of the historical awareness of the importance of prognosis, the 
science around prognosis in medicine is still lacking.72 Prognosis in psychiatry 
is traditionally based on classifications, for instance as described in the DSM-
5, and as provided in Table 1 with regard to anxiety disorders (see above). 
In these classification systems, psychiatric syndromes are delineated on the 
basis of clusters of symptoms that often co-occur. They do not classify on the 
basis of pathophysiologic characteristics. They are not meant to demarcate 
an underlying ‘disease’ but rather describe symptoms in a standardized 
way. Although the use of classification systems like the DSM-5 and its 
predecessors was vital for the development of the field of psychiatry, their 
classifications proved insufficient to base prognoses on. For instance, DSM-
IV anxiety disorder classifications yield less precise course predictions in 
comparison to clinical characteristics such as severity of symptoms, duration 
of symptoms and level of disability.57 Improving course prediction would be 
an important step towards personalized medicine, which aims to individually 
tailor diagnosis and prognosis based on individual disease factors to derive 
a personalized treatment plan. Operationalizations of personalized medicine 
in psychiatry are often touted as “precision psychiatry”. Providing reliable 
prognoses is a vital aim for precision psychiatry. Prediction models seem 
promising for improving evidence-based prognosis and thereby further 
evolve the field of precision psychiatry. Prediction models aim to combine 
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different types of data to predict a future outcome.70 Different statistical 
methods can underlie such models, for instance machine learning algorithms 
show a lot of promise in deriving prediction models in psychiatry.73 
As is clear from this introduction, due to the high levels of chronicity and 
disability in anxiety disorders, adequate identification of anxiety disorder 
patients with higher risk profiles is much needed in clinical care. In spite 
of substantial knowledge on pathophysiology of anxiety disorders and 
risk factors for clinical course in anxiety disorders, it currently remains 
impossible to adequately predict the disease course in individual patients. 
In other words, it is time for the development of evidence-based prognosis 
in psychiatry. 
Aims of this thesis
This thesis aims to contribute to the development of evidence-based 
prognosis in two ways. The first aim is to increase knowledge on factors 
that impact the clinical course in anxiety disorders. The second aim is to use 
existing knowledge on pathophysiology and risk factors for anxiety disorders 
to predict clinical course in anxiety disorders over time. 
Sample and study design
For a number of chapters in this thesis (chapters 3, 5, 6 and 7), participants 
were recruited from the Netherlands Study of Depression and Anxiety 
(NESDA), a multi-centre naturalistic longitudinal cohort study among 
adult respondents (aged 18-65) from different regions in the Netherlands. 
Respondents were recruited from the community, primary care and 
specialized mental health care settings and the sampling was stratified to 
be representative of the various developmental stages of depression and 
anxiety. At baseline, 2,981 subjects were included. The main aim of NESDA 
is to gain insight into the long-term course and consequences of anxiety 
and depressive disorders. Baseline assessments were conducted at the 
three participating sites between 2004 and 2007. Follow-up measurements 
were performed at one-year, two-year, four-year, six-year, and nine-years 
after baseline. NESDA represents ongoing research as currently thirteen-
year follow-up measurements are being performed (2019-2022). Baseline 
measurements included sociodemographics, clinical characteristics, 
psychological assessments, biological assessments and structured 
psychiatric interviews assessing DSM-IV diagnoses. Comorbid psychiatric 
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disorders were permitted with the exception of psychotic disorders, bipolar 
disorders, PTSD, obsessive-compulsive disorder, or severe SUDs, as 
reported by participants or their mental health care practitioner. Participants 
were excluded if they showed insufficient proficiency in the Dutch language. 
The Ethical Committee of participating universities approved of the study 
protocol and all participants provided their written informed consent. 
Contents of this thesis
The first part of this thesis explores the first main aim to increase knowledge 
on factors that impact the clinical course in anxiety disorders. Chapter 2 
focusses on diagnosis and early detection of anxiety disorders in a general 
hospital sample. In this chapter, a screening programme for anxiety disorders 
was tested in the cardiac emergency department. We hypothesized that 
physical and psychological anxiety responses are present in a large number 
of non-cardiac chest pain patients and that these anxiety responses are 
indicative of underlying anxiety disorders, thereby providing an opportunity 
for early recognition and referral for psychiatric treatment. Chapter 3 is 
a cross-sectional study into the effects of chronic somatic diseases on 
disability and work-loss in anxiety disorders and depressive disorders. In 
this chapter, the hypothesis that presence of comorbidity between anxiety 
disorders and chronic somatic diseases negatively impacts outcomes in 
anxiety disorders is tested. Chapter 4 describes a narrative systematic 
review into different aspects of treatment resistance in anxiety disorders. In 
this way, factors that are deemed relevant in the development of chronicity 
in anxiety disorders are gathered. In this chapter, a proposal for a consensus 
definition for treatment resistance in anxiety disorders was formulated. 
The second part of this thesis focuses on the second aim to predict clinical 
course in anxiety disorders over time. In this part of the thesis, a number of 
prediction models are developed in order to assess the predictive properties 
of combinations of different pathophysiologic factors and risk factors. 
These prediction models are presented in accordance to a methodological 
hierarchy: the first prediction model assessed is one that is based on clinician 
opinion; the second prediction model assessed is based on the results from 
a systematic review, and the third prediction model is a data-driven machine 
learning approach. Chapter 5 presents a clinical staging model that consists 
of different stages that can be ordered as ordinal categories. In this chapter, 
a clinical staging model from a well-known Australian research group was 
adapted for use in anxiety disorders and the predictive properties were tested 
in a large sample consisting of at-risk controls and anxiety disorder patients 
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over a six-year timespan. Chapter 6 presents a dimensional measurement 
instrument that can be ordered as interval categories. In this chapter, the 
results from our systematic review into definitions for treatment resistance 
in anxiety disorders (chapter 4) were incorporated into a measurement 
tool that assesses the degree of treatment resistance in anxiety disorders. 
The predictive properties for this measurement instrument were assessed 
in anxiety disorder patients who received treatments over a two-year 
period. Chapter 7 presents a dichotomous prediction model. This is a data-
driven approach in which machine learning methods were used to derive a 
prediction model for two-year outcomes in anxiety disorder based on various 
baseline measurements. The model is based on random forests classifiers 
using a wide array of baseline predictors. The predictive properties of these 
predictions were assessed over a two-year follow-up period. 
Overall, this thesis aims to contribute to the development of evidence-based 
prognosis. More accurate course predictions in anxiety disorders could have 
significant implications for clinical care. It could lead to personalized risk 
assessments. Hopefully, improved course predictions can be used in clinical 
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Abstract
Objective: This study assesses the feasibility and outcome of the 
implementation of a screening program for classifying Panic Disorder (PD) 
in patients presenting with non-cardiac chest pain (NCCP), when integrated 
in routine Cardiac Emergency Department (CED) care. 
Methods: Barrier analyses were made during the pilot phase and 
implementation period. NCCP-patients aged 18-70 years presenting at 
the CED (n=252) were eligible for screening with the Hospital Anxiety 
and Depression Scale (HADS). Those scoring above cut-off on the HADS 
were referred to the Psychiatric Department and received the Composite 
International Diagnostic Interview.
Results: Screening was initiated in 60 patients (23.8%), of whom nine 
refused participation. Staff- adherence remained low despite implementing 
several improvements in the screening procedure. In total, 39 patients 
completed the program, 8 were diagnosed with a psychiatric disorder, 
including two patients with PD.
Conclusion: Feasibility of implementation of this screening program for PD in 
NCCP-patients in routine CED care was limited, because offering screening 
frequently conflicted with providing acute care, and because  patients 
showed  relatively high refusal rates. Contrasting our assumption, various 
other psychiatric disorders besides PD were classified.
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Introduction
In 50-63% of patients with acute chest pain presenting at the Cardiac 
Emergency Department (CED), no cardiac cause is found for the complaints 
and  ‘non-cardiac chest pain’ (NCCP) is diagnosed.1,2 Panic Disorder (PD) is 
highly prevalent (12-41%) among NCCP-patients.3,4 Symptoms of a panic 
attack may occur sudden and may mimic those of a heart attack.5 In many 
PD patients presenting with NCCP, the diagnosis of PD is overlooked 1,6 
and is left untreated.7–9 When PD is recognized in NCCP-patients effective 
treatment regimes exist.7,9 This study examines the implementation process, 
patient and staff-adherence, and outcome of a screening program aimed at 
integrating psychiatric screening in routine CED care of NCCP by identifying 
persons with PD. This is the first study to evaluate psychiatric screening for 
PD in routine CED care.
Material and methods
Study design
A cohort was formed of patients aged 18-70 years who presented with NCCP 
at the CED of VU-University Medical Center; Amsterdam, the Netherlands, 
between November 2012 and August 2013. Exclusion criteria included 
inadequate understanding of the Dutch language, an earlier CED visit within 
the study period, ongoing psychiatric treatment, and a likely or definitive 
somatic cause reported by the cardiologist. Eligible patients were asked 
to fill out a screening instrument consisting of the Hospital Anxiety and 
Depression Scale (HADS). 
Measurement instruments
The HADS is a 14-item self-report questionnaire which is valid and reliable in 
populations with NCCP.10 In accordance with earlier studies we used a cutoff 
score of 8 on either anxiety or depressive subscale, which yields a sensitivity 
of 98% for the presence of anxiety disorders.1,10 Those scoring above cut-
off were contacted by the Psychiatric Department to conduct the Composite 
International Diagnostic Interview (CIDI). The CIDI is a structured interview 
with good reliability and validity 11 and was administered by telephone within 
two weeks after CED discharge. 
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Implementation process
The study started with a pilot phase in which we performed barrier analyses 
in order to optimize the implementation methods.12 The implementation 
process was adapted accordingly in three different ways. First, two CED 
nurses and a cardiology resident were made responsible for daily program 
evaluations. Second, administrative procedures were simplified. Finally, 
an experienced liaison psychiatrist (ADB) offered 1-hour  training sessions 
to the CED-staff in effectively engaging patients with regard to psychiatric 
symptoms. 
During the implementation phase CED-staff provided daily data on staff and 
patient-adherence. Staff-adherence was defined as proportion of eligible 
patients in whom screening was offered. Patient-adherence was defined as 
proportion of patients who filled out the screening tool if it was being offered. 
Monthly staff-adherence rates were fed back to the CED-staff in meetings 
by the researchers (NMB and AMB). New barriers to implementation and 
implementation goals were also identified and discussed in these meetings.
Analysis
Comparisons in gender, age and number of CED visits within the study period 
were made with Chi Squared statistics and one-way analysis of variance 
statistics (ANOVA). We compared patients with whom screening was 
initiated with those with whom it was not initiated as well as patients who 
refused screening with those who agreed to participate. 
Ethical considerations
This study was performed in accordance with the principles of the Helsinki 




Staff adherence to the screening program was low, as only 60 out of 252 
eligible patients (23.8%) were offered screening. A lack of time due to the 
primary task of providing acute cardiac care was reported most (88.0%) by 
the CED-staff.
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Initial patient-adherence was higher, as 51 out of 60 patients (85.0%) agreed 
in screening. Most patients who refused participation saw no benefit in 
psychiatric screening in relation to their perceived life-threatening symptoms 
(n=6). However, in the second phase of screening, patient-adherence was 
low: twelve out of 24 patients (50%) refused administration of the CIDI, six 
of whom insisted on seeking psychiatric care with their General Practitioner 
(GP). See figure 1 for the flow-chart of inclusion into study.
During the course of this program we found no significant improvement 
in levels of adherence (data not shown). We were not able to resolve the 
barriers resulting in low adherence by offering assistance to administering 
the HADS nor by training staff  to adequately address psychiatric problems. 
Outcome
There were no differences in age, gender and number of CED visits between 
those who were offered screening and those who were not or between those 
who refused screening and those who participated. In 24 out of 51 patients 
HADS scores were above cut-off. Based on known prevalence numbers for 
PD of 12-41% in NCCP-patients 3,4 our cohort was estimated to include 38-
130 PD patients. Ultimately, our screening program identified only 2 PD 
patients. Additionally, we classified Generalized Anxiety Disorder (n=1), 
Post-Traumatic Stress Disorder (n=1), Major Depressive Disorder (n=4), any 
Somatoform Disorder (n=4), and Alcohol Dependence (n=1). 
Discussion and conclusion
The presence of heterogenic psychiatric disorders in patients with NCCP 
calls for a more personalized approach, instead of a screening program 
aimed at identifying those with PD. Screening refusal rates may be improved 
by approaching patients a couple of days after CED presentation, as done 
by Kuijpers et al.,10 or by involvement from patients’ GP, as some patients 
reported preferred consulting their GP. A limitation of this study was the 
sparse data-collection on reasons for low staff-adherence. 
In a sample of CED patients with NCCP (n=252) we deemed screening for 
PD of limited feasibility when implemented in routine CED care. The main 






Somatic cause likely or definitive, n= 28
Receives psychiatric treatment, n= 15
Language problem, n= 22
No screening initiated, n= 192
other tasks more prioritized, n= 169
incorrectly assumed somatic cause, n= 22
psychiatric screening deemed inappropriate, n= 1
Refuses, n= 9
sees no value in psychiatric screening, n= 6
wants to address problems with somatic doctors, n= 2
agreed in screening but left CED 
before completing, n= 1
Refuses, n= 12
arranges psychiatric referral 
themselves, n= 6
no time/ doesn’t want to, n= 3
no reason, n= 2



















Figure 1. Flowchart of the screening program
* screening program completers
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Future programs aimed at psychiatric screening in NCCP-patients should 
be performed after the acute phase, could benefit from GP involvement and 
should target a broad range of psychiatric disorders.
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Anxiety and/or Depressive Disorders (ADDs) and Chronic Somatic Diseases 
(CSDs) are associated with substantial levels of health-related disability 
and work impairment. However, it is unclear whether comorbid ADDs and 
CSDs additively affect functional outcomes. This paper examines the impact 
of ADDs, CSDs, and their comorbidity on disability, work absenteeism and 
presenteeism.
Methods 
Baseline data from the Netherlands Study of Depression and Anxiety 
(n=2,371) were used. We assessed presence of current ADDs (using 
psychiatric interviews, CIDI) and presence of self-reported CSDs. Outcome 
measures were disability scores (WHO-DAS II questionnaire, overall and 
domain-specific), work absenteeism (≤2 weeks and >2 weeks; TiC-P) 
and presenteeism (reduced and impaired work performance; TiC-P). We 
conducted multivariate regression analyses adjusted for socio-demographics.
Results 
Both ADDs and CSDs significantly and independently impact total disability, 
but the impact was substantially larger for ADDs (main effect unstandardized 
β=20.1, p<.001) than for CSDs (main effect unstandardized β=3.88, p<.001). 
There was a positive interaction between ADDs and CSDs on disability 
(unstandardized β interaction=4.06, p=.004). Although CSDs also induce 
absenteeism (OR for extended absenteeism=1.42, p=.015) and presenteeism 
(OR for impaired work performance=1.42, p=.013), associations with ADDs 
were stronger (OR for extended absenteeism=6.64, p<.001; OR for impaired 
work performance=7.51, p<.001). 
Conclusion 
Both CSDs and ADDs cause substantial disability, work absenteeism and 
presenteeism, but the impact of ADDs far exceeds that of CSDs. CSDs and 
ADDs interact synergistically on disability, thereby bolstering the current 
view that patients with physical mental comorbidity (PM-comorbidity) form 
a severe subgroup with an unfavourable prognosis. 
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Introduction
Disability and work impairment are important indicators of poor health, 
from both a societal and a clinical perspective.1,2 Those with Anxiety and/
or Depressive Disorders (ADDs; either Anxiety Disorders or Depressive 
Disorders) or Chronic Somatic Diseases (CSDs) are known to suffer from 
many years lived with disability (YLD).3–5 Globally, YLD are highest in 
low back pain, with other CSDs such as iron deficiency anaemia, other 
musculoskeletal disorders, lung disease, migraine, and diabetes among the 
top ten most disabling diseases. Among the ADDs, Depressive Disorders 
ranked second and Anxiety Disorders ranked sixth.5 Those with CSDs and 
ADDs also suffer from substantial levels of work impairment.1,3,6 However, 
CSDs and ADDs were found to frequently co-occur: a phenomenon referred 
to as physical mental comorbidity (PM-comorbidity).3,6–8 Among those with 
ADDs, higher incidences of lung disease, diabetes, obesity, cardiovascular 
diseases, hypertension, stroke, Alzheimer’s disease, peptic ulcers, 
symptoms of Irritable Bowel Syndrome, and osteoarthritis have been 
found.7,9 Likewise, higher incidences of ADDs were found among those with 
lung diseases, hypertension, allergies, peptic ulcers, autoimmune disease, 
thyroid disease, chronic back problems, osteoarthritis, and migraine.6,8,10,11 
Therefore, it is evident that a wide variety of CSDs form PM-comorbidity 
with ADDs. The current literature on PM-comorbidity suggests that it forms 
a relevant subgroup characterized by a worse prognosis with regard to 
several clinical outcome measures, including functional outcomes 4,6,11 and 
less favourable CSD-related treatment response.12–14 Despite the known 
separate impact of CSDs and ADDs on disability and work impairment, the 
high prevalence of PM-comorbidity, and its associations with unfavourable 
health-related outcomes, little is known of the effect of PM-comorbidity on 
disability and work impairment. 
A number of studies on disability found that comorbidity with ADDs increased 
disability associated with CSDs.3,15 Both Armenian (1998) and Stein (2006) 
assessed interaction effects between CSDs and ADDs on disability, but 
whereas Armenian found an interaction effect, Stein did not.15,16 However, 
these studies included a limited number of CSDs, and separate interaction 
effects for specific CSDs or specific disability domains were not reported. 
With regard to work impairment, a number of studies found increased work 
impairment in those with PM-comorbidity, compared to those with either 
ADDs or CSDs alone.6,11,17,18 Kessler et al. 6 and Buist-Bouwman et al. 11 found 
interaction effects between ADDs and CSDs on work impairment. However, 
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the latter studies only included a limited number of CSDs and assessed 
absenteeism (absence from work due to health issues) but not presenteeism 
(presence at work while hindered by health issues), while presenteeism is 
regarded a highly prevalent and costly form of work impairment.19,20 These 
inconclusive findings warrant further research to clarify the nature of 
associations of CSDs, ADDs, and PM-comorbidity with regard to disability, 
work absenteeism and presenteeism.
Aims of the study
We aim to expand on the current literature by studying severity of disability, 
work absenteeism and presenteeism associated with Anxiety and/or 
Depressive Disorders (ADDs), Chronic Somatic Diseases (CSDs) and their 
comorbidity in a wide range of CSDs. This paper examines the relative 
separate effects of CSDs and ADDs on total disability, disability domains, 
work absenteeism and presenteeism. In addition to the separate effects, 
we will assess whether synergistic effects (i.e. positive interaction effects) 
between CSDs and ADDs exist. We expect ADDs and CSDs to have substantial 
separate main effects on disability and work impairment, and expect a 
positive interaction effect in those with PM-comorbidity.
Method
Design and sample
Respondents were derived from the Netherlands Study of Depression and 
Anxiety (NESDA), an ongoing cohort study consisting of 2,981 respondents 
(aged 18-65) at baseline. Since the aim of NESDA is to gain insight into the 
long-term course and consequences of Anxiety and Depressive Disorders, 
those with Anxiety Disorders or Depressive Disorders were oversampled. 
NESDA recruitment took place in three settings: community, primary care, 
and specialized mental health care, in order to represent all developmental 
stages of ADDs. Exclusion criteria included a primary diagnosis of other 
psychiatric disorders, such as bipolar, obsessive compulsive, substance 
use or psychotic disorders and insufficient command of the Dutch language. 
Baseline assessments were conducted between 2004 and 2007 and included 
a structured diagnostic psychiatric interview. A full description of the NESDA 
study design is available elsewhere.21 The Ethical Committee of participating 
universities approved of the study protocol and all respondents provided 
written informed consent. The current study uses the baseline data and 
included persons with presence of current (i.e. six-month) ADDs (n=1,737), 
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and controls without current and lifetime presence of ADDs (n=634). We 
excluded 610 respondents due to presence of lifetime, but not current, 
diagnoses of ADDs.
Anxiety and/or Depressive Disorders (ADDs)
ADDs were defined as presence of either a Depressive Disorder (Depressive 
or Dysthymic Disorder) or an Anxiety Disorder (Generalized Anxiety Disorder, 
Social Phobia, Panic Disorder with or without Agoraphobia). We assessed 
Depressive and Anxiety Disorders combined since both groups of disorders 
are associated with increased disability 3–5 and comorbidity levels between 
these disorders are known to be high in other studies 22 but also in our own 
study.23 Presence of ADDs was assessed using the Composite International 
Diagnostic Interview (CIDI, version 2.1), which classifies diagnoses 
according to DSM-IV criteria.24,25 The CIDI has good overall reliability and 
validity and is frequently used worldwide.26 The structured CIDI interviews 
were conducted by highly trained staff.
Chronic Somatic Diseases (CSDs)
A 21-item face-to-face interview was used to assess presence of CSDs.21 
This instrument was used previously in large-scale population-based 
cohort studies.6,11,27 Respondents were asked for presence of 30 CSDs and 
were able to report any additional CSDs they may have. Individual CSDs 
were deemed present when respondents reported monitoring or receiving 
prescription medication by a General Practitioner or a medical specialist 
for that CSD. Following earlier research,28 we clustered separate CSDs into 
seven disease categories: respiratory, cardio-metabolic, musculoskeletal, 
gastrointestinal, neurological, endocrine and cancer. We used presence of 
any CSD and presence of each CSD category as outcome measures.
Disability
Disability during the previous 30 days was assessed using the WHO-Disability 
Assessment Schedule (WHO-DAS II), a 36-item self-report questionnaire.29 
It measures disability in six domains: cognition (six items, Cronbach’s α=.92 
in our sample), mobility (five items, α=.91), self-care (four items, α=.84), 
interpersonal interactions (five items, α=.88), household activities (five 
items, α=.95), and participation in society (eight items, α =.92) on a 5-point 
Likert scale with item scores ranging from 0 (no difficulties) to 4 (extreme 
difficulties/cannot do). We excluded four items concerning work-related 
disability, as a substantial proportion of our sample (n=905) was neither 
currently employed for at least eight hours a week nor attending education. 
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Domain scores were calculated by adding all domain item scores and a total 
disability score was calculated by adding all 32 item scores. There were 
49 respondents with missing data on WHO-DAS data; we replaced missing 
scores with mean scale values of total scale scores. Domain and total scores 
were standardized to derive scores ranging from 0 to 100, with higher scores 
indicating higher levels of disability. 
Work impairment
Work impairment was analysed within a subsample of employed participants, 
which we defined as having a paid job for at least eight hours a week 
divided over more than one day a week (n=1,466), thereby excluding 905 
respondents who were not employed, or who were employed for less than 
eight hours a week. We excluded another four respondents due to missing 
values on work impairment data, which yielded a sample of n=1,462. We 
used the Trimbos/iMTA questionnaire for Costs Associated with Psychiatric 
Illness (TiC-P) to assess two aspects of work impairment: absenteeism and 
presenteeism.30 Absenteeism was calculated by dividing the total number 
of hours that respondents were absent from work during the previous six 
months by the number of hours that respondents were supposed to work 
per week. Work absenteeism is measured in weeks and ranges from 0 to 26 
weeks. Presenteeism is defined as the number of workweeks in which quality 
of work was reduced due to health issues, multiplied by a self-reported 
proportional score for severity of work quality reduction.31 Presenteeism 
scores ranged from 0 to 26. As absenteeism and presenteeism data did not 
meet normality assumptions, we categorized these into ‘no absenteeism’, 
‘short absenteeism’ (≤2 weeks), and ‘extended absenteeism’ (>2 weeks); 
and ‘no presenteeism’ (score=0), ‘reduced work performance’ (0< highest 
quartile) and ‘impaired work performance’ (>highest quartile), as done 
previously.19,31
Statistical analyses
To compare baseline characteristics of ADD patients to controls, two-tailed 
Pearson’s Chi Squared statistics were used for categorical variables and 
independent samples t-tests were used for continuous variables. 
To compare presence of CSDs in ADD patients versus controls, we performed 
logistic regression analyses, which yielded Odds Ratios (OR) for ADD 
patients for having any CSD and for having each of the seven CSD categories. 
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To test the impact of ADDs, CSDs, and their interaction on disability total and 
domain scores, we performed multivariate linear regression analyses using 
presence of ADDs (0=no, 1=yes), CSDs (0=no, 1=yes), and their interaction 
term (ADD*CSD) as independent variables, and the WHO-DAS II total and 
domain scores as dependent variables. In this model, interactions were 
tested on an additive scale, with a significant positive interaction effect 
implying that the effect of comorbid CSDs and ADDs on disability scores is 
greater than the sum of separate effects for CSDs and ADDs: synergy. In 
addition, impact on disability among different CSD categories was examined 
by repeating these analyses on total disability scores using seven CSD 
category variables instead of the overall CSDs variable. 
We tested the impact of ADDs, CSDs, and PM-comorbidity on work 
absenteeism and presenteeism by performing multinomial logistic 
regression analyses with categorized absenteeism and presenteeism as 
dependent variables. First, we determined main effects for ADDs and CSDs; 
second, we divided our sample into those with purely physical disorders 
(presence of any CSD but absence of ADDs), those with purely mental 
disorders (presence of ADD but absence of CSDs) and those with PM-
comorbidity (presence of CSD and ADD).
Finally, we performed several sensitivity analyses in order to check for 
possible bias. First, we considered the possibility that antidepressant side 
effects caused respondents to report presence of CSDs by conducting 
logistic regression analyses for presence of CSDs in those with ADDs, 
adjusted for antidepressant use. Second, we checked the possibility that ADD 
patients overreported presence of CSDs by performing logistic regression 
analyses for presence of CSDs with a more stringent criterion of CSDs based 
on medication use. Third, we repeated linear regression analyses on total 
disability to assess whether associations with disability are different for 
those with more severe CSDs or ADDs, compared to those with less severe 
CSDs or ADDs. A complete list of methods used have been added to the 
supplement. We used an α-value of .05 for all our analyses. All regression 
analyses were adjusted for covariates age (years), sex, and education 
(years). Statistical analyses were performed using SPSS Statistics, version 




Table I shows the baseline characteristics of the total sample (n=2,371) 
and the employed subsample (n=1,462). ADD patients were more likely to 
be female, less educated, and to have higher levels of disability and work 
impairment as compared to controls. Table II shows that CSDs were more 
often present in ADD patients (42.8%) than in controls (35.6%) (p=.002). 
Odds Ratio for presence of any CSD was 1.34 (95%-CI:1.09-1.64). Especially 
the odds for having gastrointestinal disease were significantly raised in ADD 
patients (Table II). Figure 1 shows the unadjusted mean standardized total 
disability scores stratified for presence of CSDs and ADDs. 
Impact of CSDs, ADDs, and PM-comorbidity on disability
Multivariate regression analysis on total disability showed that the main 
effect for CSDs (unstandardized β=3.88, p<.001) was surpassed by that of 
ADDs (unstandardized β=20.1, p<.001), see Table III (Model 1). Both ADDs 
and CSDs negatively influenced all disability domains. The main effect of 
ADDs was greatest in the domains of ‘participation in society’, ‘cognition’, 
‘interpersonal interactions’, and ‘household activities’, whereas the main 
effect of CSDs was greatest in the domains of ‘mobility’, ‘self-care’ and 
‘participation in society’. Nevertheless, on all domains, the regression 
coefficients of ADDs were 3-5 times larger than those of CSDs. The 
interaction term for CSD*ADD on total disability was positive and statistically 
significant (unstandardized β=4.06, p=.004, Table III, Model 2). This suggests 
that, on average, those with PM-comorbidity suffer from disability levels that 
exceed the sum of disability associated with CSDs and ADDs. This translates 
to an additional 4-5 points on the total WHO-DAS II score. The interaction 
term CSD*ADD was positive and statistically significant in three domains: 
‘mobility’, ‘household activities’ and ‘self-care’. The magnitude of impact of 
CSDs on disability was not driven by specific CSD categories. Main effects on 
total disability score for different CSD categories ranged from 0.70 to 4.65 
(data not shown). 
Impact of CSDs, ADDs, and PM-comorbidity on work impairment
Table IV (Model 1) shows that presence of ADDs was associated with 
worse absenteeism and presenteeism outcomes in an employed subsample 
(n=1,462): short absenteeism (OR 2.88, 95%CI: 2.16-3.84), extended 
absenteeism (OR 6.64, 95%CI: 4.69-9.40), reduced work performance 
(OR 1.83, 95%CI: 1.38-2.43), and impaired work performance (OR 7.51 
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Table I. Baseline characteristics for respondents with current (six month) Anxiety and/or 
Depressive Disordersb (ADDs) compared to controls without lifetime diagnosis of ADDsb 
(n=2,371 for total sample, n=1,462 for employed subsample).






(n=634) (n=1,737) t χ2 p
Socio-demographics
Gender, female 61.7% 67.0% 5.74 .017
Age, mean ±SD 41.1 ±14.7 41.3 ±12.4 -0.45 .681
Education (in years), mean ±SD 12.8 ±3.2 11.8 ±3.3 7.01 <.001
Somatic variables, mean ±SD
Number of chronic somatic disease categories 0.47 ±0.74 0.63 ±0.86 -4.06 <.001
Disability variables, mean ±SD a
WHO-DAS II, total score 7.8 ±9.3 29.0 ±16.4 -30.7 <.001
Domains:
Cognition 8.4 ±11.5 32.4 ±20.5 -27.8 <.001
Mobility 5.1 ±12.0 19.0 ±21.6 -15.3 <.001
Self-care 3.0 ±8.5 14.7 ±17.9 -15.9 <.001
Interpersonal interactions 9.5 ±13.7 35.3 ±23.0 -26.5 <.001
Household activities 12.6 ±18.3 39.5 ±27.0 -23.3 <.001
Participation in society 8.2 ±11.3 33.5 ±20.1 -30.0 <.001
(n=424) (n=1,038)
Work functioning variables
Absenteeism, last six monthsc 
No absenteeism 
Short absenteeism (≤2 weeks)








Presenteeism (score), last six monthsd
No presenteeism (0) 
Reduced work performance (0 < highest quartile)








a a higher score indicates higher severity of disability, standardized scores (range 0-100).
b Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized Anxiety 
Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic of Major Depressive Disorder).
c absenteeism is represented by number of weeks absent from work during the last six months. 
d presenteeism is represented by number of workweeks in which quality of work was reduced due to health issues, multiplied by a 
self-reported proportional score for severity of work quality reduction. 
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Table II. Odds of having presence of Chronic Somatic Diseases (CSDs) for Anxiety and/






Current Anxiety and/or Depressive 
Disordera
(n=1,737)
% % OR (95% CI) p
Any chronic somatic 
disease
All those listed below 35.6 42.8 1.34  (1.09-1.64) .002
Respiratory Asthma, chronic bronchitis, pulmonary 
emphysema, other lung diseases
6.8 10.0 1.39  (0.98-1.98) .067
Cardio-metabolic Hypertension, angina pectoris, history of 
cardiac disease, stroke, diabetes, vascular 
abnormalities
16.6 16.2 1.05  (0.79-1.39) .745
Musculoskeletal Osteoarthritis, rheumatoid arthritis, 
systemic lupus erythematodes, 
fibromyalgia, RSI, congenital skeletal 
deformation
8.2 10.8 1.33  (0.95-1.85) .101
Gastrointestinal Ulcer, irritable bowel syndrome, Crohn’s 
disease, colitis ulcerosa, diverticulitis, 
liver cirrhosis, hepatitis, constipation, 
oesophageal disease, gastric sphincter 
dysfunction, other gastrointestinal 
disease
3.9 12.2 3.29  (2.15-5.05) <.001
Neurological Migraine, epilepsy, multiple sclerosis, 
peripheral neuropathy, hernia
2.2 3.7 1.78  (0.98-3.22) .057
Endocrine Thyroid dysfunction 2.8 2.9 1.12  (0.64-1.96) .696
Cancer 
 
Throat, thyroid, lymphoid, lung, 
oesophagus, bowel, stomach, liver, 
uterus, cervix, ovary, bladder, testicle, 
prostate, skin, brain, blood
6.3 6.8 1.10  (0.75-1.61) .633
All ORs were adjusted for gender, age, and education.
a Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized Anxiety 
Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic of Major Depressive Disorder)
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95%CI: 5.11-11.1). Presence of CSDs was solely associated with extended 
absenteeism (OR 1.42, 95%CI: 1.07-1.88) and impaired work performance 
(OR 1.42, 95%CI: 1.08-1.87). Table IV (Model 2) shows that odds for 
each form of absenteeism and presenteeism are highest in those with 
PM-comorbidity, followed by those with ADDs (without CSDs) and those 
with CSDs (without ADDs). Effects of separate CSD categories on work 
impairment outcomes were less clear. Respiratory and musculoskeletal 
diseases were associated with increased odds for extended absenteeism 
(OR 1.65, 95%CI 1.01-2.69 for respiratory diseases and OR 2.65, 95%CI 1.60-
4.41 for musculoskeletal diseases), whereas cardio-metabolic diseases 
were associated with decreased odds for extended absenteeism (OR 0.64, 
95%CI 0.43-0.97). No associations between separate CSD categories and 









No CSD At least one CSD
No lifetime ADDs Current ADDs
 
Figure 1. Mean levels of disability (standardized WHO-DAS II total score) for those 
with any self-reported Chronic Somatic Diseases (CSDs), those with Anxiety and/or 
Depressive Disorders (ADDs) and those with PM-comorbidity.
Sensitivity analyses
Sensitivity analyses showed that antidepressant use was not accountable 
for differences in presence of CSDs in an antidepressant-adjusted model 
(see supplement). Furthermore, there was no evidence for a self-report bias 
of CSDs in ADD patients, as associations with CSDs in ADD patients were 
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comparable when applying more stringent CSD definitions. Additionally, the 
positive interaction effects with ADDs on total disability were comparable 
for those with only one CSD and those with multiple CSDs. Finally, although 
the total disability scores are highest in those with comorbid Anxiety and 
Depressive Disorders, the positive interaction effects with CSD status were 
comparable for those with pure Anxiety or Depression compared to those 
with comorbid Anxiety and Depressive Disorders. All sensitivity analyses can 
be found in the supplement. 
Table III. Adjusted unstandardized regression coefficients for the association between 
Chronic Somatic Diseases (CSDs) and Anxiety and/or Depressive Disordersb (ADDs) on 















n β β β β β β β
Model 1,  
main effects
Constant 12.4** 18.5** 8.84** 14.0** 12.7** 6.00 14.1**
Any CSD 969 3.88** 2.32** 6.05** 3.72** 2.87** 4.93** 4.05**
ADDsb 1,737 20.1** 23.0** 12.0** 10.7** 25.3** 25.6** 24.3**
Model 2,  
main effects and 
interaction effect
Constant 13.1** 18.8** 10.3** 14.7** 13.4** 7.29* 14.4**
Any CSD 969 0.80 1.15 0.22 1.12 0.20 -0.29 2.68
ADDsb 1,737 18.6** 22.4** 9.13** 9.38** 24.0** 23.1** 23.6**
Interaction term 
CSD*ADDc
743 4.06** 1.53 7.68** 3.42* 3.51 6.86** 1.81
These regression models were controlled for socio-demographics (gender, education, and age), β are unstandardized regression 
coefficients.
a WHO-DAS total and domain scores were standardized to values 0-100, a higher score indicates higher severity of disability. 
*: p<.05, **: p<.01.
b Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized 
Anxiety Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic of Major Depressive 
Disorder) 
c in this model, interactions are tested on an additive scale, a significant positive interaction effect (for instance: β 
interaction=4.06) implies that the effect of comorbid CSD and ADD on disability score is larger than the sum of separate effects 
for CSD and ADD (i.e. synergistic effect modification).
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Table IV. Multinomial regression coefficients for impact of Chronic Somatic Diseases 
(CSDs) and current Anxiety and/or Depressive Disorders (ADDs) on absenteeism and 
presenteeism in employed respondents (n=1,462).
Absenteeisma Presenteeismb
Short absenteeism  





(>2 weeks) vs.  
no absenteeism (ref)
Reduced work 




performance vs.  
no presenteeism 
(ref)
n OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Model 1,  
main effects
Any CSD 536 1.07 (0.80-1.42) 1.42 (1.07-1.88)* 1.06 (0.80-1.41) 1.42 (1.08-1.87)*
ADDsc 1,038 2.88 (2.16-3.84)** 6.64 (4.69-9.40)** 1.83 (1.38-2.43)** 7.51 (5.11-11.1)**
Model 2,  
main effects 
Controls 
No CSDs, no ADDs
281 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Purely physical 
CSDs present, no 
ADDs
143 1.03 (0.61-1.74) 1.44 (0.75-2.75) 0.99 (0.59-1.67) 3.22 (1.54-6.73)**
Purely mental 
no CSDs, ADD 
present
645 2.84 (2.00-4.02)** 6.68 (4.27-10.5)** 1.81 (1.29-2.53)** 11.6 (6.55-20.7)**
Physical mental 
(PM-)comorbidity 
CSD present, ADD 
present
393 3.07 (2.05-4.59)** 9.50 (5.88-15.3)** 1.93 (1.30- 2.85)** 14.9 (8.17-27.1)**
These regression models were controlled for socio-demographics (gender, education, age).
a absenteeism is represented by number of weeks absent from work during the last six months. 
b presenteeism is represented by number of workweeks in which quality of work was reduced due to health issues, multiplied by a 
self-reported proportional score for severity of work quality reduction. 
*: p<.05, **: p<.01.
c Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized Anxiety 
Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic of Major Depressive Disorder)
Discussion
This paper aims to examine the impact of ADDs, CSDs, and PM-comorbidity 
on disability and work impairment. First, we found that the relative impact 
of ADDs far exceeded that of CSDs on total disability, disability domains, 
work absenteeism, and presenteeism. Second, a synergistic effect existed 
between CSDs and ADDs with regard to disability; those with PM-comorbidity 
were burdened with levels of disability that were more than what would 
be expected on the basis of separate CSD and ADD effects. Likewise, work 
absenteeism and presenteeism were affected the most in those with PM-
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comorbidity. This is the first paper to establish this association for work 
presenteeism. Third, this synergistic effect of CSDs and ADDs was present in 
a number of disability domains, but not dependent on specific separate CSD 
categories. 
Levels of disability and work impairment were substantial in our sample. Our 
finding that mean disability and odds of worse work impairment outcomes 
are higher in those with ADDs than those with CSDs is in accordance with 
earlier research, and underscores the high burden of disease associated 
with ADDs.3,15 This largely corresponds with findings elsewhere, although 
Buist-Bouwman (2006) reports mobility to be affected more substantially by 
CSDs compared to ADDs.3,5 This difference could be because Buist-Bouwman 
et al. included only arthritis and heart disease. Moreover, sensitivity 
analyses did not show an increase of effect of CSDs on disability or work 
impairment when applying a more stringent criterion for presence of CSDs 
(see supplement), thereby making it unlikely that the higher impact of ADDs 
is due to misclassification of CSDs. 
Most notably, we were able to replicate a positive interaction effect on 
disability found earlier by Armenian (1998).16 Whereas Armenian et al. did 
not quantify the magnitude of this synergistic effect, we did: those with 
PM-comorbidity suffered from disability levels which exceeded the sum 
of disability associated with CSDs and ADDs by 4-5 points on the total 
(unstandardized) WHO-DAS scale. Our analyses showed that those with PM-
comorbidity also have the highest rates of work impairment. Furthermore, 
in addition to work absenteeism, we found increased rates of reduced and 
impaired work performance in those with PM-comorbidity. This could 
indicate that loss of work productivity in those with PM-comorbidity adds to 
the already high societal costs of PM-comorbidity.20,31
These findings indicate that those with PM-comorbidity should be regarded 
as a distinctly identifiable and highly burdened subgroup. Moreover, 
there is growing evidence in current literature that standard treatment is 
less effective in those with PM-comorbidity. For instance, Anxiety and/
Depressive Disorder (ADD) patients are known to have lower levels of 
adherence to somatic medication 12 and require different psychosocial 
approaches.32 Antidepressant medication, frequently used in ADDs, may 
induce metabolic syndrome, which could cause additional disability by 
causing cardiovascular events.14 Additionally, some medications regularly 
used in somatic medicine may worsen psychiatric functioning.33 As a result, 
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some authors argue that tailored rehabilitation programmes should be 
employed in order to effectively deal with disability and work impairment in 
those with PM-comorbidity.32,34 This is in line with the theoretical concepts 
of applying clinical staging models in psychiatry, for which an increased 
amount of interest has been shown in recent years.35,36 Currently, clinical 
staging models for psychiatric disorders are being developed. Our findings 
implicate that presence of PM-comorbidity should be incorporated in future 
clinical staging models for psychiatric disorders due to the evident effects 
on functional outcomes and prognosis. 
In our sample, interaction effects were statistically significant for the 
more physically oriented domains of disability, i.e. mobility, self-care, and 
household activities. This implicates that, by means of a synergistic effect 
with CSDs, ADDs have a bigger impact on physical outcome measures than 
is apparent from their individual coefficient. We did not find separate CSD 
category effects that exceeded the overall CSD effect, therefore increased 
disability and work impairment rates were not driven by specific CSD 
categories.
The main strength of this study is the extensive way in which the interaction 
effects between CSDs and ADDs were examined on various outcome 
measures in a large sample. Furthermore, the generalizability of findings 
from this study was increased by examining a wide range of CSDs as opposed 
to a limited number. The present study had several limitations. First, for 
assessing presence of CSDs we relied on self-report evaluation, which is 
accompanied by a risk of self-report bias. Still, good concordance between 
self-report and diagnoses by a medical doctor were found 28,37 and our 
sensitivity analyses ruled out the possibilities of self-report bias of CSDs 
in those with ADDs, as associations remained comparable when applying 
more stringent CSD criteria (see supplement), thereby validating the use of 
our less stringent CSD classification. Moreover, we ruled out the possibility 
that presence of CSDs in ADD patients was due to antidepressant side 
effects. Second, as our sample is relatively young, prevalence of serious 
CSDs is bound to be relatively low as prevalence of serious CSDs increases 
dramatically in ageing populations.38 Third, by analysing Anxiety Disorders 
and Depressive Disorders simultaneously, our population became more 
heterogeneous. Post hoc analyses showed that although severity of disability 
and work impairment was dependent on psychiatric diagnosis (comorbidity 
between Anxiety and Depressive Disorders induced the most disability and 
work impairment, followed by Depressive Disorders and Anxiety Disorders); 
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interaction effects showed comparable results among different psychiatric 
diagnoses (supplementary Table VI) and among those with single or multiple 
CSDs (supplementary Table V). This is a strong argument for examining both 
disorder groups together with regard to disability, work absenteeism and 
presenteeism. 
To conclude, PM-comorbidity is associated with additional disability and 
high rates of work absenteeism and presenteeism and should be regarded 
as a clinically distinct subgroup of patients with a worse prognosis. Given 
the synergistic effect on disability and the high rates of work impairment 
in those with PM-comorbidity, more research into the efficacy of targeted 
interventions for those with PM-comorbidity is needed to improve 
functioning in this group.
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We performed a number of sensitivity analyses in order to check for possible 
bias. First, the use of antidepressants could be a confounder for presence of 
CSD in ADD patients. We performed logistic regression analysis for presence 
of CSD categories in patients with ADDs, while adjusting for antidepressant 
use. In these analyses, antidepressant use was determined by inspecting 
medication containers and by referencing Anatomical Therapeutic Chemical 
(ATC) classifications. Antidepressant use was deemed present in those 
taking selective serotonin reuptake inhibitors (ATC code N06AB), tricyclic 
antidepressants (N06A A) or other antidepressants (N06AF/N06AX) at least 
50% of the time. 
In addition, a self-report bias could exist in which patients with ADDs report 
more CSDs than controls. In order to examine this possible self-report bias, 
we repeated our analyses with a more stringent operationalization of CSDs 
by checking whether current medication containers were in accordance with 
the CSD category respondents reported, as done previously [26]. In this 
more stringent operationalization, in addition to the self-report of certain 
CSDs, appropriate medication use was necessary for presence of a certain 
CSD category. Furthermore, frequency of medication use had to be at least 
50% of the time, unless stated otherwise. See Supplementary Table I for an 
overview of Anatomical Therapeutic Chemical (ATC) classifications used in 
assessing medication-controlled CSDs.
In this way we identified 377 respondents who reported presence of 
CSDs but who did not use appropriate medications. We excluded these 
respondents from post hoc analyses in order to increase contrast between 
respondents with and without CSDs to be able to determine whether a more 
stringent operationalization of CSDs altered our findings. We repeated 
logistic regression analysis to assess differences in odds for CSD categories 
in patients with ADDs. Moreover, we repeated multivariate linear regression 
analysis to examine whether impact of CSDs, ADDs, and PM-comorbidity 
on disability differed after these adjustments for possible self-report bias. 
Finally, we repeated multivariate nominal logistic regression analyses 
to assess the impact of medication-controlled CSDs, ADDs, and their 
interaction on absenteeism and presenteeism.
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Finally, we repeated multivariate linear regression analyses on total 
disability scores using different categorical variables for CSDs (no CSD, 1 
CSD, 2+ CSDs) in interaction with ADDs; and for ADDs (no ADD, pure ADDs, 
comorbid ADDs) in interaction with CSDs. In this analysis, pure ADDs were 
defined as presence of either anxiety disorder or depressive disorder and 
comorbid ADDs were defined as presence of both anxiety and depressive 
disorders. We assessed separate main effects and interaction effects. We 
Supplementary Table I. Medication controlled CSD categories.
CSD category ATC code
Respiratory Asthma, chronic bronchitis, pulmonary 
emphysema, other lung diseases
R01 (nasal preparations), R03 (Medication for 
obstructive airway diseases), R05 (Cough and cold 
preparations), R06 (Antihistaminics for systemic 
use), R07 (Other respiratory system products), H02 
(Corticosteroids for systemic use)
Cardio-metabolic Hypertension, angina pectoris, history of cardiac 
disease, stroke, diabetes, vascular abnormalities
C02 (antihypertensives), C03 (diuretics), C07 (beta 
blocking agents), C08 (calcium channel blockers), 
C09 (agent a/o renin-angiotensin system), C10 (Lipid-
modifying agents), C01DA* (Nitrate vasodilators), 
B01 (Anti-coagulant / Anti-platelet agents), 
N02BA15 (Anti-coagulant / Anti-platelet agents), 
N02BA01 (Anti-coagulant / Anti-platelet agents), A10 
(Medication used in diabetes), 
Musculoskeletal Osteoarthritis, rheumatoid arthritis, systemic 
lupus erythematodes, fibromyalgia, RSI, 
congenital skeletal deformation
M01 (Anti-inflammatory and anti-rheumatic products), 
N02A (Opioids), N02B (Other analgesics and 




Ulcer, irritable bowel syndrome, Crohn’s 
disease, colitis ulcerosa, diverticulitis, liver 
cirrhosis, hepatitis, constipation, oesophageal 
disease, gastric sphincter dysfunction, other 
gastrointestinal disease
A02 (Medication for acid related disorders), A03 
(Medication for functional gastrointestinal disorders), 
A04 (Antiemetics and antinauseants), A05 (Bile and 
liver therapy), A06 (laxatives), A07 (Antidiarrheals-
intestinal anti-inflammatory/ anti-infective agents), 
H02 (Corticosteroids for systemic use), L04** 
(Immunosuppressants)
Neurological Migraine, epilepsy, multiple sclerosis, peripheral 
neuropathy, hernia
N02 (Analgesics), M01A (Non-steroidal anti-
inflammatory and anti-rheumatics products), 
M01B (Anti-inflammatory and anti-rheumatic 
agents in combination), N03 (Antiepileptics), 
H02 (Corticosteroids for systemic use), L03AB02 
(Interferons)
Endocrine Thyroid dysfunction H03 (Medication used in thyroid dysfunction)
Cancer 
 
Throat, thyroid, lymphoid, lung, oesophagus, 
bowel, stomach, liver, uterus, cervix, ovary, 
bladder, testicle, prostate, skin, brain, blood
L01/L02/L03/L04 (Medication used in cancer 
treatment), N02A (Opioids), N02B (Other analgesics 
and antipyretics), M01A (Non-steroidal anti-
inflammatory and anti-rheumatics products), M01B 
(Anti-inflammatory and anti-rheumatic agents in 
combination)
* when taken at least ‘if necessary’
** when taken <50% of time
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formulated the following interaction terms: “1 CSD*ADD”, “2+ CSD*ADD” 
(Table V, Model 2), and “pure ADD*CSD”, “comorbid ADDs*CSD” (Table VI, 
Model 2). 
Supplementary results and discussion
Associations between any CSD and ADDs remained the same after adjusting 
for antidepressant use (OR=1.32, 95%-CI: 1.06-1.64). Antidepressant use 
was more widespread in patients with ADDs, but was not accountable for 
differences in presence of CSDs. 
Supplementary Table II shows associations of ADD patients with presence 
of medication-controlled CSDs. Odds for presence of any medication-
controlled CSD are comparable to odds for any (uncontrolled) CSD (OR=1.31, 
95%CI: 1.01-1.69). Odds for CSD categories are generally comparable, 
although odds were raised in those with ADD of having medication-controlled 
musculoskeletal disease (OR=1.81, 95%CI: 1.00-3.26) and neurological 
disease (OR=3.24, 95%CI:1.13-9.30). Still, in our original analyses, odds for 
presence of musculoskeletal and neurological diseases were raised in those 
with ADDs (OR=1.33, 95%CI: 0.95-1.85 for musculoskeletal disease and 
OR=1.78, 95%CI: 0.98-3.22 for neurological diseases), with p-values just 
above significance (p=.101 and p=.057, respectively). We therefore deemed 
these small differences as inconsequential with regard to our hypotheses.
Supplementary Table III shows that disability was raised more in those 
with ADDs (β=19.8) than those with medication-controlled CSDs (β=4.22), 
and interaction effects remained the same (β interaction=4.49) when using 
medication-controlled CSDs. Likewise, results for disability domains were 
comparable when using medication-controlled CSDs.
Supplementary Table IV shows that work impairment outcomes when using 
medication-controlled CSDs are generally comparable to work impairment 
outcomes when using non medication-controlled CSDs. Most notably, odds 
for all forms of work impairment are raised in those with PM-comorbidity (OR 
short absenteeism=2.96, 95%CI: 1.84-4.76; OR extended absenteeism=7.13, 
95%CI:4.18-12.2; OR minor presenteeism=2.04, 95%CI: 1.25-3.31; OR 
extended presenteeism=16.8, 95%CI: 8.81-32.0) when compared to those 
with ADDs (without medication-controlled CSD) and those with medication-
controlled CSDs (without ADDs). Therefore, applying a more stringent 
definition for presence of chronic somatic diseases did not alter our findings.
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Supplementary Table V shows that the interaction effect of CSDs and ADDs on 
total disability does not differ when dividing CSDs into different categories 
(0 CSDs vs 1 CSD vs 2+ CSDs), as both 1 CSD and 2+CSDs interaction terms 
with ADD yielded significant positive interaction coefficients. Thus, the 
interaction effect between CSDs and ADDs is not driven by those with few or 
multiple CSDs, but can be generalized.
Supplementary Table II. Odds of having presence of Chronic Somatic Diseases (CSDs) 
(medication controlled) for Anxiety and/or Depressive Disorder (ADD) patients in 













Any of the listed below, medication 
controlled







Asthma, chronic bronchitis, pulmonary 








Hypertension, angina pectoris, history 









Osteoarthritis, rheumatoid arthritis, 
systemic lupus erythematodes, 









Ulcer, irritable bowel syndrome, Crohn’s 
disease, colitis ulcerosa, diverticulitis, 
liver cirrhosis, hepatitis, constipation, 
oesophageal disease, gastric sphincter 

























Throat, thyroid, lymphoid, lung, 
oesophagus, bowel, stomach, liver, 
uterus, cervix, ovary, bladder, testicle, 






All OR’s were adjusted for gender, age and education.
* Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized Anxiety 
Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic of Major Depressive Disorder)
‡ n in psychiatric groups vary as we excluded those with self reported chronic somatic disease but without being prescribed 
adequate medication from each somatic disease category. 
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In a similar sensitivity analysis, supplementary Table VI shows that the 
interaction terms for two subgroups of ADD severity (no ADDs vs pure ADD 
(either anxiety or depressive disorder present) vs comorbid ADDs (anxiety 
and depressive disorders present) are both positive and significant. So, the 
effect between CSDs and ADDs on total disability is not driven by those with 
comorbid ADDs (those with both anxiety and depressive disorders), or by 
those with pure disorders. 
Supplementary Table III. Adjusted regression coefficients for the association between 
medication controlled Chronic Somatic Diseases (CSDs) and Anxiety and/or Depressive 
Disorders (ADDs) on total disability and disability domains (n=1,994). 












β β β β β β β
Model 1, main effects
Constant 12.3** 18.8** 9.53** 13.3** 11.0** 6.62 13.7**
Any CSD, medication 
controlled 
4.22** 1.49 7.56** 4.28** 2.37* 6.00** 4.04**
ADDs*** 19.8** 22.6** 11.8** 10.5** 24.9** 25.2** 24.1**
Model 2, main effects and 
interaction effect
Constant 12.9** 18.9** 10.9** 13.9** 11.5** 7.75* 13.9**
Any CSD 0.79 0.80 0.20 0.90 -0.39 0.00 2.98
ADDs*** 18.6** 22.4** 9.17** 9.31** 23.9** 23.0** 23.7**
Interaction term CSD*ADD‡ 4.49** 0.91 9.63** 4.42* 3.61 7.85** 1.39
All regression models were controlled for socio-demographics (gender, education, and age), β  are unstandardized regression 
coefficients.
¶ WHO-DAS total and domain scores were standardized to values 0-100, a higher score indicates higher severity of disability.
*: p<.05, **: p<.01.
*** Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized 
Anxiety Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic or Major Depressive 
Disorder) 
‡ in this model, interactions are tested on an additive scale, a significant positive interaction effect (for instance: β =4.49) implies 
that the effect of comorbid CSD and ADD on disability score is larger than the sum of separate effects for CSD and ADD.
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Supplementary Table IV. Multinomial regression coefficients for impact of medication 
controlled Chronic Somatic Diseases (CSDs) and current Anxiety and/or Depressive 
Disorders (ADDs) on absenteeism in employed respondents (n=1,230).
Absenteeism§ Presenteeism‡
Short absenteeism  












presenteeism vs.  
no presenteeism (ref)
n OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Model 1, main effects
Any CSD 305 1.09 (0.76-1.57) 1.12 (0.78-1.59) 1.17 (0.81-1.70) 1.63 (1.15-2.32)**
ADDs*** 864 2.74 (2.02-3.72)** 6.42 (4.37-9.42)** 1.77 (1.31-2.39)** 8.19 (5.32-12.6)**
Model 2, main effects
Controls 
No CSDs, no ADDs
281 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Purely physical 
CSD present, no ADDs
85 1.24 (0.66-2.34) 1.19 (0.53-2.67) 1.22 (0.65-2.32) 3.89 (1.69-8.97)**
Purely mental 
no CSDs, ADD present
644 2.85 (2.02-4.03)** 6.57 (4.20-10.3)** 1.81 (1.29-2.54)** 11.7 (6.59-20.9)**
Physical mental comorbidity 
CSD and ADD present
220 2.96 (1.84-4.76)** 7.13 (4.18-12.2)** 2.04 (1.25-3.31)** 16.8 (8.81-32.0)**
These regression models were controlled for socio-demographics (gender, education, age).
§ absenteeism is represented by number of weeks absent from work during the last six months. 
‡ presenteeism is represented by number of workweeks in which quality of work was reduced due to health issues, multiplied by 
a self-reported proportional score for severity of work quality reduction. 
*: p<.05, **: p<.01.
*** Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized 
Anxiety Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic or Major Depressive 
Disorder)
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Supplementary Table V. Sensitivity analysis to assess whether the interaction effects 
between CSDs and ADDs persist with increasing number of CSDs (n=2,371).
Level of disability  (WHO-DAS II)a
n β
Model 1, main effects
constant 12.8**
1 CSD (reference 0 CSDs) 657 2.74**
 2+ CSDs (reference 0 CSDs) 312 6.69**
ADDsb 1,737 20.0**
Model 2, main effects and interaction effect
constant 13.5**
1 CSD (reference 0 CSDs) 657 0.36
2+ CSDs (reference 0 CSDs) 312 2.92
ADDsb 1,737 18.6**
Interaction term 1 CSD*ADDc 485 4.65*
Interaction term 2+CSD*ADDc 258 3.21*
These regression models were controlled for socio-demographics (gender, education, and age), β are unstandardized regression 
coefficients.
a WHO-DAS total and domain scores were standardized to values 0-100, a higher score indicates higher severity of disability. 
*: p<.05, **: p<.01.
b Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized Anxiety 
Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic or Major Depressive Disorder)
c in this model, interactions are tested on an additive scale, a non-significant positive interaction effect (for instance: β 
interaction =4.65) implies that the effect on disability score of comorbid ADDs in those with 1 CSD is larger than the sum of 
separate effects for CSD and ADD (i.e. synergistic effect modification).
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Supplementary Table VI. Sensitivity analysis to assess whether the interaction effects 
between CSDs and ADDs persist with increasing number of ADDs (n=2,371).
Level of disability (WHO-DAS II)a
n β
Model 1, main effects
constant 10.1**
 CSDs 969 3.54**
1 ADDb (reference 0 ADDs) 947 14.9**
Comorbid ADDs (anxiety and depression, reference 0 ADDs) 790 26.9**
Model 2, main effects and interaction effect
constant 10.8**
 CSDs 969 0.79
1 ADDb (reference 0 ADDs) 947 13.7**
Comorbid ADDs (anxiety and depression, reference 0 ADDs) 790 25.2**
CSD*1 ADD 387 3.17*
CSD*comorbid ADDs 356 4.15**
These regression models were controlled for socio-demographics (gender, education, and age) , β are unstandardized regression 
coefficients.
a WHO-DAS total and domain scores were standardized to values 0-100, a higher score indicates higher severity of disability. 
*: p<.05, **: p<.01.
b Anxiety and/or Depressive Disorders were defined as presence of either an Anxiety Disorder (Social Phobia, Generalized Anxiety 
Disorder, Panic Disorder with or without Agoraphobia) or a Depressive Disorder (Dysthymic or Major Depressive Disorder)
c in this model, interactions are tested on an additive scale, a significant positive interaction effect (for instance: β interaction 
=4.15) implies that the effect of comorbid CSD and ADD on disability score is larger than the sum of separate effects for CSD and 
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Abstract
Anxiety Disorders often show a chronic course, even when treated with 
one of the various effective treatments available. Lack of treatment effect 
could be due to Treatment Resistance (TR). Consensus on a definition for 
TR Anxiety Disorders (TR-AD) is highly needed as currently many different 
operationalizations are in use. Therefore, generalizability in current TR-
AD research is suboptimal, hampering improvement of clinical care. The 
objective of this review is to evaluate the currently used definitions of TR-
AD by performing a systematic review of available literature. Out of a total 
of n=13,042, 62 studies that operationalized TR-AD were included. The 
current review confirms a lack of consensus on TR-AD criteria. In 62.9% of 
the definitions, TR was deemed present after the first treatment failure. 
Most studies (93.0%) required pharmacological treatment failures, whereas 
few (29.0%) required psychological treatment failures. However, criteria 
for what constitutes “treatment failure” were not provided in the majority of 
studies (58.1%). Definitions for minimal treatment duration ranged from at 
least four weeks to at least six months. Almost half of the TR-AD definitions 
(46.8%) required elevated anxiety severity levels in TR-AD. After synthesis 
of the results, the consensus definition considers TR-AD present after both 
at least one first-line pharmacological and one psychological treatment 
failure, provided for an adequate duration (at least eight weeks) with 
anxiety severity remaining above a specified threshold. This definition could 
contribute to improving course prediction and identifying more targeted 
treatment options for the highly burdened subgroup of TR-AD patients. 
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Introduction 
Up till now, a widely used definition for treatment resistance in Anxiety 
Disorders does not exist.1–5 This is surprising because it is well known 
that a substantial proportion of adults with Anxiety Disorders experience 
suboptimal treatment results after evidence-based treatments.6–8 Selective 
Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine 
Reuptake Inhibitors (SNRIs) are widely regarded the first-line 
pharmacological treatments for Anxiety Disorders.9–11 Cognitive Behavioural 
Therapy (CBT) is the psychological first-line treatment option for Anxiety 
Disorders.12 First-line treatments show a moderate effect size in meta-
analytic comparisons with placebo.13,14 After first-line treatment up till 30-
60% of patients have substantial and impairing remaining symptoms.7,9,15
A wide variety of terms are in use for the phenomenon of suboptimal 
treatment results in anxiety disorders: “refractory anxiety”, “treatment 
resistance”, “medication resistance”, “treatment refractory cases”, 
“remaining symptomatic” and “persistent symptoms”.16–21 In other psychiatric 
disorders the term “treatment resistance” (TR) is preferred to describe 
a subgroup of patients who have a prior history of unfavorable treatment 
effects,22–25 which also implies having less favorable future treatment 
effects.22–25 The varying terminology reflects the absence of consensus 
regarding the criteria for TR.1,5,26–28 This lack of consensus on criteria for 
TR-AD was first recognized in 2004; however, fourteen years later still no 
consensus exists.1–5,29
Most authors define Treatment Resistant Anxiety Disorders (TR-AD) as the 
persistence of anxiety symptoms, or as the absence of response, recovery 
or remission of the disorder after some form of active treatment.1,30–34 These 
active treatments should represent evidence-based treatment regimes, 
provided at an adequate dosage and for an adequate duration.3,35 However, 
the absence of anxiety symptoms does not always indicate full disorder 
remission.2,36 A substantial amount of residual disease burden may be 
present in persisting behavioural changes such as avoidance, or in altered 
cognitive functioning, for instance in excessive rumination. Additional 
emphasis on functional recovery is therefore advocated by a number of 
authors when assessing TR-AD.2,36 No systematic review into the definition 
for TR-AD is yet performed. 
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The aim of this study is to summarize and discuss the different criteria used 
for TR-AD. In order to do this, we will perform a systematic literature review. 
Second, by summarizing and comparing the different criteria used for TR in 
anxiety disorders, we aim to propose a consensus definition for TR-AD. 
Methods
The methods for this systematic review were specified in advance in a study 
protocol which was documented in the PROSPERO database (reference 
number CRD42017055864). The current paper was drafted in accordance 
with the PRISMA guidelines for reporting on systematic reviews.37
Literature search
A systematic search across MEDLINE, PubMed (non-MEDLINE), EMBASE, 
PsycINFO, and Web of Science for available literature until April 2018 was 
performed. In order to derive all articles that might include a definition for 
TR in anxiety disorders we searched for Anxiety Disorders (according to 
DSM-5)38 in combination with various free-text synonyms for ‘treatment 
resistance’ (see Panel 1 for the full search query). 
All publication types in English were included with the exception of 
conference summaries, editorials, columns, book reviews and manifestos 
as these were unlikely to include a full description of a TR-AD definition. 
Studies were selected when they included adults or elderly persons with 
anxiety disorders (Panic Disorder, with or without Agoraphobia, PD(A), 
Social Anxiety Disorder (SAD), Generalized Anxiety Disorder (GAD), Specific 
Phobia (SP), Selective Mutism, and Separation Anxiety). No restrictions in 
presence of comorbidity were used. Exclusion criteria included studies with 
an average study population below 21 years, and studies reporting primarily 
on Post-Traumatic Stress Disorder (PTSD) or Obsessive-Compulsive 
Disorder (OCD), because these are no longer classified as Anxiety Disorders. 
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Panel 1.
Overview of search terms used in this systematic review (formatted for 
MEDLINE)
((“Anxiety Disorders”[Mesh:NoExp] OR “Agoraphobia”[Mesh] OR 
“Anxiety, Separation”[Mesh] OR “Neurocirculatory Asthenia”[Mesh] 
OR “Neurotic Disorders”[Mesh] OR “Panic Disorder”[Mesh] OR “Phobic 
Disorders”[Mesh] OR anxiety disorder* [tiab] OR generalized anxiety 
disorder* [tiab] OR generalised anxiety disorder* [tiab] OR anxiety 
state* [tiab] OR agoraphobi* [tiab] OR panic* [tiab] OR phobi* [tiab] 
OR selective mutis* [tiab])) 
AND 
(“Retreatment” [Mesh] OR “Drug Resistance” [Mesh:NoExp] OR 
“Drug tolerance” [Mesh] OR treatment resistan* [tiab] OR refractor* 
[tiab] OR poor respon* [tiab] OR partial respon* [tiab] OR non-
respon* [tiab] OR nonrespon* [tiab] OR loss of respons* [tiab] OR 
medication resistan* [tiab] OR drug resistan* [tiab] OR tachyphyl* 
[tiab] OR resilien* [tiab] OR persistan* [tiab] OR immune [tiab] OR 
insusceptib* [tiab] OR irresponsive* [tiab] OR unreceptive* [tiab] 
OR resistive [tiab] OR unsuccessful treatment* [tiab] OR treatment 
failur* [tiab] OR failed treatment* [tiab] OR “Patient Dropouts”[Mesh] 
OR patient dropout* [tiab] OR treatment dropout* [tiab] OR “Patient 
Compliance”[Mesh] OR non-complian* [tiab] OR noncomplian* 
[tiab] OR non-adheren* [tiab] OR nonadheren* [tiab] OR remaining 
symptom* [tiab] OR pseudo-resistan* [tiab] OR dropping out [tiab] 
OR augmentation [tiab] OR inadequate respon* [tiab] OR intractab* 
[tiab] OR partially respon* [tiab] OR resistant patient* [tiab] OR 
remain symptom* [tiab] OR remaining symptom* [tiab] OR non-
remitting [tiab] OR nonremitting [tiab] OR partial improvement* 
[tiab] OR incomplete respon* [tiab] OR residual symptom* [tiab] OR 
anxiolytic toleran* [tiab])
Eligibility assessment
Eligibility assessment on title and abstract was performed independently 
by two reviewers (WB, GW, JG) by using the Cochrane-supported review 
program Covidence (www.covidence.org). Disagreements were resolved 
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by consensus after discussion. A flow chart for inclusion of eligible studies 
according to PRISMA guidelines is provided in figure 1. Full-text screening 
was performed independently by two reviewers (WB and JG). During the 
full-text screening phase, articles were excluded if a full-text version could 
not be retrieved or if any of the exclusion criteria were present. Studies 
were included if their definition for TR-AD could be implicitly deduced 
from inclusion criteria used in a study. Reviews, meta analyses and book 
chapters were included if they provided their own definition for TR-AD but 
were excluded if they repeated other studies’ definitions without providing 
rationale for choosing this definition over others. As the vast majority of 
studies used TR and “refractory” interchangeably we chose to regard them 
as synonyms and will refer to these phenomena as TR-AD. 
Data extraction
From trials we extracted data on study characteristics: number of subjects, 
population of interest, intervention, comparator condition, follow-up 
period, primary outcomes and results; from reviews we extracted data 
on study design and population of interest. With regard to the definitions 
for TR-AD, we extracted data on nine predefined putative criteria for the 
definition, based on criteria used in the Maudsley Staging Method for 
treatment resistant depressive disorders.23 Additionally, we extracted one 
TR-AD criterion (treatment response), that was not predefined in our study 
protocol. The ten criteria were: minimal number of failed treatments, failed 
psychotherapy trials, failed pharmacological trials, failed other biological 
treatments, minimal length of treatment, treatment response criterion 
(i.e. which post-treatment change constitutes response/ failure), minimal 
duration of anxiety disorder, severity of symptoms, presence of functional 
impairment, and presence of comorbidity. We evaluated which of these ten 
criteria were present in TR-AD definitions across included studies (yes/no). 
Specific values for each criterion were extracted as well.
Quality of definitions
We assessed the definition quality in each included study. As there are no 
formal risk of bias tools available for the purpose of our study, and as we 
are not interested in potential sources of study outcome bias we assessed 
definition quality in two ways; first, by counting the total number of TR-
AD criteria included in each study’s definition, second, by determining the 
degrees of precision with which the definition for TR-AD is presented in each 
paper. The total number of TR-AD criteria was a count variable counting 
presence of all ten dichotomized TR-AD criteria. Degrees of precision was 
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categorized into ‘high’, ‘medium’ and ‘low’. Precision was considered ‘high’ if 
a study provided an explicit definition for TR-AD, for example in this study by 
De Salas-Cansado et al. (2013): 
Figure 1. PRISMA flow chart for study inclusion.
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Refractory was defined as subjects with persistent symptoms/
suboptimal response, a Hamilton-anxiety (HAM-A) scale score 
≥16 and a Clinic Global Impression (CGI) score ≥3 at baseline, 
after a standard dose regimen of any anti-anxiety drug, alone or in 
combination, for at least 6 months, given prior to the baseline study 
visit. (p987)39
The degree of precision was deemed ‘medium’ if the criteria were only 
implicitly attributable to the concept of TR-AD, or if multiple terms were used 
interchangeably, for instance in a study by Lohoff, Etemad, Mandos, Gallop, 
& Rickels (2010) in patients with “refractory GAD”:
Subjects also had to have treatment failure of at least 1 adequate trial 
of an SSRI, an SNRI, a BZ, or a combination of these agents. Patients 
who were on an SSRI, an SNRI, a BZ, or a combination of these agents 
before enrollment had to be on a stable dose for 4 weeks. Inclusion 
further required a total score of 16 or higher on the Hamilton Anxiety 
Scale (HAM-A) and a score of 4 or greater on the Clinical Global 
Impression Severity of Illness Scale (CGI-S) (p186).40
Finally, if the study only provided a description of the concept of TR-AD, 
without operationalizing it in specific criteria, the degree of precision was 
deemed ‘low’, for instance: 
“failure of an adequate clinical trial of medication” (Stein, 2004).30
Data synthesis
In order to synthesize the results of the systematic review into a new 
operationalization for TR-AD, frequencies for presence of each individual 
TR-AD criterion were assessed. The most frequently used values for each 
individual criterion were considered the most appropriate operationalization 
for that criterion and were chosen for the consensus definition. However, 
if an unspecified category for a certain criterion (for example “unspecified 
type of pharmacological treatment”) was the most frequently used value, 
we did not consider this category for the new definition if a more specified 
value was available. Additionally, criteria that were included only in a small 
minority (<10%) of the studies were not used for the new definition, as they 
were then judged to be lacking a convincing empirical basis.
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Statistical analyses
To test associations between total number of criteria provided in definitions, 
degrees of precision and publication year, we performed Kruskall-Wallis 
tests for differences in mean rank. We hypothesized that higher definition 
quality studies (i.e. more total criteria or a higher degree of precision) 
would be the most recent studies. Fisher’s Exact tests were performed to 
investigate whether the two definition quality variables were associated with 
different frequencies for values of each TR-AD criterion. For instance: did 
high definition quality studies more often require a higher number of failed 
treatments or more often mention a SSRI/SNRI failure as requisite for TR-AD 
compared with lower definition quality studies? 
Results
Study selection
The electronic database search yielded 18,702 results. After deduplication 
13,042 entries remained. During title and abstract screening, 12,654 studies 
were excluded. We assessed 388 full-text studies, of which 207 did not 
contain a definition, 53 were a wrong article type (conference abstracts and 
editorials), 34 could not be retrieved, 15 did not meet language requirements, 
8 reported on a different type of “resistance” (e.g. “resistance” in the 
psychodynamic paradigm), 7 were previously unrecognized duplicates and 2 
reported on a different patient population. This resulted in the final inclusion 
of sixty-two studies (for a flow chart see Figure 1). 
Characteristics of included studies
Included studies were published between 1986 and 2018. They consisted of 
eight narrative reviews,2,4,9,34,36,41–43 five systematic reviews,1,16,44–46 of which 
three also performed meta-analyses,1,16,46 seven treatment guidelines/
algorithms,30,47–52 three book chapters,53–55 twenty-one open-label trials, 
26,56–75 eight RCTs,40,76–82 four retrospective cohorts,83–86 one prospective 
cohort,87 three case series,88–90 one cost-effectiveness analysis,39 and one 
trial protocol.32 Thirty-three studies pertained to PD, thirty-four to GAD, 
twenty-one to SAD, two to SP, and five to Anxiety Disorders in general. For 
a summary of study characteristics see Table 1. For full details, see eTable 1 
(trials, cohort studies and meta-analyses) and eTable 2 (reviews, treatment 
guidelines and book chapters).
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Table 1. Study characteristics for included studies.
Study characteristics n %
Publication type
Book chapter 3 4.8
Case series 3 4.8
Cost-effectiveness analysis 1 1.6
Narrative review 8 12.9
Open-label trial 21 33.9
Prospective cohort study 1 1.6
Randomized controlled trial 8 12.9
Retrospective cohort study 4 6.5
Systematic review 2 3.2
Systematic review + meta-analysis 3 4.8
Trial protocol 1 1.6
Treatment guidelines/ algorithms 7 11.3
Population of interest1
Anxiety disorders (in general) 5 8.1
Generalized anxiety disorder 34 54.8
Panic disorder 33 53.2
Social anxiety disorder 21 33.9
Specific phobia 5 8.1
Type of intervention used (if any)
Adjunctive psychotherapy 8 12.9
Any therapy 1 1.6
Any adjunctive therapy 1 1.6
Combination treatment: pharmacological and psychological 4 6.5
Either pharmacologic monotherapy or pharmacologic augmentation therapy 1 1.6
Pharmacologic augmentation or combination treatment 17 27.4
Pharmacologic monotherapy 7 11.3
Nervus vagus stimulation 1 1.6
Self-management 1 1.6




 1 Some studies described more than one population of interest.
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Definition quality
The total number of criteria per study ranged from 1 to 6 (mean=3.58, 
SD=1.31). With respect to the assessment of the degree of precision for TR-
AD definitions it appeared that 13 studies (21.0%) provided a high degree 
of precision, 44 (71.0%) a medium degree, and 5 (8.1%) a low degree of 
precision. 
There was a significant association between total number of criteria and year 
of publication (Χ2(df=5)=13.01,p=0.02): the studies with the highest number 
of criteria were, on average, the most recent. For degrees of precision no 
association with publication date existed (Χ2(df=2)=2.13,p=0.34). Neither 
studies with a higher total number of criteria, nor studies with a higher 
degree of precision provided a different perspective on the ten TR-AD 
criteria. Since definition quality did not change operationalizations for TR-
AD, all studies were used in the synthesis of results.
Main results
By applying a systematic review approach it became apparent that a large 
majority of studies on the topic of TR-AD (n=207) do not provide a definition 
for the phenomenon of TR-AD. Furthermore, the included studies (n=62) 
yielded many different definitions for the concept of TR-AD (see eTable 3 for 
all definitions). Trials often used the presence of one failed pharmacological 
treatment as an adequate definition for TR-AD. Other studies provided 
additional criteria. When the frequencies for each of the ten extracted TR-AD 
criteria were compared across included studies, some distinctive patterns 
arose (see Table 2).
The minimal number of required failed treatments, regardless of treatment 
type, was reasonably consistent across studies: 39 studies (62.9%) required 
one treatment failure for TR-AD, with other studies varying between two 
(n=3) and five (n=1) failed previous treatments. Failed psychotherapy trials 
were only included in 18 studies (29.0%). These studies all regarded CBT an 
appropriate treatment, with seven studies (11.3%) restricting TR-AD to CBT 
failure alone, whilst others (n=9, 14.5%) also regarded other psychological 
treatments appropriate. 
Contrastingly, a large majority (n=58, 93.5%) required at least one failed 
pharmacotherapy trial for their definition for TR-AD. Of these, some studies 
(n=15, 24.2%) considered at least one failed SSRI/SNRI trial sufficient to be 
classified as TR-AD. A substantial number of studies did not specify type of 
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pharmacotherapeutic treatment failure required for TR-AD (n=27, 43.5%), 
for instance by referring to “first-line” or “standard” antianxiety treatments. 
A few used a varying number of treatment types in a stepped-care or staging 
algorithm (n=2, 3.2%) or considered other pharmacotherapeutic treatment 
failures adequate (n=14, 22.6%). See eTable 3 for detailed descriptions of 
type of pharmacotherapy. Whether failed trials were caused by a lack of 
effect, or a lack of tolerability was usually not reported. Other biological 
treatments were not included in TR-AD definitions. 
Most studies (n=34, 54.8%) used a minimal treatment length criterion 
ranging from four weeks to six months, while the most often used adequate 
minimal treatment duration was eight weeks (n=15, 24.2%). 
A substantial number of studies (n=26, 41.9%) gave a response criterion. 
The most commonly used cut-off values were a <50% posttreatment 
improvement on the Hamilton Anxiety Rating Scale (HAM-A) and a 
posttreatment Clinical Global Impression Improvement scale (CGI-I) score 
greater than two (i.e. “minimal improvement”, at best). Severity of anxiety 
symptoms was often included in definitions (n=29, 46.8%), with cut-off 
scores commonly provided: a HAM-A score of above 16 (for any Anxiety 
Disorder), a Clinical Global Impression Severity Scale (CGI-S) score of four 
or higher (for any Anxiety Disorder), a total score above 3, or any item above 
1 on the Panic Disorder Severity Scale (PDSS) for PD and a score above 60 
on the Leibowitz Social Anxiety Scale (LSAS) for SAD. For GAD, no disorder-
specific measurement instrument was reported in TR-AD definitions. Finally, 
minimal disease duration (n=2, 3.2%), presence of functional impairments 
(n=5, 8.1%) and presence of comorbidity (n=1, 1.6%) were sparsely included 
in definitions for TR-AD. See Table 2 for a summary per TR-AD criterion, and 
eTable 4 for a full overview of included TR-AD criteria per study. 
Synthesis of results
In order to propose a consensus definition for TR-AD that reflects the current 
literature, we included the most prevalent values for all criteria that were 
provided consistently across studies into the new TR-AD definition. Failed 
SSRI/SNRI trials were most often considered as criterion for TR-AD. Studies 
typically referred to SSRI/SNRI trials as ‘first-line’ treatment. Therefore, 
failure of at least one first-line treatment (SSRI/SNRI) was included in the 
new definition. Although psychotherapeutic treatment failure was less often 
incorporated in TR-AD definitions, CBT was usually referred to as ‘first-line’ 
psychological intervention. Therefore, first-line psychological interventions 
83
Chapter 4 - Treatm
ent resistance in anxiety disorders
(CBT) failure was included in the new definition. Although the most often 
provided criterion for minimal number of treatments was one, by including 
both pharmacological and psychological treatment failures into the 
definition, the minimal number of failed treatments in the new definition rose 
to at least two. A minimal adequate treatment duration of eight weeks was 
included in the consensus definition. In studies that permitted psychotherapy 
failures as criterion for TR-AD (n=21), only five provided a minimal treatment 
duration criterion, ranging from 4 weeks to 20 sessions CBT (see eTable 4). 
Therefore, a minimal duration of 8 weeks was maintained for psychotherapy 
trials.
Table 2. Criteria included in definitions for treatment resistance anxiety disorders.
Treatment resistance definition criteria n %
Minimal number of failed treatments
Not part of definition 9 14.5
Included in definition 53 85.5
     Unspecified or varying number 7 11.3
     1 failed treatment 39 62.9
     2 failed treatments 3 4.8
     3 or more failed treatments 4 6.5
Failed psychotherapy trials
Not part of definition 44 71.0
Included in definition 18 29.0
     Any 9 14.5
     At least one failed CBT trial 7 11.3
     Varying number (stepped-care or staging approach) 2 3.2
Failed pharmacological trials
Not part of definition 4 6.5
Included in definition 58 93.5
     Unspecified number or type of failed pharmacological treatment 27 43.5
     At least one failed SSRI/SNRI trial 15 24.2
     At least one failed other pharmacotherapeutic trial 14 22.6
     Varying number or types (stepped-care or staging approach) 2 3.2
Other biological treatments
Not part of definition 62 100
Included in definition 0 0
Table continues
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Treatment resistance definition criteria n %
Minimal length of treatment
Not part of definition 28 45.2
Included in definition 34 54.8
     >4 weeks 8 12.9
     >6 weeks 3 4.8
     >8 weeks1 15 24.2
     >11 weeks or 20 sessions of CBT 1 1.6
     >12 weeks 3 4.8
     >4 months 2 3.2
     >6 months 2 3.2
Treatment response criterion
Not part of definition 36 58.1
Included in definition 26 41.9
     Cut-off values for effective/ failed treatment provided2 26 41.9
Minimal duration of anxiety disorder
Not part of definition 60 96.8
Included in definition 2 3.2
     >1 year 1 1.6
     >2 years 1 1.6
Severity of symptoms
Not part of definition 33 53.2
Included in definition 29 46.8
     Aspecific criterion (e.g. “severe”) 1 1.6
     Specific criterion (cut-off values) provided3 28 45.2
Functional impairment
Not part of definition 57 91.9
Included in definition 5 8.1
     Aspecific criterion (e.g. “marked impairments”) 4 6.5
     Specific criteria (cut-off values) provided4 1 1.6
Presence of comorbidity
Not part of definition 61 98.4
Included in definition 1 1.6
     Comorbidity as exclusion criterion for TR-AD 1 1.6
1 including studies with minimal treatment duration of ‘2 months’. 
2 the most often used criteria were: ∆HAM-A<50% or CGI-I>2
3 the most often used criteria for severe symptomatology were HAM-A<16 or CGI-S≥4 (for all Anxiety Disorders), PDSS>3 or any 
PDSS item>1 (for PD(A)), LSAS>60 (for SAD)
4 one study used SDS >1 on each item as criterion for functional impairments. 
Abbreviations: CBT= Cognitive Behavioral Therapy, SSRI=Selective Serotonin Reuptake Inhibitor, SNRI= Selective Norepinephrine 
Reuptake Inhibitor. HAM-A: Hamilton Anxiety Rating Scale, CGI-I= Clinical Global Impression Improvement Scale, CGI-S= Clinical  
Global Impression Severity Scale, PDSS= Panic Disorder Severity Scale, LSAS= Leibowitz Social Anxiety Scale, PD(A)= Panic 
Disorder (with or without agoraphobia), SAD= Social Anxiety Disorder, SDS= Sheehan Disability Scale
Table 2. Continued
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Absence of treatment response was included in the consensus definition, 
using the two most commonly provided cut-off values from studies included 
in this review. Other biological treatments, minimal duration of anxiety 
disorder, presence of functional impairments and comorbidity were only 
sporadically included in TR-AD definitions and therefore were not considered 
for the consensus TR-AD definition. See Panel 2 for the full description of 
this consensus TR-AD definition with most commonly used cut-off values for 
each criterion.
Panel 2. 




□ At least one first-line treatment (SSRI, SNRI)1
□ pre-to posttreatment difference in HAM-A <50% or posttreatment CGI-I >2
□ treatment period of at least 8 weeks
Failed psychotherapeutic treatment
□ At least one first-line psychotherapeutic treatment (CBT)2
□ pre-to posttreatment difference in HAM-A <50% or posttreatment CGI-I >2
□ provided according to local protocols and for an adequate duration (at least>8 weeks)
Current severity of anxiety symptoms
□ GAD HAM-A >15     or CGI-S > 3
□ PD HAM-A >15 or PDSS >3, or any item >1  or CGI-S > 3
□ SAD HAM-A >15 or LSAS ≥ 60    or CGI-S > 3
TR-AD is present if all six treatment boxes can be checked in addition to at least one symptom severity box 
1 SSRIs and SNRIs are considered first-line pharmacotherapeutic treatment options as per 201819,21,49
2 CBT interventions are considered first-line psychotherapeutic treatment options as per 201817,49
Abbreviations: SAD= Social Anxiety Disorder, PD= Panic Disorder, GAD= Generalized Anxiety Disorder, HAM-A= Hamilton Anxiety 
Rating Scale, PDSS= Panic Disorder Severity Scale, LSAS= Leibowitz Social Anxiety Scale, CGI-S= Clinical  Global Impression 
Severity Scale, CGI-I= Clinical Global Impression Improvement Scale, SSRI= Selective Serotonin Reuptake Inhibitor, SNRI= 
Selective Serotonin and Norepinephrine Reuptake Inhibitor, CBT= Cognitive Behavioral Therapy. 
Discussion
This paper aimed to systematically review different definitions and criteria 
for treatment resistant Anxiety Disorders (TR-AD) and showed that the 
majority of studies do not provide a definition for TR-AD and that consistency 
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and consensus across TR-AD definitions in included studies is lacking. The 
most frequently used definition for TR-AD simply consists of one failed 
first-line pharmacotherapy treatment. Both the lack of consensus in current 
TR-AD definitions and the unclear description of TR-AD in the most used 
definition make the current attempt of aligning definitions a necessity.
Out of ten putative criteria, we identified six criteria that are regularly 
integrated into the various different definitions for TR-AD: minimal number 
of treatment failures, presence (and type) of psychological treatment 
failure, presence (and type) of pharmacological treatment failure, minimal 
treatment duration (>8 weeks), specification of a response criterion (i.e. 
what constitutes a “failed treatment”), and minimal symptom severity. 
These criteria were integrated into a consensus definition. Four putative 
criteria were dismissed: “minimal duration of disorder”, “other biological 
treatment failures”, “presence of comorbidity” and “presence of functional 
impairment” due to the low frequency with which these were mentioned. 
In selecting the specific cut-off values for included criteria, we opted to 
use the most commonly mentioned cut-off values (the mode). Based on 
the most recent treatment guidelines, for the purpose of this definition we 
considered SSRIs and SNRIs as current first-line pharmacotherapy options, 
and CBT current first-line psychotherapy option.17,19,21,49 Furthermore, the 
consensus definition for TR-AD requires both a failed pharmacotherapeutic 
and psychotherapeutic trial, as these were both regularly used as criterion 
for TR-AD. 
This is the first study to systematically assess different criteria for TR-AD. 
A systematic approach was complicated by the absence of a risk of bias 
assessment tool for the purpose of the current study. Tools such as the 
Cochrane risk of bias tool for randomized studies 91 or the RoBANS for non-
randomized studies 92 determine the level of confidence with which the 
results of a certain study can be interpreted. However, the data we extracted 
from studies referred to the definition for treatment resistance they used, not 
the outcome of the study. Therefore, we chose to assess definition quality by 
determining the total number of criteria provided and the degree of precision 
with which the definition was provided. After analyzing these data, it seemed 
that the quality of included definitions did not impact operationalization of 
TR-AD. 
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A limitation in this study was that although integration of the definitions 
was done systematically the final consensus definition could still reflect 
some subjective choices by the authors of the current study. Furthermore, 
it was apparent that some criteria might have been underreported in the 
included studies, for instance on minimal treatment duration in CBT. Another 
limitation in our methodology was the lack of studies that incorporated 
evaluation of pseudo-resistance into their TR-AD definitions. Pseudo-
resistance refers to any non-response in treatments that are not employed 
to their full potential. Before treatment resistance can be deemed present, 
pseudo-resistance should always be ruled out. In pharmacotherapy trials 
this could be due to a wrong indication, an inadequate dosage or inadequate 
duration.3,35 In psychotherapy trials this could be due to clinicians not 
following the treatment protocol or patients not being compliant with 
homework assignments.3,12 In addition to this, in clinical care it should 
always be assessed whether the anxiety disorder diagnosis is incorrect, 
whether another comorbid disorder is the primary problem or whether there 
are exogenous factors like caffeine overuse, alcohol or substance use or 
medical diagnoses that contribute to treatment resistance.3,35 Also, in some 
studies it was not possible to assess whether previous treatment failures 
that were counted towards presence of TR-AD consisted of evidence-based 
anti-anxiety treatments. Finally, although psychological treatments like CBT 
were repeatedly proven effective in Anxiety Disorders,14,93 in many parts of 
the world they are not readily available.94 Therefore, generalizability of our 
findings may be limited in these regions.
Furthermore, for the purpose of this study we regarded TR-AD, “refractory 
anxiety” and other related terms as synonyms. Even though this approach 
is in line with the majority of the studies, a minority consider TR-AD and 
“refractory anxiety” to be different entities. For instance, in a Cochrane 
review, Ipser et al. (2006) propose the term TR for Anxiety Disorder patients 
who failed one pharmacologic treatment, whereas “refractory anxiety” 
refers to Anxiety Disorder patients with more than one failed treatment.95 
Their approach can be viewed as a staging approach, distinguishing patients 
with end-stage TR-AD disorders from those with early stage TR-AD. This 
approach is also advocated by Cosci & Fava (2013), who propose a staging 
model for TR Panic Disorders.44 In their model, the level of TR increases 
when more treatment regimens within pharmacologic, psychological and 
combination treatment have failed. In a number of treatment algorithms, 
a stepped care approach hints to the author’s underlying assumption of 
a staging model for levels of TR.49 In staging models, treatment decision 
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making is based on the stage of disease progression in which the patient 
currently is classified. This could lead to evidence-based stepped-care 
treatment algorithms. We did not incorporate this staging paradigm for TR-
AD into the current paper, as no consensus exists for definitions of TR-AD, 
nor for staging approaches in TR-AD. 
Future studies could empirically investigate the consensus definition for TR-
AD. A first step could be to apply the proposed TR-AD definition to an Anxiety 
Disorder cohort and evaluate the longitudinal course of patients with TR-
AD compared to patients without TR-AD. Possibly, this could also yield risk 
factors for development of TR-AD. Further research could also focus on the 
validity of a staging approach in TR-AD, as suggested by Cosci & Fava (2013) 
and Ipser et al. (2006).44,95
In depression, a staging paradigm for TR is in use with the Maudsley Staging 
Method.23,96,97 A similar approach could be beneficial for Anxiety Disorders. 
The criteria comprising TR-AD that were described in the current paper could 
be studied on their merits as individual components in a staging method for 
TR-AD, to reflect the various degrees of TR-AD. 
Conclusions
The majority of studies on treatment resistant Anxiety Disorders (TR-AD) do 
not demarcate this phenomenon. Across studies that do provide a definition 
for TR-AD there are many inconsistencies, which are likely to halt progress 
in Anxiety Disorder research. The current systematic review integrated the 
current literature into a consensus definition for TR-AD (see Panel 2). This 
consensus definition should be regarded as a first step to advance the field 
further. The definition provided in this paper could contribute in harmonization 
of the process of evaluating presence of TR-AD, which is a necessary first step 
towards improvement of the prognosis for TR-AD patients.
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Abbreviations used in eTables
ACT Acceptance and Commitment Therapy MGHAP CGI-S  Massachusetts General Hospital 
Anchored Panic CGI-S
ADs antidepressants MI  Mobility Inventory
BDZ Benzodiazepine na  not available
CAS+PA Clinical Anxiety Scale with panic attacks OCD  Obsessive Compulsive Disorder
CAU care as usual OQ-45.2  outcome measure 45.2
CBT Cognitive Behavioral Therapy PAS  Panic and Agoraphobia Scale 
CGI-I Clinical Global Impression Improvement Scale PD   Panic Disorder (with or without 
agoraphobia)
CGI-S Clinical  Global Impression Severity Scale PDSS  Panic Disorder Severity Scale
DSM-IV Diagnostic and Statistical Manual, fourth edition PSQ  Panic Self Questionnaire
ECT Electroconvulsive therapy PTSD  Post Traumatic Stress Disorder
ER  extended release RCT  randomized controlled trial
FU follow-up refr  refractory
GAD Generalized Anxiety Disorder SAD  Social Anxiety Disorder
GAF Global Assessment of Functioning SCL-90-R  Symptom Checklist-90, Revised
HAM-A Hamilton Anxiety Rating Scale SDS  Sheehan Disability Scale
HAM-D Hamilton Depression Rating Scale SNRI   selective Serotonin and 
Norepinephrine Reuptake Inhibitor
H high SP  Specific Phobia
IIP-64 Inventory of Interpersonal Problems SRI  Serotonin Reuptake Inhibitor
L low SSRI   Selective Serotonin Reuptake 
Inhibitor
LSAS Leibowitz Social Anxiety Scale TCA  Tricyclic Antidepressant 
M medium TR  treatment resistant
MAO-I Monoamine Oxidase inhibitor XR  extended release
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eTable 2. Study characteristics for included reviews, treatment guidelines and book 
chapters.
Authors, year of 
publication
Study design Population Study description
Bakker, Van Balkom, & 
Stein, 2005
Narrative review Treatment refractory PD Examines first-line pharmacotherapy, optimal 
duration of maintenance pharmacotherapy, and 




Book chapter Non-responsive GAD Examines first-line pharmacotherapy, optimal 
duration of treatment, and best interventions 
after non-response of first-line and second-line 
treatments in GAD patients
Bandelow, Zohar, 
Hollander, Kasper, & 
Moller, 2002
Guideline GAD, PD, SAD, SP, OCD and 
PTSD
Guideline for the pharmacological treatment of GAD, 
PD, SAD, SP, OCD and PTSD
Bandelow, 2008 Guideline GAD, PD, SAD, SP, OCD and 
PTSD
First revision of a guideline for the pharmacological 
treatment of GAD, PD, SAD, SP, OCD and PTSD
Bandelow et al., 2008 Narrative review GAD, PD, SAD and OCD Summary of pharmacological treatment 
recommendations for GAD, PD, SAD and OCD
Bystritsky, 2006 Narrative review TR GAD, PD, SAD and OCD Reviews reasons for TR and strategies for improving 
outcome in TR patients
Chen & Tsai, 2016 Narrative review TR PD Presents definitions, risk factors, pathophysiology 
hypotheses and therapeutic strategies for TR PD
Cosci & Fava, 2013 Systematic 
review 
PD Synthesizes 78 studies to describe the different 
models of staging currently known in clinical 
psychology and psychiatry (including a staging 
model for panic disorder)
Deligiannidis & 
Rothschild, 2010
Book chapter GAD, OCD, PTSD, bipolar 
disorder, depressive disorders
Reviews the evidence base for the use of 
antipsychotic medication in this population
Holt & Lydiard, 2007 Narrative review PD Reviews the pathophysiology, existing and emerging 
treatment options and strategies for optimizing 
treatment response in PD and presents a diagnostic 
approach for unresponsive PD
Lorenz, Jackson, & 
Saitz, 2010
Narrative review TR GAD Reviews the safety and efficacy of atypical 
antipsychotics as augmentation to pharmacotherapy 
in TR GAD patients
National Institute for 
Health and Clinical 
Excellence, 2011
Guideline GAD and PD Treatment guideline for PD and GAD patients
Pollack, 2009 Narrative review GAD Summarizes clinical and demographic 
characteristics and pharmacotherapeutic strategies 
for GAD
Samuel, Zimovetz, 




GAD Reviews eight studies with regard to efficacy and 
safety of treatments for refractory GAD
Starcevic, 2008 Narrative review PD Reviews developments and future challenges in the 
treatment of PD
Stein et al., 2001 Algorithm SAD Primary care pharmacotherapy algorithm for SAD
Stein et al., 2010 Algorithm SAD Updated version of a primary care pharmacotherapy 
algorithm for SAD
104
Authors, year of 
publication
Study design Population Study description
Stein, 2003 Algorithm GAD, PD, SAD, OCD and PTSD Pharmacotherapy algorithm for GAD, PD, SAD, OCD 
and PTSD
Stein, 2004 Algorithm GAD, PD, SAD, OCD, PTSD, 
MDD
Primary care pharmacotherapy algorithm for MDD, 
GAD, PD, SAD, PTSD and OCD
Van Ameringen, 
Mancini, & Patterson, 
2009
Book chapter SAD and SP Overview of efficacy of pharmacological treatments 
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A clinical staging approach to 
improving diagnostics in anxiety 
disorders: is it the way to go?
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Clinical staging is a paradigm in which stages of disease progression are 
identified; these, in turn, have prognostic value. A staging model that 
enables the prediction of long-term course in anxiety disorders is currently 
unavailable but much needed as course trajectories are highly heterogenic. 
This study therefore tailored a heuristic staging model to anxiety disorders 
and assessed its validity.
Methods
A clinical staging model was tailored to anxiety disorders, distinguishing 
nine stages of disease progression varying from subclinical stages (0, 1A, 
1B) to clinical stages (2A-4B). At-risk subjects and subjects with anxiety 
disorders (n = 2,352) from the longitudinal Netherlands Study of Depression 
and Anxiety (NESDA) were assigned to these nine stages. The model’s 
validity was assessed by comparing baseline (construct validity) and two-
year, four-year and six-year follow-up (predictive validity) differences in 
anxiety severity measures across stages. Differences in depression severity 
and disability were assessed as secondary outcome measures.
Results
Results showed that the anxiety disorder staging model has construct 
and predictive validity. At baseline, differences in anxiety severity, 
social avoidance behaviors, agoraphobic avoidance behaviors, worrying, 
depressive symptoms and levels of disability existed across all stages (all 
p-values <0.001). Over time, these differences between stages remained 
present until the six-year follow-up. Differences across stages followed a 
linear trend in all analyses: higher stages were characterized by the worst 
outcomes. Regarding the stages, subjects with psychiatric comorbidity 
(stages 2B, 3B, 4B) showed a deteriorated course compared with those 
without comorbidity (stages 2A, 3A, 4A). 
Conclusions
A clinical staging tool would be useful in clinical practice to predict disease 
course in anxiety disorders. 
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Introduction
Anxiety disorders are characterized by highly heterogenic course 
trajectories. The longitudinal course of anxiety disorders is characterized 
as “chronic” in almost 60% of the cases after two years 1 and in 20% to 60% 
of the cases after 12 years.2 In contrast, another subset of anxiety disorder 
patients experience a mild course with moderate symptom severity and lower 
subjective need for care.1,3 Information on prognosis is essential to tailor 
treatment to individual needs. However, such information is not provided by 
a DSM classification. Any tool that contributes to course prediction in anxiety 
disorders would be of great clinical relevance.4–6
In clinical staging, stages are distinguished that reflect increasing levels 
of disease progression. Disorders of individual patients are assigned 
to a certain stage according to their risk profile. One of the most widely 
recognized clinical staging models for psychiatric disorders is the heuristic 
model developed by McGorry and colleagues.7,8 This model covers the 
spectrum from asymptomatic, at-risk subjects (stage 0) to severe, chronic 
illness (stage 4). This model showed some promise in predicting the 
longitudinal course in adolescents seeking help for a variety of psychiatric 
disorders and in adults with major depressive disorder.8,9 A study in young 
adults who presented with social anxiety showed clinical applicability.10 
Until now, no staging model has been studied empirically in adult patients 
with anxiety disorders.
In this study, we tailored McGorry’s staging model to anxiety disorders 
and examined its validity in a heterogeneous anxiety disorder sample. For 
a staging model to be valid, two assumptions must be met: (i) with each 
successive stage, probabilities of unfavorable disease markers should 
increase; (ii) with each successive stage, longitudinal course should 
worsen.4 The first assumption was tested cross-sectionally (construct 
validity), while the second assumption was tested with longitudinal data 
(predictive validity). In these comparisons, we distinguished two sets of 
validators: (a) anxiety severity measures and (b) general psychopathology 
measures. These sets of validators were chosen as the symptoms for anxiety 
disorders often overlap with those in other common mental disorders. We 
hypothesized that distributions of construct and predictive validators in 
our model would show linearity across stages with increasing baseline and 
follow-up severity in higher stages. This would implicate that the model is 
valid. If a staging model in anxiety disorders appears to be valid, treatment 
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guidelines could be improved by differentiating treatment according to the 
level of disease progression (e.g. Andrews et al., 2018; Bandelow et al., 
2008; National Institute for Health and Clinical Excellence, 2013).11–13 
Methods 
Sample
Data were derived from the Netherlands Study of Depression and Anxiety 
(NESDA), a naturalistic longitudinal cohort study, using a sample (n = 2,981) 
that is representative of the various developmental stages of depression and 
anxiety. An extensive description of the study design for NESDA is provided 
elsewhere.14 
For the purpose of this study, we included subjects with anxiety disorders 
(n = 1,305). Subjects without anxiety disorders were included if they had 
risk factors for development of anxiety disorders (n = 1,115: see below for 
definition). Healthy controls without risk factors were excluded (n = 156). 
Subjects with a diagnosis of major depressive disorder (MDD) were excluded 
if they did not have an anxiety disorder (n = 396). Subjects with missing data 
(n = 77) were also excluded. The total sample size for this study was n = 
2,352. Of these, 2,042 (86.8%) were reassessed after two years (T2), 1,895 
(80.6%) after four years (T4) and 1,772 (75.3%) after six year of follow-up 
(T6). 
Measurements
Clinical staging model 
The present study was based on a staging model developed by McGorry 
and colleagues, which we tailored to anxiety disorders.7,8 The subjects were 
assigned to a certain stage in the staging model, based on their baseline 
measurements. The different stages included stage 0 (asymptomatic), 1A 
(nonspecific symptoms), 1B (attenuated syndromes), 2A (discrete disorder), 
2B (discrete disorder with comorbidity), 3A (intermittent symptoms), 3B 
(intermittent symptoms with comorbidity), 4A (chronic symptoms), and 4B 
(chronic symptoms with comorbidity). 
Stages 0, 1A and 1B were labelled “subclinical” stages and were assigned in 
subjects without DSM-IV anxiety disorders but who did have at least one risk 
factor for developing an anxiety disorder. Three risk factors for developing 
an anxiety disorder were derived from the literature: lifetime history of 
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anxiety disorders,15,16 exposure to childhood trauma,15,17,18 and family history 
for psychiatric disorders.15,19 Stage 0 was assigned to subjects with low 
symptom severity, stage 1A to subjects with mild to moderate symptom 
severity, and stage 1B to subjects with moderate to severe symptom severity. 
Table 1. Adaptation of the staging model.
Stages 
Hickie et al.:
Definition: Adapted stages for 
anxiety disorders:
Assignment criteria:
Stage 0 ‘asymptomatic subjects’, at risk, 
no current anxiety symptoms
Stage 0 Presence of anxiety disorder risk factor ¤ 
Absence of anxiety disorder
Low anxiety severity §
Stage 1A ‘help-seeking’, nonspecific 
symptoms of mild to moderate 
anxiety.
Stage 1A Presence of anxiety disorder risk factors ¤ 
Absence of anxiety disorder
Mild to moderate anxiety severity §
Stage 1B ‘attenuated syndromes’, specific 
symptoms of for instance 
severe anxiety or moderate 
depression.
Stage 1B Criteria for stage 1A, but with moderate to 
severe anxiety severity § 
Stage 2 ‘discrete disorders’.
Stage 2A  
no comorbid disorders
Stage 2B  
comorbid disorder 
present
Presence of at least one anxiety disorder
No chronic duration (<30% of the time presence 
of symptoms during 4 years before baseline)
Criteria for stage 2A, with comorbid current 
MDD, Dysthymia or Alcohol Dependency
Stage 3 ‘intermittent or persistent disorder’





Presence of at least one anxiety disorder
intermittent symptoms (30-80% of the time 
presence of symptoms during 4 years before 
baseline)
Criteria for stage 3A, with comorbid current 
MDD, Dysthymia or Alcohol Dependency
Stage 4 ‘severe, chronic and unremitting illness’
Stage 4A  
no comorbid disorders
Stage 4B  
comorbid disorder 
present
Presence of at least one anxiety disorder
Chronic course (>80% of time presence of 
symptoms during the 4 years prior to baseline 
measurement)
Criteria for stage 4A, with comorbid current 
MDD, Dysthymia or Alcohol Dependency 
This model was derived from I.B. Hickie, E.M. Scott, D.F. Hermens, et al. Applying clinical staging to young people who 
present for mental health care. Early Interv. Psychiatry. 7 (2013) 31–43. 
¤ Anxiety disorder risk factors were either a positive family history for psychiatric disorders (family tree method) (Fyer 
& Weissman 1999)1998: Am. J. Med. Genet. (Neuropsychiatr. Genet., traumatic life events in youth (Childhood Trauma 
Inventory) (Graaf et al. 2002), or lifetime diagnosis of anxiety disorder, currently in remission (CIDI) (World Health 
Organization 1998). 
BAI = Beck’s Anxiety Inventory, PSWQ = Penn State Worry Questionnaire, FQ (So) = Fear Questionnaire, social phobia 
subscale, FQ (Ag) = Fear Questionnaire, agoraphobia subscale, MDD = Major Depressive Disorder. 
§ Cut-off values anxiety severity, low: BAI <10 and PSWQ <24 and FQ (Ag) <15 and FQ (So) <12; mild to moderate: BAI 
10<30, or PSWQ 24<39, or FQ (Ag) 15<19, or FQ (So) 12<18; moderate to severe: BAI ≥30, or PSWQ ≥39, or FQ (Ag) ≥19, 
or FQ (So) ≥18. 
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Stages 2 through 4 were labeled the “clinical” stages. We assigned subjects 
to stages 2, 3 or 4 when they had any current DSM-IV anxiety disorder: either 
panic disorder, panic disorder with agoraphobia, agoraphobia, generalized 
anxiety disorder or social anxiety disorder. Subjects with a non-chronic 
duration prior to baseline measurements were assigned to stage 2, subjects 
with an intermittent duration prior to baseline measurements to stage 3, and 
subjects with a chronic duration prior to baseline measurements to stage 
4. We adapted McGorry’s model to account for the presence of psychiatric 
comorbidity (e.g. MDD, alcohol dependency) for two reasons. First, anxiety 
often co-occurs with these comorbidities,20 and second, these comorbidities 
strongly predict a worse course in anxiety disorders.1,2 Subjects with 
comorbid MDD, dysthymia or alcohol dependency were assigned to ‘B’ 
substages. See Table 1 for explicit assignment criteria and Figure 1 for a 
flowchart. See the supplementary materials for full information on the 
measurement instruments as well as the rationale behind the cut-off values 
used in stage assignment. 
Instruments used for stage assignment
The World Health Organization (WHO) Composite International Diagnostic 
Interview (CIDI, version 2.1) was used at baseline to assess lifetime history 
of anxiety disorders, family history for psychiatric disorders, presence of 
DSM-IV panic disorder, panic disorder with agoraphobia, agoraphobia, 
generalized anxiety disorder, social anxiety disorder, MDD, dysthymia 
and alcohol dependency (six-month recency) and age of onset for these 
disorders. The CIDI is a structured interview with good reliability and 
validity.21
Duration of anxiety and avoidance symptoms during the last four years prior 
to baseline were assessed with the Life Chart Interview (LCI), a structured 
retrospective interview using a calendar approach.22 The LCI has adequate 
reliability and validity.23 We calculated proportional scores reflecting the 
duration of anxiety or avoidance symptoms: “not chronic” (<30% of months 
in previous four years), “intermittent” (30-80% of months in previous four 
years) and “chronic” (>80% of months in previous four years). 
Validators
Two sets of outcome measures were used to assess construct and predictive 
validity: (i) anxiety severity measures (main outcome measure), and (ii) 
general psychopathology measures (depression severity and disability: 
secondary outcome measure). The latter were included since longitudinal 
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anxiety course is known to show high levels of comorbidity with depression 
and because remission of symptoms does not always indicate that the 
subject has recovered from the disability.20,24–27
Construct validation
Baseline measures were used to assess construct validity. Severity of 
anxiety was measured with the Beck Anxiety Inventory (BAI), a 21-item 
self-report questionnaire.28 Severity of avoidance behaviors was measured 
with the Fear Questionnaire (FQ), a 15-item self-report questionnaire.29 
For the purpose of this study, two of its subscales were used: agoraphobic 
avoidance (FQ Ag) and social avoidance (FQ So). Severity of pathological 
worrying was assessed using the 11-item self-report version of the Penn 
State Worry Questionnaire (PSWQ).30 Depressive symptoms were measured 
with the Inventory of Depressive Symptomatology-SR (IDS), a self-report 
questionnaire on severity of depression.31 Levels of disability were measured 
with the WHO Disability Assessment Schedule (WHO DAS II), a 36-item self-
report questionnaire measuring levels of disability.32
Predictive validation
At two-year, four-year and six-year follow-up, all these measurements were 
repeated to assess predictive validity. Furthermore, at these timepoints, 
presence of any anxiety disorder and presence of any psychiatric disorder 
(either anxiety disorder, MDD, dysthymia or alcohol dependency) were used 
to assess predictive validity. 
Statistical analyses
Construct validity analyses
After assigning subjects to stages, baseline clinical characteristics and 
construct validators in our sample were compared using Pearson chi-
squared statistics for dichotomous variables and one-way ANOVAs for 
continuous variables. Additionally, Mantel Haenszel’s trend analyses and 
(Wilcoxon-type of) nonparametric tests for trend across ordered groups 33 
were performed to investigate whether an increase across stages could be 
demonstrated while taking the ordinal distributions of the staging model into 
account. We applied Bonferroni correction (α(corrected) = α/k hypotheses) 
for the ten construct-validator statistical tests. This yielded an α(corrected) 
of 0.05/10 = 0.005. To ensure that attrition from the cohort did not lead to a 
power problem, the number of events per variable (EPV) at two-year, four-
year and six-year timepoints were calculated for the main outcome measure. 
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Predictive validity analyses
Binary measures (e.g. presence of anxiety disorder) were linked to the 
staging model by fitting generalized estimating equations (GEE) models 
with an exchangeable correlation structure to longitudinal data (T2, T4 and 
T6), estimating effects for stages (categorical), time-points (categorical) 
and for all stage*time-point interactions. We adjusted these for baseline 
age because age was correlated with the pre-baseline duration of anxiety: 
younger subjects had lower duration of anxiety. From these models, odds-
ratios (ORs) for presence of diagnoses at successive time-points for different 
stages were derived using the combined subclinical stages 0-1B at two-year 
follow-up as reference. For continuous measures (e.g. anxiety severity) 
linear mixed models were used. While GEE and mixed model analyses are 
quite similar, mixed models perform better in linear analyses in cases of 
incomplete data.34 In these models, fixed effects for stages (categorical), 
time-points (categorical) and for all stage*time-point interactions were 
estimated while adjusting for age. These models included a random 
intercept. From these models, expected severity scores at successive time-
points for each stage were derived. 
Sensitivity analysis
Inclusion of any predictors used in stage assignment would only be justified 
when each showed predictive power. To check this, a multivariable logistic 
regression model that incorporated all stage-assignment variables 
independently was made to predict two-year presence of anxiety disorders. 
We hypothesized that all variables that were used in stage assignment 
were significant predictors of longitudinal course when adjusted for other 




Table 2 shows baseline demographics and clinical characteristics, stratified 
per stage. Gender, age, and education years were unevenly distributed 
across stages. The number of years of education attained was lower 
in higher stages (p<0.001). For most clinical characteristics, a pattern 
indicating a higher severity in higher stages was present. The exceptions 
were age of onset and presence of panic disorder without agoraphobia, 
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most prevalent comorbidity (82.2-89.4%), followed by alcohol dependency 
(29.1-33.1%) and dysthymia (11.2-38.9%). Presence of MDD and alcohol 
dependency was evenly distributed across stages 2B, 3B and 4B, whereas 
dysthymia was more prevalent in higher stages (linear trend Χ2(1) = 55.3, 
p<0.001). Furthermore, subjects in higher stages had greater chances of 
receiving current psychiatric treatments (Table 2). Percentages of subjects 
receiving treatment were highest in the comorbidity stages 2B, 3B, 4B (57.7-
59.9%). 
Construct validation
We tested the assumption that with each successive stage at baseline, 
probabilities of unfavorable disease markers would increase. In all anxiety 
measures, this dose-response pattern was found; namely, increasing anxiety 
severity in higher stages. After Bonferroni correction, linear trends were 
significant for all construct validators. The only exception was stage 4A, 
which was associated with levels of severity comparable to subjects in stage 
3A; for example, mean anxiety severity in stage 3A = 15.9 (SD = 9.24), in stage 
4A = 16.2 (SD = 11.1); mean social avoidance in stage 3A = 14.5 (SD = 9.45), in 
stage 4A = 14.7 (SD = 9.31). For the general psychopathology measures, the 
patterns were somewhat different. There was a gradual increase in levels of 
general psychopathology until stage 3, after which they remained constant. 
As expected, comorbidity stages (2B, 3B and 4B) all showed substantially 
higher baseline severity scores than non-comorbid stages (2A, 3A and 4A). 
See Table 2 for means and standard deviations of these measures across 
stages at baseline. 
Predictive validation
The second assumption we tested was that with each successive stage, 
longitudinal course would worsen. At two-year follow-up, proportions 
of subjects with an anxiety disorder ranged from 2.7% (stage 0) to 68.0% 
(stage 4B). At four-year follow-up, anxiety disorders were present in 3.0% 
(stage 0) to 59.0% (stage 4B), at six-year follow-up in 3.1% (stage 0) to 
55.1% (stage 4B). These were incident disorders, recurrent disorders and 
persistent disorders. This amounts to 78.4 (two-year) to 47.5 (six-year) 
events per variable (EPV). For all stages, proportions of anxiety disorders 
were lowest at six-year follow-up, followed by four-year and two-year 
follow-up. Figure 2 shows GEE derived age-adjusted ORs for presence of 
follow-up anxiety disorders at different time-points, using the combined 
subclinical stages (0-1B) as comparison. Odds for having an anxiety disorder 
at follow-up followed a linear trend, with higher stages being at higher risk: 
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at six-year follow-up, presence of anxiety disorders for stage 4B: OR = 11.8 
(95%CI: 8.39-16.6), stage 4A: OR = 6.27 (95%CI: 4.10-9.58), stage 3B: OR = 
5.60 (95%CI: 3.84-8.15), stage 3A: OR = 5.52 (95%CI: 3.31-9.21), stage 2B: 
OR = 3.30 (95%CI: 2.25-4.85), and stage 2A: OR = 2.45 (95%CI: 1.48-4.04) 
(see fig. 2A). This pattern was also present after two-year and four-year 
follow-up (fig. 2A). 
Figure 2. Odds Ratios (bars representing 95% CI) for presence of any anxiety disorder 
(A) and any psychiatric disorder (B) at 2, 4 and 6-year follow-up with combined 













Proportions of subjects having any psychiatric disorder at follow-up ranged 
from 6.5%-8.2% (stage 0) to 68.6%-81.8% (stage 4B). The same pattern as 
seen with anxiety disorder diagnoses emerged, with the difference that the 
comorbid stages (2B, 3B, 4B) consistently had the highest odds for having 
any psychiatric disorder at follow-up (see fig. 2B). For instance, at six-year 
follow-up, the OR for presence of any psychiatric disorder for stage 4B was 
10.7 (7.70-15.0), for stage 4A OR = 4.47 (95%CI: 3.00-6.65), stage 3B OR = 
6.82 (95%CI: 4.81-9.67), stage 3A OR = 3.93 (95%CI: 2.44-6.41), stage 2B 
OR = 3.59 (95%CI: 2.58-5.00), stage 2A OR = 1.83 (95%CI: 1.17-2.85). See 
eTable 1 for full GEE models.
Subjects in stage 0 had consistently low mean anxiety, depression and 
disability scores over time. For example, the mean estimated BAI score for 
stage 0 at baseline = 2.82 (95%CI: 2.16-3.48), at T2 = 2.98 (2.29-3.67), at T4 
= 3.04 (2.35-3.74), at T6 = 3.38 (2.67-4.08) (see fig. 3A). The mean anxiety, 
depression, and disability scores in all other stages were significantly higher 
in comparison with stage 0 (all p<0.01). Estimated means for stages 1B 
and 2A were not statistically different. Stages 2B, 3A and 4A did not differ 
significantly with regard to estimated mean anxiety, pathological worrying 
and social avoidance over time, but these stages all had lower scores over 
time than stage 3B (see figs. 3A-C). Estimated mean agoraphobic avoidance 
scores over time were most closely related to successive stages (see fig. 
3D). The estimated mean levels of disability and depression over time 
were significantly higher in the comorbidity stages (2B, 3B, 4B) than in the 
anxiety-only stages (2A, 3A, 4A) (see fig. 3E-F). 
Sensitivity analysis
All included predictors uniquely contributed to the prediction of presence 
of two-year follow-up anxiety disorders (all p-values <0.001: see e-table 2, 
model 1). Anxiety severity was the strongest predictor (OR for moderate to 
severe anxiety = 6.36 (95% CI: 4.00-10.0), while comorbidity had a relatively 
modest effect: OR = 1.49 (95% CI: 1.19-1.92). However, it should be noted that 
the effect of comorbidity on longitudinal course existed independently of other 
predictors. Therefore, the predictors used in the current staging algorithm are 
all deemed important individual predictors for anxiety course trajectories. 
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Figure 3. Estimated mean severity of anxiety (panel A), pathological worrying (panel 
B), social avoidance (panel C), agoraphobic avoidance (panel D), disability (panel F), 






In this study, we tailored McGorry’s clinical staging model to anxiety 
disorders and tested its construct and predictive validity in a heterogeneous 
anxiety disorders sample. First, the presence of construct validity was 
confirmed by showing that probabilities of unfavorable disease markers 
increased with each successive stage in the model. This suggests that 
this staging model is able to distinguish subgroups with increasing levels 
of disease progression. Second, predictive validity was demonstrated by 
worsening follow-up outcomes up to six years in higher baseline stages. 
All associations followed linear trends: severity of anxiety, depression, and 
disability increased in higher stages. This implies that the process of staging 
can have value in long-term course prediction in anxiety disorders. It could 
thus be used as a tool to inform patients about their probable long-term 
prognosis. Some instructions for use in clinical practice are provided in the 
supplement. This model could therefore make an important contribution 
towards the goal of personalized medicine in anxiety disorders. 
Different patterns emerged when comparing the different sets of validators: 
mean values for the anxiety measures followed the successive ordering of 
stages in the staging model more closely than the mean values of the general 
psychopathology measures. Subjects in the comorbidity stages (2B, 3B, 4B) 
had a worse overall longitudinal course compared with those in stages 2A, 
3A and 4A. This corroborates the conclusion of other longitudinal studies 
that presence of comorbidity is associated with poorer long-term outcome.20 
The data suggest that, in all stages, comorbidity impacted the outcome in 
similar ways: each “B” stage showed worse severity and longitudinal course 
in comparison with its “A” counterpart. Additionally, in some validators, 
presence of psychiatric comorbidity seemed to have a higher impact in 
comparison with anxiety duration. For instance, disability and depressive 
symptoms over a six year span were most prominent in stages 2B, 3B and 4B, 
whereas anxiety severity, pathological worrying and social avoidance over a 
six year span were most impaired in stage 4B followed by 3B.
Limitations
The current study had several limitations. First, associations between the 
staging model and the validators were not perfectly linear; for instance, 
stages 3A and 4A showed similar symptom severity at baseline and at follow-
up. This could imply that the criteria for stage assignment were not optimal 
and should be fine-tuned. For instance, in a previous study, threshold social 
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anxiety disorder in young adults was sometimes assigned to stage 1B in 
instead of stages 2 and onwards, as social anxiety disorder is hypothesized 
to be an early stage that will develop into more severe syndromes in a 
later stage.10 Second, the current study was limited by the inclusion of only 
five DSM-IV anxiety disorders. The presence of specific phobias was not 
assessed, even though it was shown that these disorders may serve as 
predictors of worse overall longitudinal course.35 However, the simultaneous 
assessment of the anxiety disorders that were included is warranted, 
as these disorders share genetic vulnerability,36 are highly comorbid,20 
generally show a comparable course,1 and show diagnostic instability over 
time.24,25 Third, from a methodological perspective, the current results might 
represent an overestimation (i.e. optimism). Applying another external 
validation dataset or applying a bootstrapping approach might have resulted 
in more modest estimations on predictive power. However, the lowest EPVs 
in any of our binary predictive analyses were well above the suggested 
threshold of 20.37 As EPVs in our study were high, optimism is likely to be 
small. Furthermore, it remains unclear whether the current clinical staging 
model will be associated with underlying pathophysiological processes 
involved in etiology of anxiety disorders. Possibly, stage assignment criteria 
need to be refined to reflect underlying disease processes in the future. 
Finally, one of the major goals of clinical staging models is to derive more 
targeted interventions that prevent progression across stages of anxiety 
disorders.38 However, we were not able to test the applicability of the current 
model in treatment decision-making, because NESDA is a naturalistic cohort 
study. This should be a priority in future research as increasing knowledge 
of effective stage-specific treatments can contribute significantly to the 
development of personalized medicine.
Future research
In staging models for depressive and bipolar disorders, anxiety disorders are 
viewed as a nonspecific prodromal phase, which could function as a gateway 
to development of these end-stage syndromes.39 Conceptually, staging 
models for different end-stage syndromes can include similar nonspecific 
prodromal stages as this is in line with the transdiagnostic assumptions 
underlying staging models.4,40 This implies that a person with subthreshold 
anxiety symptoms is considered to be at stage 1 of both an anxiety disorder and 
a bipolar disorder staging model. Further research should identify profilers 
that critically determine the pathways to various end-stage syndromes. 
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In this tailored staging model, patients with remitted anxiety disorder were 
assigned to a subclinical stage, making the model bidirectional. Due to 
the “waxing and waning” longitudinal course of anxiety disorders, such a 
bidirectional model is most likely to fit best.41 On the other hand, it is also 
plausible that patients with multiple episodes of anxiety disorders have 
a less favorable prognosis, suggesting a one-directional model. Future 
studies could compare bidirectional to one-directional staging models in 
anxiety disorders. 
In our adaptation of McGorry’s clinical staging model, comorbidity was 
added as “B” substages. The current results suggest that this approach 
is valid. However, future studies could compare anxiety disorder staging 
models with and without comorbidity substages, or with a different role in 
stage assignment for presence of comorbidity, to evaluate this approach 
further. The current model could be refined by studying anxiety disorder 
relapses in subjects after remission. Supplementary validation of the current 
staging model could also be carried out by prospectively applying it to an 
anxiety disorders cohort, as is done in youth mental health care.8,42 
Improving longitudinal course predication in anxiety disorders might also 
be possible using other methodological approaches,4,43,44 such as machine 
learning algorithms,45 or network analysis.46 The advantage of clinical 
staging over these alternative approaches, however, is its reliance on simple 
clinical parameters that both clinicians and patients are familiar with.7 
Additionally, staging models are widely used in other fields of medicine, 
which improves familiarity of patients and clinicians with these models and 
will thus aid their implementation of these models. 
Conclusion
The present study is the first attempt to tailor a staging model to anxiety 
disorders. The results show that such a model could be clinically meaningful. 
In this study, we not only predicted anxiety disorder specific phenomena, but 
also adapted a transdiagnostic view by predicting “any psychiatric disorder” 
at two, four and six years. Both approaches were effective. This suggests 
that, in providing individual course prognosis, not only persistence of anxiety 
disorders should be considered, but also other disorders such as depressive 
disorders and substance-use disorders. If these results could be replicated 
and fine-tuned, clinical stage assignment could improve the diagnostic 
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process of patients with an anxiety disorder. The results from the current, 
first study on staging in anxiety disorders are promising. To evolve the field 
of individualized course prediction and treatment decision-making in anxiety 
disorders, clinical staging could definitely be the way to go. 
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The main aim of the Netherlands Study of Depression and Anxiety (NESDA) 
is unravelling the factors that determine the natural course of depression 
and anxiety. NESDA used a stratified sampling approach, including subjects 
from the community, primary health care and specialized mental health care 
in different regions in The Netherlands. Exclusion criteria included a primary 
diagnosis of other psychiatric disorders, such as psychotic disorders, 
bipolar disorder, posttraumatic stress disorder, or obsessive-compulsive 
disorder. Those with insufficient control of the Dutch language were also 
excluded. At baseline, 2,981 subjects were included. Measurements included 
sociodemographics, clinical characteristics, psychological assessments, 
biological assessments and structured psychiatric interviews assessing 
DSM-IV diagnoses. The Ethical Committee of participating sites approved 
of the study design and all subjects provided written informed consent. An 
extensive description of the study design is provided elsewhere.1
We used data from baseline measurements (2004-2007) and from 2, 4 and 
6-year follow-up measurements. As clinical staging tools were designed to 
assign at-risk subjects and subjects seeking help for mental health issues to 
clinical stages, but not healthy controls 2,3, we included symptomatic subjects 
(presence of any DSM-IV anxiety disorder) and asymptomatic subjects at 
risk for developing an anxiety disorder from the NESDA baseline sample. We 
operationalized this as either having a lifetime diagnosis of an anxiety disorder 
(n=1,772), having been exposed to childhood trauma (n=1,442), or having a 
positive family history for psychiatric disorders (n=2,585), as these factors are 
important predictors of future anxiety disorder development.4–7 In this manner, 
156 healthy controls who did not have risk factors were excluded. 
Non-response was associated with lower years of education (p < 0.001, 
Cohen’s d=0.29), childhood trauma (p<0.001) and lifetime history of anxiety 
disorders (p<0.001). In comparison with clinical stage 0, non-response 
was significantly greater in stages 2A, 2B, 3B, 4A, and 4B, with ORs varying 
between 2.37 (stage 2B) and 2.75 (stage 3B). This introduced a small bias 
towards the null hypothesis. Non-response was not associated with gender, 
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Measurements
Staging model 
Our main independent variable was a new staging model aimed at staging 
subjects with anxiety disorders. McGorry’s generic model 2,3 was adapted 
to derive this staging model. In their generic model, stages are described 
within a transdiagnostic conceptual framework. However, in order to 
assess the staging model empirically, we had to deviate from their model 
in two important ways. First, we chose to investigate anxiety disorders as 
primary end-stage syndromes. Therefore, in our sample we excluded other 
psychiatric end-stage syndromes if anxiety was absent. Second, in order to 
assign subjects to stages, we needed to operationalize the proposed criteria 
in a quantitative manner (see below).
The different stages in this model were stage 0 (asymptomatic), 1A 
(nonspecific symptoms), 1B (attenuated syndromes), 2A (discrete disorder), 
2B (discrete disorder with comorbidity), 3A (intermittent symptoms), 3B 
(intermittent symptoms with comorbidity), 4A (chronic symptoms), 4B 
(chronic symptoms with comorbidity). Various assignment criteria were 
used to assign subjects to our adaptation of McGorry’s model (see Table 1 for 
an overview). 
Subclinical stages
Subthreshold symptoms were permitted in these stages. This was done 
as McGorry’s staging model is aimed at at-risk populations, not healthy 
individuals. Lifetime anxiety disorder diagnoses were assessed using the 
WHO-Composite International Diagnostic Interview (CIDI, version 2.1). The 
CIDI is a structured interview that classifies according to DSM-IV criteria.8,9 
Childhood trauma was assessed in a face-to-face interview, using the 
Childhood Trauma Interview (CTI), which was used before in the Netherlands 
Mental Health Survey and Incidence Study.10 For the purpose of this study, 
childhood trauma was deemed present when subjects experienced at least 
one instance of emotional neglect, psychological abuse, physical abuse or 
sexual abuse before the age of sixteen. Family history for anxiety disorders, 
MDD and alcohol dependency was assessed in a structured manner by 
asking subjects about the possible symptomatology in family members using 
the family tree method 11.
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Distributions across the subclinical stages were made by using severity of 
anxiety, worrying and avoidance behaviors, based on symptom severity cut-
off scores: stage 0 for low symptom severity, stage 1A for mild to moderate 
symptom severity, and stage 1B for moderate to severe symptom severity. 
Severity of anxiety was measured with the Beck Anxiety Inventory (BAI), a 
21-item self-report questionnaire.12. Although the BAI is not a diagnostic 
tool, there is evidence that it may discriminate between subjects with and 
without anxiety disorders. A score below a cut-off value of 10 resulted in a 
negative predictive power of 0.97 for not having an anxiety disorder, whereas 
a score above the cut-off value of 30 resulted in a positive predictive value 
of 0.40 for having an anxiety disorder.13. We regarded a score of <10 as low 
anxiety severity, and one of >30 as moderate to severe anxiety.
Severity of avoidance was measured with the Fear Questionnaire (FQ), a 
15-item self-report questionnaire.14 The FQ reflects the rate of avoidance 
in three subscales: agoraphobia (FQ Ag), social phobia (FQ So) and blood 
injury phobia. The third subscale was omitted for the purpose of this study, 
as specific phobias are not within the scope of this study. Different cut-off 
values were used in the FQ subscales. A study by Schadé et al used more 
lenient cut-off values (<15 for FQ Ag and <12 for FQ So) in comparison with 
the study of van Zuuren (<19 for FQ Ag and <18 for FQ So).15,16 For the purpose 
of this study, we combined the cut-off scores: low avoidance severity was 
defined by scores below the cut-off values by Schadé et al. and moderate to 
severe avoidance was defined by scores above those by van Zuuren.
Severity of pathological worrying was assessed using the 11-item self-
report version of the Penn State Worry Questionnaire (PSWQ).17,18 The PSWQ 
was repeatedly shown to have good reliability and validity.17,19 A total score 
below 24 indicates low levels of pathological worrying, whereas a score 
above 39 indicates severe levels of pathological worrying.20 In summary, the 
three subclinical stages were defined as follows:
low: BAI<10  and PSWQ<24 and FQ (Ag)<15  and FQ (So) <12
mild to moderate: BAI 10<30  or PSWQ 24<39 or FQ (Ag) 15<19  or FQ (So) 12<18
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Clinical stages
To account for differences in number of months in the current calendar year 
that were assessed, number of months were recalculated into proportional 
scores. These proportional scores reflect duration of anxiety disorders: ‘not 
chronic’ (<30% of months), ‘intermittent’ (30-80% of months), and ‘chronic’ 
(>80% of months). These values were chosen to reflect different levels of 
chronicity for anxiety disorders, in order to conform to Hickie’s descriptions 
for each different stage. 
If current MDD, dysthymia or alcohol dependency was present, subjects 
were assigned to the ‘b’ stages 2B, 3B and 4B, otherwise, they were assigned 
to the ‘a’ stages 2A, 3A and 4A. The decision to include the presence of 
comorbid psychiatric disorders as a sub-stage criterium, or ‘profiler’, was 
informed by the high levels of comorbidity between anxiety disorders with 
other common mental disorders, such as depressive disorders and alcohol 
dependence.  As many as 63% of persons with a current anxiety disorder 
also have a current depressive disorder.21 Those with comorbid disorders 
are also burdened by higher degrees of anxiety severity, disability and other 
markers of poor outcome,21,22 making anxiety disorders and depressive 
disorders highly intertwined. As comorbidity is such an essential aspect of 
anxiety disorders, and as staging models aim for a transdiagnostic approach, 
it is in our view essential to include comorbidity into the model. Even though 
we only assessed the staging model at baseline, in our staging model it is 
theoretically possible to decrease in clinical stage after follow-up (i.e.: 
bidirectional). See Table 1 for all assignment criteria and figure 1 for a 
flowchart of inclusion and stage assignment.
Construct validators
In clinical staging, it is assumed that patients with more advanced disease 
are burdened with greater levels of symptomatology. As symptoms in anxiety 
disorders often overlap with those in other common mental disorders, 
we distinguished two sets of validators: anxiety validators and general 
psychopathology validators. The set of anxiety validators consisted of 
four baseline variables: severity of anxiety (BAI), severity of agoraphobic 
avoidance behaviors (FQ), severity of social phobia (FQ), and severity of 
pathological worrying (PSWQ). Incorporating general psychopathology 
validators is in line with earlier research establishing the need to take 
functional recovery into account as an important outcome measure, not only 
remission status of anxiety disorders.23 It also takes diagnostic instability 
within anxiety disorders and between anxiety disorders and depressive 
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disorders into account.24 General psychopathology validators were severity 
of depressive symptoms and levels of disability. Depressive symptoms were 
measured with the Inventory of Depressive Symptomatology-SR (IDS), a 
self-report questionnaire on severity of depression;25 levels of disability 
were measured with the WHO-Disability Assessment Schedule (WHO-DAS 
II), a 36-item self-report questionnaire measuring levels of disability.26 
Predictive validators
Follow-up measurements for the construct validators were used as 
predictive validators. Additionally, presence of DSM-IV anxiety disorders 
(CIDI, see above) and presence of any psychiatric disorder (either anxiety 
disorder, MDD, dysthymia or alcohol dependency; CIDI, see above) were 
used as predictive validators. These validators were measured at 2, 4 
and 6-year follow-up.  It was assumed that worse follow-up outcomes 
on DSM classifications reflect a worse longitudinal course, as these 
represent persistent or relapsed disease. Depressive disorders and alcohol 
dependency were included as general psychopathology validators because 
longitudinal anxiety course is known to show high levels of comorbidity and 
diagnostic instability: during progression of or even after remission of an 
anxiety disorder other psychiatric disorders frequently occur,21,24,27 which 
indicates a poor outcome. In this way it was possible to evaluate the model 
in a transdiagnostic manner. As the main goal of this model is to predict 
longitudinal course of anxiety, anxiety course was regarded our primary 
longitudinal outcome and general psychopathology course a secondary 
longitudinal outcome.
Sample characteristics
A number of demographic and clinical characteristics were assessed in order 
to describe our sample. Age, gender and education level were recorded at 
baseline by using a demographics questionnaire. Whether subjects received 
psychotherapy was assessed with the Perceived Need for Care Questionnaire 
(PNCQ). The PNCQ is a semi-structured interview assessing the current 
mental health care use and patient’s perceived need for mental health care 
interventions,28 and was slightly altered for use in the NESDA study.29 We 
derived data on proportion of subjects currently receiving psychotherapy, 
as defined by at least 5 consultations with a psychologist, psychiatrist, 
psychotherapist or other mental health care worker during the previous 
6 months, as done before.6 The use of psychotropic medication (tricyclic 
antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), 
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inhibitors (MAO-i), and other antidepressants) was assessed via inspection 
of medication containers and via classification according to the Anatomical 
Therapeutic Chemical (ATC) classification. For the purpose of this study, we 
extracted data on frequent use (>50% of days) of any antidepressant. We 




The GEE models were specified by a binomial distribution for the dependent 
variable, a logit link function, an exchangeable correlation structure, and 
were fitted to the longitudinal data of wave T2, T4 and T6 to estimate effects 
of stage (indicators of stages 2A, 2B, 3A, 3B, 4A and 4B with the reference 
group that consisted of the combined stages 0, 1A and 1B), time-points 
(discrete indicators of T4 and T6 with the reference time point T2) and all 
stage*time-point interactions, adjusting for baseline age. This approach 
nullifies selective attrition effects at follow-up by estimating effects for 
each stage, each timepoint, and stage*time interactions in one model. Full 
model details are provided in this supplement (Supplementary Table 7). 
For continuous validators linear mixed models were performed. A 2-level 
model with a random intercept was employed in which subject-identifier 
was the highest level, this way correlations among subjects across follow-
up measurements were taken into account. For continuous outcomes the 
use of an LMM was preferred over the use of GEE because of its superiority 
in handling incomplete datasets.30 We calculated mean values with 95% 
confidence intervals for each stage at each time-point (data for confidence 
intervals available at request). 
Sensitivity analyses
In order to test whether all variables that were included in the staging model 
indeed had a unique contribution to the longitudinal outcome prediction, an 
analysis in which all variables used in stage assignment were included to a 
logistic regression model predicting two-year presence of anxiety disorders. 
In this model we included categorical predictors severity of anxiety, 
according to the cut-off values we used in the staging model. So, like in 
the staging model, we categorized into three groups: low severity, mild to 
moderate severity and moderate to severe. The second categorical predictor 
in this logistic regression model was duration of anxiety and/or avoidance 
symptoms. For this categorical predictor with mutually exclusive groups, the 
same cut-off values that were used in the staging model were used: 
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No anxiety symptoms: subjects without anxiety disorders 
No chronic duration:   <30% of the months presence of anxiety and 
avoidance symptoms during the last four years 
before baseline
Intermittent duration:  30-80% of the months presence of anxiety or 
avoidance symptoms (highest value counts) during 
the last four years before baseline
Chronic duration:  >80% of the months presence of anxiety or avoidance 
symptoms (highest value counts) during the last four 
years before baseline
The other predictors in the logistic model were presence of comorbidity 
(six month diagnoses of major depressive disorder, dysthymia, or alcohol 
dependency), age, gender and education level (years). The combination 
of these variables represent the totality of information used for stage 
assignment. Logistic regression analysis on presence of two-year anxiety 
disorders were performed in order to assess whether all variables used in 
stage assignment have a contribution to course prediction. This was done 
in a multivariable model, to assess each variables’ unique contribution. We 
hypothesized that all variables that were used in stage assignment were 
significant predictors longitudinal course, justifying our decision of using 
them in stage assignment. 
Secondly, logistic regression analysis which included the clinical stages 
as categorical predictor variables were performed. In comparison to the 
first model all other predictors were removed, except for age, gender and 
education level. We hypothesized that if the second model properties would 
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Supplementary results
In eTable 1, the full GEE model can be found. 
As can be seen in eTable 2 (Model 1), all included predictors had a unique 
contribution to prediction of presence of two-year follow-up anxiety 
disorder (all p-values <0.001), while sociodemographic variables did not 
predict anxiety course. Anxiety severity was the strongest predictor (OR for 
moderate to severe anxiety= 6.36 (95% CI: 4.00-10.0), while comorbidity 
had a relatively modest effect: OR=1.49 (95% CI: 1.19-1.92). However, it 
should be noted that the effect of comorbidity on longitudinal course exists 
independently from anxiety severity or duration. Therefore, the presence 
of comorbidity should be considered an important individual predictor for 
anxiety course.
In the second model, all clinical stages predicted two year presence 
of anxiety disorders (all p-values <0.001) and ORs ranging from 6.18 
(stage 1A) to 74.6 (stage 4B). Sociodemographic variables did not predict 
longitudinal course. The c-statistic, which is statistically similar to the Area 
under the curve for predictions based on this logistic regression model, is 
very comparable between these two models: 0.821 (95% CI: 0.802-0.839) 
for Model 1 and 0.815 (95% CI: 0.797-0.834) for model 2. Overall, these 
c-statistic values indicate a good fit (>0.80). The lack of difference between 
the two models indicates that a stratified approach does not lead to loss of 
predictive power.
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eTable 1. Odds Ratio’s estimated from GEE models for presence of any anxiety disorder 
and for presence of any psychiatric disorder. 
Any anxiety disorder Any psychiatric disorder
OR 95%-CI p-value OR 95%-CI p-value
Stage
  stage 0,1A,1B 1.00 1.00
  stage 2A 4.70 (3.11, 7.09) <0.001 3.46 (2.37, 5.06) <0.001
  stage 2B 6.53 (4.64, 9.19) <0.001 7.34 (5.34, 10.11) <0.001
  stage 3A 7.13 (4.43, 11.46) <0.001 4.29 (2.72, 6.76) <0.001
  stage 3B 13.38 (9.43, 18.99) <0.001 12.78 (8.99, 18.17) <0.001
  stage 4A 9.69 (6.54, 14.33) <0.001 6.11 (4.21, 8.87) <0.001
  stage 4B 19.97 (14.28, 27.92) <0.001 21.76 (15.20, 31.14) <0.001
Time
  2 years 1.00 1.00
  4 years 0.77 (0.59, 1.01) 0.055 0.83 (0.68, 1.01) 0.069
  6 years 0.66 (0.50, 0.87) 0.004 0.68 (0.55, 0.85) <0.001
Stage by Time interaction terms
  stage2A*2years 0.81 (0.48, 1.39) 0.449 0.78 (0.48, 1.26) 0.308
  stage2A*4years 0.77 (0.44, 1.37) 0.373 0.77 (0.47, 1.28) 0.317
  stage2B*2years 1.08 (0.70, 1.65) 0.737 0.92 (0.62, 1.35) 0.659
  stage2B*4years 0.75 (0.48, 1.19) 0.224 0.71 (0.48, 1.07) 0.100
  stage3A*2years 1.00 (0.56, 1.81) 0.991 1.25 (0.72, 2.18) 0.422
  stage3A*4years 1.16 (0.63, 2.13) 0.634 1.35 (0.76, 2.38) 0.305
  stage3B*2years 0.82 (0.53, 1.26) 0.354 0.82 (0.54, 1.24) 0.346
  stage3B*4years 0.63 (0.40, 0.99) 0.047 0.78 (0.51, 1.20) 0.259
  stage4A*2years 1.07 (0.66, 1.74) 0.784 1.30 (0.82, 2.05) 0.259
  stage4A*4years 0.99 (0.59, 1.64) 0.958 1.07 (0.67, 1.71) 0.787
  stage4B*2years 0.90 (0.59, 1.36) 0.607 0.59 (0.39, 0.90) 0.013
  stage4B*4years 0.90 (0.59, 1.38) 0.625 0.72 (0.47, 1.10) 0.133
Age/10 0.95 (0.89, 1.02) 0.138 1.00 (0.95, 1.07) 0.895
Constant 0.13 (0.10, 0.19) <0.001 0.21 (0.15, 0.28) <0.001
QIC – null model 7916.282 9345.107
QIC – model with ICS 5305.043 9051.020
QIC – model with ECS 5304.766 6050.778
QIC = model fit in terms of Quasi-likelihood under the Independence model Criterion, ICS = Independent Correlation Structure, 
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eTable 2. Odds Ratio’s estimated from logistic regression analysis models for presence 
of any anxiety disorder at two year follow-up, comparing individual assignment criteria 
with the staging model.
Model 1 Model 2
OR 95% CI df p OR 95% CI df p
constant 0.04 na 1 <0.001 0.04 na 1 <0.001
Age 1.00 (0.99, 1.01) 1 0.72 1.00 (0.99, 1.01) 1 0.65
Gender (ref = male) 1.19 (0.94, 1.52) 1 0.15 1.25 (0.98, 1.59) 1 0.07
Education level 0.98 (0.95, 1.01) 1 0.20 0.98 (0.94, 1.01) 1 0.15
Severity of anxiety: 2 <0.001
Low (ref)
Mild to moderate 3.66 (2.32, 5.79) 1 <0.001
Moderate to severe 6.36 (4.00, 10.1) 1 <0.001
Anxiety/ avoidance duration: 3 <0.001
No anxiety disorder (ref)
Duration <30% 2.57 (1.81, 3.64) 1 <0.001
Duration 30-80% 4.39 (3.04, 6.34) 1 <0.001
Duration >80% 5.81 (4.10, 8.23) 1 <0.001
Presence of comorbidity 1.49 (1.16, 1.92) 1 <0.001
Clinical staging model
Stage 0 (ref) 8 <0.001
Stage 1A 6.18 (3.36, 11.4) <0.001
Stage 1B 9.36 (4.84, 18.1) <0.001
Stage 2A 18.4 (9.67, 34.9) <0.001
Stage 2B 24.5 (13.5, 44.6) <0.001
Stage 3A 27.3 (13.8, 54.0) <0.001
Stage 3B 51.8 (28.3, 94.7) <0.001
Stage 4A 35.8 (19.1, 67.2) <0.001
Stage 4B 74.6 (41.1, 135.4) <0.001
Model properties:
c-statistic 0.821 (0.802, 0.839) <0.001 0.815 (0.797, 0.834) <0.001
1Severity of anxiety was defined by applying validated cut-off values for Beck’s anxiety Inventory (BAI), Penn State Worry 
Questionnaire (PSWQ), Fear Questionnaire agoraphobic avoidance (FQ (Ag)), and Fear Questionnaire agoraphobic avoidance  
(FQ (Ag)). 
2 low:  BAI<10  and PSWQ<24  and FQ (Ag)<15  and FQ (So)<12 
3 mild to moderate: BAI 10<30  or PSWQ 24<39  or FQ (Ag) 15<19  or FQ (So) 12<18
4 moderate to severe: BAI ≥30  or PSWQ ≥39  or FQ (Ag) ≥19  or FQ (So) ≥18.
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Instructions for use in clinical practice
The generic, heuristic staging model that was operationalized and validated 
in the current study is available elsewhere 3. In order to apply the current 
model in clinical practice, a regular clinical assessment should be made by 
the practitioner. In this assessment, three steps should be followed.
1. In persons presenting with anxiety symptoms, first assess the presence 
of DSM 5 anxiety disorders in accordance with guidelines. If any anxiety 
disorder is present, the patient will be assigned to the clinical stages 2, 3 
or 4.  If no anxiety disorder is present, the person will be assigned to the 
subclinical stage (0, 1A, 1B).
2. For patients with a DSM anxiety disorder diagnosis, assess the duration of 
anxiety disorder symptoms.
- If the anxiety disorder symptoms were present for at least 4 out the 
previous five years, the patient is assigned to stage 4. 
-  If the anxiety disorder symptoms were present for at least 1.5 out of the last 
five years, but not more than four out of the five previous years, the patient 
is assigned to stage 3.
-  If the symptoms of the disorder were present in less than 1.5 
years during the last five years, the patient is assigned to stage 2. 
NOTE: for research purposes, in our study the life chart inventory was 
used.31 This approach optimizes this part of the assessment by using 
affectively laden personal memory anchors. It was shown previously that 
these personal memory anchors aid recollection of previous symptoms.32 
It is therefore recommended to use a memory anchor method, like the Life 
chart method to assess the previous duration of anxiety disorder symptoms. 
For patients without DSM diagnosis, assess the severity of anxiety 
symptoms.
-  If the presenting symptom is social anxiety, use a dedicated social phobia 
rating scale to assess severity of symptoms. We used the social phobia 
subscale derived from the Fear Questionnaire but other measurement 
scales can be used as well, e.g. Leibowitz Social Anxiety Scale (LSAS), 
or the Social Interaction Anxiety Scale (SIAS). However, in the current 
paper we did not examine cut-off values for these measurement scales, so 
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-  If the presenting symptom is generalized anxiety, use a dedicated rating 
scale. For instance the Beck Anxiety Inventory (BAI) or the Penn State 
Worry Questionnaire (PSWQ). Proposed cut-off values are presented 
below.
-  If the presenting symptom is panic attacks, use a dedicated rating scale. 
We used the BAI and Fear Questionnaire (agoraphobia subscale), for which 
reference values are presented below. Alternatively, the Panic Disorder 
Severity Scale (PDSS) can be used, but for these, no cut-off values were 
examined and therefore we advise to use the Fear Questionnaire.
Proposed cut-off values for measurement instruments used in our study:
Stage 0:  BAI<10   PSWQ<24  FQ (Ag)<15  FQ (So) <12
Stage 1A:  BAI 10<30  PSWQ 24<39  FQ (Ag) 15<19  FQ (So) 12<18
Stage 1B: BAI ≥30   PSWQ ≥39  FQ (Ag) ≥19  FQ (So) ≥18.
3.  In clinical stages, assess the presence of comorbid psychiatric disorders 
according to guidelines. If dysthymia, (uni- or bipolar) depressive 
disorders, alcohol use disorder, posttraumatic stress disorders, obsessive 
compulsive disorders, personality disorders or psychotic disorders are 
present, assign patients to B stages (2B, 3B, 4B); otherwise, assign 
patients to A stages (2A, 3A, 4A). 
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Evaluating a dimensional approach 
to treatment resistance in anxiety 
disorders: a two-year follow-up 
study








Treatment resistance in anxiety disorders (TR-AD) has been previously 
defined by failed prior treatments and by various clinical aspects, but the 
impact of these aspects on course during subsequent treatments was never 
studied. Moreover, TR-AD was never studied using a dimensional approach. 
This study validated aspects of TR-AD and examined whether a TR-AD score 
was related to two-year course during treatment.
Methods
From the NESDA cohort, anxiety disorder patients who subsequently 
received treatment were selected (n=679). Literature-derived aspects 
of TR-AD at baseline included anxiety severity, functional impairments, 
psychiatric comorbidity, duration, and previous treatments. These were 
combined into a dimensional TR-AD score. Individual aspects of TR-AD and 
the TR-AD score were linked to anxiety disorder persistence at two-year 
follow-up using logistic regression analyses. Predictive properties for the 
TR-AD score were assessed.
Results
Current symptom severity, psychiatric comorbidity, functional impairments 
and previous duration of symptoms were closely associated with two-year 
anxiety disorder persistence, while treatment history was not. The TR-AD 
score (10.8±2.3, range 2-23) was linked to two-year persistence (OR per 
point increment 1.29, p<0.01). The predictive properties of the TR-AD score 
appeared modest (AUC=0.66).
Limitations
In the current study, treatment history and ongoing treatments were 
retrospectively assessed. It was not evaluated whether prior treatments 
failed or succeeded. 
Conclusions
The results in the current study suggest that when assessing TR-AD and 
designing a treatment plan, evaluations of treatment history should be 
accompanied with assessments of clinical characteristics. The dimensional 
TR-AD measurement presented here could be used for this purpose.
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Chapter 6 - M
easuring treatm
ent resistance in anxiety disorders
Introduction
Many patients with Anxiety Disorders experience suboptimal treatment 
results.1–4 In clinical practice, patients are considered to have treatment 
resistant anxiety disorders (TR-AD) when evidence-based treatments do 
not yield sufficient symptom reduction, symptom severity is substantial 
and pseudo-resistance has been ruled out.5–7 Pseudo-resistance may be 
due to unrecognized anxiogenic factors such as coffee or substances, or 
to inadequate treatment type, insufficient treatment duration, inadequate 
dosage regimes or nonadherence to treatments.7,8 After adequate treatment, 
up till 30-60% of patients with anxiety disorders have substantial and 
impairing remaining symptoms.1,9,10 Furthermore, even after successful 
treatments, around 12-20% of patients show a relapse after three years,11 
while relapse rates were approximately 50% in young patients after six 
years.12 Patients with suboptimal treatment outcomes show increased levels 
of disability, comorbidity, loss of (work) functioning, reduced quality of 
life, increased mortality and higher health care costs.13 Identifying TR-AD 
is thus of great clinical relevance due to its negative impact on subsequent 
course. However, the concept of TR-AD is poorly demarcated with many 
different definitions currently in use.5,7 Generally, TR-AD is considered a 
dichotomous concept, i.e. patients either have treatment resistance or don’t 
have treatment resistance. Using a dimensional approach to TR-AD might 
be more beneficial. Thereby, a sound understanding of TR-AD and a way to 
assess TR-AD in clinical care are much needed. 
A dimensional approach for assessing the TR in depression (TR-D) exists 
in the Maudsley Staging Method (MSM), which is based on empirically 
validated aspects of TR-D.14 The MSM and an adaptation, the Dutch Measure 
for quantification of Treatment Resistant Depression (DM-TRD) have proven 
useful tools in clinical care in depression.15–17 Depressed patients with high 
levels of TR-D show a less favorable long term course in comparison to 
those with lower levels of TR-D.18 In analogy to this, the current levels of TR-
AD are assumed to be related to subsequent course in anxiety disorders in 
patients receiving treatments.19,20
From a recent systematic review into definitions for TR-AD various 
clinical aspects were identified as criteria for TR-AD.5 These criteria for 
TR-AD included symptom severity, presence of functional impairments, 
psychiatric comorbidity, previous duration of symptoms, number of adequate 
pharmacological and psychological treatments. However, these aspects 
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of TR-AD have not been studied in concert in a sample of anxiety disorder 
patients who receive treatment. Furthermore, no dimensional measurement 
instrument exists for assessing levels of TR-AD, and hence, it is unknown 
whether such a quantified TR-AD measurement could be useful in clinical 
care.
The aim of this study is to operationalize a dimensional assessment of TR-
AD. First, it will be assessed whether individual aspects of TR-AD derived 
from the literature are related to course during treatment in a sample with 
varying levels of treatment resistance at baseline. Next, by tailoring the DM-
TRD for use in anxiety disorders, we will develop a dimensional tool to assess 
the level of TR-AD, expressed in a TR-AD score. The association between the 
TR-AD score and anxiety disorder status will be described in this sample of 
anxiety disorder patients who received treatments over the course of the 
follow-up period. Finally, the predictive properties of this newly developed 
dimensional TR-AD score will be examined.
Methods
Study sample
Subjects were derived from the ongoing Netherlands Study of Depression 
and Anxiety (NESDA), a naturalistic cohort study that examines the course of 
depression and anxiety in adults. At baseline, 2,981 subjects were included 
from the community, primary care and specialized mental health care. They 
had a major depressive disorder (MDD, n=1,222, 41%), anxiety disorder 
(n=1,305, 44%) or were healthy controls (n=632, 22%). Patients with a 
primary diagnosis of psychotic disorders, obsessive compulsive disorder, 
bipolar disorders, or severe substance abuse disorders were excluded. 
Baseline data were collected from 2004-2007 and two-year follow-up data 
from 2006-2009. Full methods for NESDA were previously described in 
detail.21
For the purpose of this study, we selected 1,305 subjects from all inclusion 
sites with a current anxiety disorder diagnosis at baseline: panic disorder 
(PD), agoraphobia, generalized anxiety disorder (GAD) and social anxiety 
disorder (SAD). By including subjects from all sampling sites we ensured 
inclusion of subjects with varying levels of TR-AD. Only subjects who at two-
year follow-up reported to have received treatment in the period between 
baseline and follow-up were selected for the purpose of this study. The 
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reported treatments included psychotherapy, pharmacotherapy, or regular 
appointments with a mental health care worker. Ongoing treatments 
between baseline and follow-up were retrospectively assessed at follow-
up using the Perceived Need for Care Questionnaire (PNCQ) 22. By selecting 
subjects with confirmed ongoing treatments it was possible to assess the 
association of aspects of TR-AD with long term outcomes during treatment. 
Psychiatric disorders at baseline and two-year follow-up were assessed 
according to DSM-IV criteria with the Composite International Diagnostic 
Interview (CIDI, version 2.1).23–25 The CIDI is a structured interview which 
was conducted by trained research staff. The CIDI was shown to have good 
overall reliability and validity and is frequently used worldwide.24
A total of 230 subjects who did not participate in the two-year follow-up were 
excluded, 378 subjects who did not receive treatment between baseline and 
follow-up, and a further 18 subjects with incomplete baseline data, yielding 
a total sample of 679 subjects. The 230 subjects who were excluded due to 
missing follow-up data did not differ significantly from included subjects in 
age, gender, type of anxiety disorder, presence of psychiatric comorbidity, 
and various clinical characteristics (p>0.10). However, they had fewer 
education years (11.1 vs 12.0, p<0.001).
Aspects of TR-AD
A recent systematic review into TR-AD identified various criteria for TR-AD. 
These included minimal number of adequate pharmacological treatments, 
minimal number of adequate psychological treatments, minimal anxiety 
disorder symptom severity, presence of functional impairments, presence of 
psychiatric comorbidity, and minimal previous duration of symptoms.5 These 
literature-derived criteria were included in the current study as aspects of 
TR-AD and were assessed at baseline. Treatments were assessed twice. 
The first assessment was done retrospectively at baseline with regard to the 
three years prior to baseline and the second assessment was done at follow-
up with regard to the period between baseline and follow-up measurements.
First- and second line pharmacotherapy
For the purpose of the current study, ‘adequate pharmacologic treatment’ 
was defined as first- and second-line evidence-based anti-anxiety drugs 
taken daily for at least two months at an effective dosage. All current 
pharmacotherapeutic use was assessed using inspection of medication 
containers and coded according to Anatomical Therapeutic Chemical 
(ATC) codes at baseline.26 Historic use of anti-anxiety drugs during the 
168
three-year period prior to baseline was assessed using retrospective self-
reports. Data from current and previous three year pharmacotherapeutic 
trials were combined into number of first-line and number of second-line 
pharmacotherapy trials. Categorization into first-line and second-line 
treatments was based on National Institution Clinical Excellence anxiety 
disorder guidelines and the Dutch anxiety disorder treatment guidelines.27–29 
SSRIs and SNRIs (venlafaxine or duloxetine) were considered first-
line anti-anxiety pharmacotherapy trials.27–29 Second-line anti-anxiety 
pharmacotherapy trials included tricyclic antidepressants, tetracyclic 
antidepressants (mirtazapine and trazodone), monoamine-oxidase 
inhibitors, high potency benzodiazepines (alprazolam, clonazepam, 
lorazepam, diazepam and bromazepam), pregabaline and buspirone.27–29 
For each drug the daily dosages subjects reported were checked and were 
required to meet the registered daily derived dosage (DDD) for that drug.26 In 
subjects who did not know the quantity of previous medication, we estimated 
their daily dosage using the lowest available quantity tablets available and 
multiplying that with the number of tablets they reported taking daily.
Adequate psychological treatments
Psychological treatments prior to baseline assessment were assessed using 
the PNCQ, in which subjects were asked which types of care they received.22 
From these, we included psychotherapy trials when subjects reported 
having had at least ten sessions with a psychologist, individual psychiatrist 
or psychotherapist, or when they reported at least 16 sessions at a mental 
health care institution. 
Anxiety disorder symptom severity
Symptom severity was defined using both severity of anxiety (according 
to the Beck Anxiety Inventory, BAI)30 and severity of avoidance behaviors 
(according to the Fear Questionnaire, FQ).31 The BAI is a 21-item self-report 
questionnaire that measures severity of anxiety. The BAI has adequate 
psychometric properties.32,33 Anxiety severity was categorized according to 
previously identified cut-off values: mild (BAI < 10), moderate (BAI 10 < 30) 
and severe (BAI ≥ 30).33,34 
The FQ is a 15-item questionnaire that measures avoidance in three 
domains: agoraphobia (Ag), social phobia (So) and blood injury phobia. The 
latter domain was omitted for the purpose of this study as specific phobias 
fall outside the scope of this study. Different cut-off values are used for the 
FQ subscales. Cut-off values for clinically relevant levels of agoraphobic 
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avoidance (FQ Ag) vary from ≥15 to ≥19, whereas cut-off values for clinically 
relevant social phobia avoidance (FQ So) vary from ≥12 to ≥18.35,36 The 
severity of avoidance behaviours was categorized according to FQ scores: 
mild severity was defined as FQ Ag below 15 and FQ So below 12, moderate 
severity was defined as FQ Ag between 15 and 19 and FQ So between 12 and 
18, severe was defined as FQ Ag at 19 or above and FQ So at 18 or above. 
For the purpose of data analysis, for each patient the symptom severity was 
defined by the highest value on either the BAI or the FQ according to the cut-
off values described, creating a single variable for symptom severity (mild, 
moderate or severe), as done before.34
Presence of functional impairments
Levels of functional impairment were assessed using the WHO-DAS, 32 
item version.37 The WHO-DAS measures disability in six domains: cognition, 
mobility, self-care, interpersonal interactions, household activities, and 
participation in society on a 5-point Likert scale with item-scores ranging 
from 0 (no difficulties) to 4 (extreme difficulties/cannot do). A total 
disability score was calculated by adding all 32 item-scores. The WHO-DAS 
has excellent internal consistency (α=0.95).37 Total scores were compared 
against a conversion table to derive the general population percentile score 
for each subject.38 Levels of functional impairments were categorized into 
‘low’ (< 50th general population percentile), ‘moderate’ (50th < 75th general 
population percentile) and ‘severe’ (> 75th general population percentile). 
Presence of psychiatric comorbidity
The presence of current (6-month) dysthymia, major depressive disorder 
and alcohol dependency were assessed with the CIDI and psychiatric 
comorbidity was considered present if any of these disorders were classified.
Previous duration of symptoms 
Previous duration of symptoms was retrospectively assessed at baseline 
using the Life chart method.39 It uses a calendar based approach to provide 
memory anchors for subjects in order to assess the presence of anxiety and 
avoidance symptoms during each month of the current and four previous 
calendar years. The LCI has adequate reliability and validity.40 If either 
anxiety or avoidance was present in at least 80% of the months prior to 
baseline, previous duration was ‘long’. If anxiety or avoidance was present 
in 30-80% of the time, previous duration was ‘intermediate’, and if anxiety 
or avoidance was present in less than 30% of the previous months, previous 
duration was ‘short’. 
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Dimensional TR-AD score
Levels of TR-AD were assessed using a combined score comprised of the 
different individual aspects of TR-AD. Scoring for this dimensional score 
was based on the Dutch Measure for quantification of Treatment Resistance 
in Depression (DM-TRD).17 The scoring system used in the DM-TRD was 
maintained as aspects of TR-AD were identical to aspects for TR-D used in 
the DM-TRD (see Panel 1 for scoring). Each of the aspects of TR-AD were 
scored in accordance with the DM-TRD to derive a single score for each 
subject. This yielded a dimensional measurement instrument for levels of 
TR-AD with a potential range of 2-23.
Main outcome variable
Persistence of anxiety disorders was assessed at two-year follow-up, 
defined as 6-month presence of PD, GAD, agoraphobia or SAD, diagnosed 
with the CIDI. 
Main analyses
In order to relate baseline individual aspects of TR-AD to outcome at two-
year follow-up, bivariate logistic regression analyses were performed. 
Odds Ratios (OR) for each aspect of TR-AD were reported. Next, logistic 
regression analyses were performed to link the dimensional TR-AD score 
assessed at baseline to outcome at two-year follow-up. To assess the 
predictive properties for the dimensional TR-AD score, the Youden-index,41 
which is indicative of the most optimal cut-off score; sensitivity, specificity, 
positive predictive values and negative predictive values for different cut-
off values were calculated. A Receiver Operator Curve (ROC) was plotted 
and area under the curve (AUC) was calculated. Statistical analyses were 
performed using IBM SPSS 23.
Sensitivity analyses
In the design of this study it was retrospectively assessed at follow-up 
whether subjects received treatment in the period leading up to follow-up. 
In this approach it was not clear, however, when treatments were initiated. 
Therefore, a sensitivity analysis was performed in which the main analyses 
were repeated in a subsample who presented at specialized mental health 
care at baseline (n=405). Within the design of NESDA, all subjects that 
were included at specialized mental health care institutions were initiated 
evidenced-based care directly after inclusion into the study. This yielded a 
sample in which treatments were initiated at the moment of inclusion and in 
which treatments were ongoing at follow-up. 
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Panel 1. Dimensional assessment of degree of Treatment Resistant anxiety disorders 
(TR-AD).

































(Degree of TR-AD) (2-23)
1 mild: Beck Anxiety Inventory (BAI) <10, Fear Questionnaire (FQ), agoraphobia subscale (Ag) <15 and FQ, social phobia (So) 
subscale <12; moderate: BAI 10<30, or FQ (Ag) 15<19, or FQ (So) 12<18; severe: BAI ≥30, FQ (Ag) ≥19, or FQ (So) ≥18).
2 World Health Organisation Disability Assessment Schedule 2.0 general population percentile scores: none<25th, low: 25th-50th, 
moderate: 50th-75th, severe >75th 
3  major depressive disorder, dysthymia, alcohol dependency.
4 short: <30% of months during the previous five calendar years spent with symptoms, intermediate: 30<80% of months during 
the previous five calendar years spent with symptoms, long: >80% of months during the previous five calendar years spent with 
symptoms.
5 selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs).
6 tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAO-i), tetracyclic antidepressants, high potency 
benzodiazepines, pregabalin, and buspirone.





The sample of n=679 subjects was 40.4 ± 11.1 years old, 452 subjects 
were female (66.6%) and subjects received 12.0 ± 3.3 years of education. 
The sample consisted of subjects diagnosed with PD (n=348, 51.3%), 
agoraphobia (n=84, 12.4%), SAD (n=373, 54.9%) and GAD (n=270, 39.8%). 
Prior to inclusion, subjects received 0.44 ± 0.65 first-line pharmacotherapy 
treatments, 0.12 ± 0.38 second-line pharmacotherapy treatments and 0.14 
± 0.36 psychotherapy treatments. The total number of previous treatments 
(pharmacotherapy or psychotherapy) was 0.69 ± 0.94, with a range of 0-5 
previous treatments. The mean TR-AD-score was 10.8 ± 2.3. See Table 1 for 
baseline characteristics. 
Table 1. Baseline characteristics of treated anxiety disorder sample (n=679).
n (%) mean ± SD
Demographic characteristics
 Age 40.4 ± 11.9
 Female gender 452 (66.6%)
 Education 12.0 ± 3.3
 Basic 47 (6.9%)
 Intermediate 426 (62.7%)
 High 206 (30.3%)
Sampling site
 General population 49 (7.2%)
 Primary care 225 (33.1%)
 Specialised mental health care 405 (59.6%)
Type of anxiety disorder
 panic disorder 348 (51.3%)
 agoraphobia 84 (12.4%)
 social anxiety disorder 373 (54.9%)
 generalized anxiety disorder 270 (39.8%)
Aspects of Treatment Resistance
 Number of first-line pharmacotherapy trials 0.44 ± 0.65
 0 433 (63.8%)
 1 208 (30.6%)
 2 31 (4.6%)
 3 or more 7 (1.0%)
Table continues
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Main analyses
Most baseline aspects of TR-AD were significantly associated with 
persistence of anxiety disorders at two-year follow-up in bivariate models 
(See Table 2). For example, high levels of functional impairments were 
related to persistence: OR=2.90; 95% Confidence Interval (CI), 1.51-5.63, 
p=0.001. Symptom severity was strongly associated with persistence (OR 
severe symptoms vs mild symptoms =6.48; 95% CI,  3.29-12.8, p<0.001). 
Surprisingly, previous pharmacotherapy treatments and previous 
psychotherapy treatments were not significantly related to two-year 
persistence, nor was the combined total number of treatments. Higher 
scores on the dimensional TR-AD measurement were associated with 
 Number of second-line pharmacotherapy trials 0.12 ± 0.38
 0 615 (90.6%)
 1 52 (7.7%)
 2 or more 12 (1.8%)
 Number of psychotherapy trials 0.14 ± 0.36
 0 591 (87.0%)
 1 84 (12.4%)
 2 4 (0.6%)
 Symptom severity
 Mild 52 (7.7%)
 Moderate 272 (40.1%)
 Severe 355 (52.3%)
 Levels of functional impairments
 Low  <50th percentile of general  
   population 4 (0.6%)
 Moderate   50th-75th percentile 39 (5.7%)
 Severe   >75th percentile 636 (93.7%)
 Psychiatric comorbidity
 No 213 (31.4%)
 Yes 466 (68.6%)
 Previous duration of anxiety (previous five years)
 Short  <30% months 229 (33.7%)
 Intermediate  30-80% months 197 (29.0%)
 Long  >80% months 253 (37.3%)
 TR-AD score (2-23) 10.8 ± 2.3(range 2-16)
Table 1. Continued
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two-year persistence: OR (per point increment) =1.29; 95% CI, 1.20-1.39, 
p<0.001, which translates into OR (per SD increase) =1.81; 95%CI, 1.53-2.15, 
p<0.001. 
Table 2. Bivariate associations between baseline aspects of treatment-resistance in 
anxiety disorders with two-year persistence in anxiety disorder patients (n=679).
Two-year  
persistence
Bivariate baseline predictors OR (95% CI)
Age 1.01 (0.99-1.02)
Female gender 0.87 (0.63-1.20)





High levels of functional impairment 2.90 (1.51-5.63)
Presence of psychiatric comorbidity 1.73 (1.25-2.39)
Previous duration of anxiety 
(% of months during last 5 years)
Short (<30%) 1.00 (ref)
Intermediate (30-80%) 2.22 (1.49-3.21)
Long (>80%) 2.79 (1.94-4.03)
Number of first-line pharmacotherapy trials 1.10 (0.87-1.39)
Number of second-line pharmacotherapy trials 1.39 (0.91-2.12)
Number of psychotherapy trials 1.11 (0.73-1.69)
Total number of treatments 1.12 (0.95-1.32)
Degree of TR-AD 1.29 (1.20-1.39)
Boldface indicates p< 0.05 
The optimal cut-off for the dimensional TR-AD score based on the highest 
Youden index was 11 or higher. When using this cut-off value, sensitivity 
was 0.70 and specificity 0.57. Positive predictive value (PPV) and negative 
predictive value (NPV) were modest: 0.68 (PPV) and 0.60 (NPV). See figure 
1 for the ROC using baseline levels of TR-AD as predictor for two-year 
persistence. From this ROC, the AUC was calculated at 0.66 (see Figure 1).
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Figure 1. Receiver operator curve and predictive properties for baseline degree of TR-
AD score on two-year anxiety disorder persistence.
Sensitivity analyses
The main analyses were repeated in a subsample of patients who were 
included in specialized mental health care (n=405). In comparison with 
subjects that were sampled elsewhere (n=274), this subset was younger 
(mean age= 38.3 versus 43.6, p<0.001), included a lower proportion of 
female patients (62.7% vs. 72.3%, p=0.006), higher proportions of PD 
diagnoses (56.5% vs. 43.4%, p=0.001), higher proportions of GAD diagnoses 
(42.7% vs. 35.4%, p=0.03), higher symptom severity (56.5% in severe 
severity vs. 46.0%, p=0.03), higher proportions of psychiatric comorbidity 
(75.3% vs. 58.8%, p<0.001), longer duration of symptoms (31.6% with 
moderate duration vs. 25.2%, p=0.04), more often had previous first-line 
pharmacological treatments (mean number=0.54 vs. 0.28, p<0.001), more 
often had previous second-line pharmacological treatments (mean number= 
0.16 vs. 0.04, p<0.001). The subsample had similar educational levels 
(mean education years= 11.8 versus 12.2, p=0.15), similar proportions of 
176
social phobia diagnoses (57.0% vs. 51.8%, p=0.10), similar overall levels 
of functioning (92.8% in fourth WHODAS quartile vs. 94.9%, p=0.53) and 
similar number of psychological treatments (mean number of treatment= 
0.15 vs. 0.12, p=0.27) in comparison with the subjects sampled in other 
inclusion sites. These differences in baseline characteristics were to be 
expected, as in the Dutch health care system more severely affected patients 
are more likely to be referred to specialized mental health care. In spite of 
these baseline differences, all analyses showed comparable results to the 
whole sample. The  same predictors for course after treatment were found 
in this subsample (see Table 3) and the psychometric properties for the 
dimensional TR-AD score were very similar (see Figure 2). 
Table 3. Sensitivity analysis: Two-year bivariate associations between clinical 
characteristics and previous treatment types with persistence in anxiety disorder 
patients who were initiated treatments in specialized mental health care (n=405) with 
confirmed ongoing treatment after two years.
Two-year persistence
Bivariate baseline predictors OR (95% CI)
Age 1.01 (0.99-1.02)
Female gender 0.85 (0.57-1.29)





High levels of functional impairment 2.90 (1.31-6.40)
Presence of psychiatric comorbidity 1.86 (1.18-2.94)
Previous duration of anxiety 
(% of months during last 5 years)
Short (<30%) 1.00 (ref)
Intermediate (30-80%) 2.66 (1.59-4.43)
Long (>80%) 3.22 (1.96-5.29)
Number of first-line pharmacotherapy trials 1.06 (0.80-1.41)
Number of second-line pharmacotherapy trials 1.16 (0.72-1.85)
Number of psychotherapy trials 1.07 (0.63-1.81)
Total number of treatments 1.07 (0.88-1.29)
Degree of TR-AD 1.29 (1.17-1.42) 
Boldface indicates p<0.05
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Figure 2. Sensitivity analysis: Receiver operator curve and predictive properties for 
baseline degree of TR-AD score on two-year anxiety disorder persistence in sample 
that initiated treatments after inclusion into the cohort (n=405).
Discussion
Despite the relevance in clinical care, defining and assessing treatment 
resistance in anxiety disorders (TR-AD) has hardly been a focus in scientific 
research. This study examined aspects of TR-AD and examined whether 
combining these aspects into a dimensional TR-AD score could adequately 
predict two-year course in a sample of anxiety disorder patients who 
received treatment during a two-year period.
The first aim was to empirically validate literature-derived aspects of TR-
AD. Higher baseline symptom severity, levels of functional impairment, 
presence of psychiatric comorbidity and longer previous duration of 
symptoms were critically related to persistence of anxiety disorders at 
two-year follow-up in a treated sample. These clinical characteristics are 
sometimes identified as prognostic factors in clinical care, and are included 
as such in treatment guidelines.42 Surprisingly, in our study treatment history 
showed no significant impact on two-year course. This is a counterintuitive 
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finding because failed treatment is regarded the core criterion for TR in any 
disorder and hence, assessment of treatment history is common practice in 
clinical care.2 Additionally, treatment history is the main criterium on which 
treatment guidelines base their recommendations for evidence-based 
stepped-care algorithms in which nonresponse on a low intensity treatment 
usually leads to recommending more aggressive treatments.28,42 Therefore, 
in current stepped-care algorithms the number of failed treatments indicates 
the current level of TR-AD. In our study, it was unclear whether previous 
treatments had failed or were successful at the time, while only failed 
treatments define TR. Moreover, a previous study showed that adherence to 
treatment guidelines was suboptimal in the NESDA sample. In one third of 
included patients, the treatments provided were fully adherent to treatment 
guidelines, while in a small majority, the treatments received were not fully 
adherent to treatment guidelines.43 Therefore, the method of data collection 
could have contributed to the lack of association between treatment history 
and two-year course. However, a recent study into TR factors in depressed 
NESDA subjects used the same approach to assess treatment history and 
this study did show an association between treatment history and two-
year outcomes in depression.18 In depression this association is in line with 
the existing literature, for example, the STAR*D trial empirically showed 
that a history of pharmacotherapy trial failures preceded subsequent lack 
of treatment response.44 Even as this mechanism was never empirically 
demonstrated in anxiety disorders, it is generally assumed to be present as 
well.19,20 It is possible that the association between treatment history and 
subsequent course during treatment in anxiety disorders is less robust in 
comparison with depression. This could be due to differences in naturalistic 
course: anxiety disorders more often show chronicity, whereas MDD 
more often shows an episodic course.45 The results in this study could be 
indicative of the shortcomings of using treatment history as the cornerstone 
in assessments of TR-AD and in stepped-care treatment algorithms and it is 
unclear whether this cornerstone position of assessing treatment history is 
fully warranted. Findings of the present study suggest that higher levels of 
anxiety duration, symptom severity, psychiatric comorbidity and functional 
impairments contribute to higher levels of TR-AD. Based on the findings 
presented here, these aspects should be used alongside assessments of 
previous treatment failures in the process of assessing treatment resistance 
and designing treatment plans. 
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A second aim of the present study was to develop a dimensional tool to 
assess the levels of TR-AD, reflected as a TR-AD score. We tailored the 
Dutch Measure for quantification of Treatment Resistance in Depression 
(DM-TRD) for use in anxiety disorders, based on literature-derived aspects 
of TR-AD. Each point increment in the dimensional TR-AD score was 
associated with increased Odds of 1.29 on persistence of anxiety disorders, 
which translates into increased Odds of 1.81 per SD increase. Predictive 
power was moderate, with an AUC of 0.66. This magnitude of effect similar 
is to that in TR depression (TR-D). The level of TR-D, as measured with 
the MSM, was linked to “persistent depression” (>50% of the time spent 
with depressive symptoms) at two-year follow-up: each point increment 
was associated with 1.40 increased Odds for persistent depression.18 But 
whereas the dimensional TR-AD score presented here had a range of 2-23 
with a sample SD of 2.34, the MSM has a range of 3-15 with a sample SD of 
1.22 18. Therefore, the Odds increase per SD increment of 1.81 are higher in 
the current TR-AD sample in comparison with the TR-D sample. Comparing 
the AUCs was not possible as no AUC was reported in the paper by van 
Belkum et al (2018).18 Thereby, the current dimensional TR-AD score shows 
promise as a measurement tool in TR-AD. It could be used in the process of 
assessing treatment resistance and when designing a treatment plan. 
Strengths of the current study include the use of literature-derived aspects 
of TR-AD, the longitudinal approach and applying strict requirements to 
treatment regimens to take pseudoresistance into account. Some limitations 
should also be noted. First, we aimed to study effects of aspects of TR-
AD on anxiety course in subjects receiving treatments. This approach was 
chosen as it would enable identifying patients with decreased chances of 
beneficial treatment effects, which is clinically very relevant. In our main 
sample, for some patients it was unclear when these treatments were 
initiated. This could have led to reduced external validity for our results to 
be interpreted in real world treatment-seeking samples. When we repeated 
the main analyses in a subsample who initiated treatments directly after 
inclusion into the cohort (n=405) the same results after two-year follow-
up were found. Therefore, it was concluded that the uncertainty with regard 
to the moment of initiation of treatment was not a confounding factor in 
this study. The results from the sensitivity analyses suggest that the same 
underlying processes are present in both subsamples. Second, some 
limitations with regard to the assessments of previous treatments existed. 
The present study relied on current and previous three-year treatment 
history as information on lifetime treatment history was not available. As 
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a result, impact of previous treatments in assessing TR-AD may have been 
underestimated, as lifetime treatment history is considered important 
in TR.2,19,20,46,47 Also, a number of subjects reported having no previous 
treatments. This could have led to a bias towards the null hypothesis if these 
subjects had failed treatments before the assessment period (over three 
years ago). Furthermore, the current design in which previous treatments 
were assessed retrospectively via self-report introduced the risk of a recall 
bias. Patients with anxiety disorders are somewhat prone to memory biases, 
especially if the memories are emotionally laden.48 A recall bias would lead 
to underreporting of previous treatments, which also leads to a bias towards 
the null hypothesis. Additionally, as mentioned previously, no assessments 
of previous treatment effects were undertaken. This could also have led to 
a bias towards the null hypothesis as only failed treatments are considered 
to be of importance in assessments of TR. Moreover, evidence-based 
psychotherapies for anxiety disorders include homework assignments and 
incorporation of exposure interventions. These aspects of psychotherapies 
are likely related to treatment outcomes in anxiety disorders.49 In the design 
of this study, the exact contents of the psychotherapies were not known. 
As a result of these limitations, the lack of association between treatment 
history and subsequent course in anxiety disorder patients should be 
replicated in a different cohort in which these shortcomings in assessments 
of previous treatments are not present. Finally, some disorders with high 
levels of comorbidity with anxiety disorders fell outside the scope of NESDA. 
For instance, specific phobias and obsessive compulsive disorder were not 
routinely included. Likely, presence of these disorders has impact on the 
treatment history and course in anxiety. Therefore, the current findings 
cannot be generalized to populations with these comorbidities.
Future studies could aim to replicate the associations between a dimensional 
TR-AD score, as measured with the measurement instrument presented 
in this paper, with treatment effects in anxiety disorder patients. For 
future studies using a retrospective design it might be beneficial to involve 
pharmacists in determining previous pharmacological treatments. Moreover, 
asking patients to specify certain aspects of previous psychotherapies 
might increase identification of adequate psychotherapeutic treatments. 
For instance, in addition to asking the number of sessions it might be 
beneficial to ask whether homework assignments were given and whether 
the treatments included exposure interventions. Also, further research 
into the role of failed anxiety disorder treatments with regard to course 
during subsequent treatments is warranted. Ideally, a randomized trial 
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investigating a stepped-care algorithm in anxiety disorders, like STAR*D in 
depression, should be performed. This would reduce the risks of bias due to 
underreporting of previous treatments as the treatments would be assessed 
prospectively. This could further uncover the role of different aspects of TR-
AD during subsequent treatments and improve treatment decision making 
within a stepped-care algorithm. 
In summary, we showed associations between several literature-derived 
aspects of TR-AD with persistence of anxiety disorders at two-year follow-up 
in a sample receiving treatment and developed a dimensional tool to assess 
TR-AD that showed promise. There was a clear association between the 
score on this TR-AD measurement with persistence of anxiety disorders after 
a two-year follow-up period during which respondents received treatments. 
The association of TR-AD with course during treatment seems more driven 
by baseline clinical characteristics in comparison to treatment history. The 
lack of significant associations between treatment history and course during 
treatment demonstrated in this study warrants further investigation into the 
role of previous failed treatments in anxiety disorder clinical care. Ideally, all 
aspects of TR-AD should be investigated prospectively in a cohort of anxiety 
disorder patients receiving evidence-based treatments to determine which 
of these factors should be most central in treatment decision making in 
anxiety disorder patients. The current research suggests that assessments 
of severity, duration, disability and psychiatric comorbidities could have the 
highest contribution in treatment decision making. 
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Disease trajectories of patients with anxiety disorders are highly diverse 
and approximately 60% remain chronically ill. The ability to predict disease 
course in individual patients would enable personalized management of 
these patients. This study aimed to predict recovery from anxiety disorders 
within 2 years b y  applying a machine learning approach.
Methods
In total, 887 patients with anxiety disorders (panic disorder, generalized 
anxiety disorder, agoraphobia, or social phobia) were selected 
from a naturalistic cohort study. A wide array of baseline predictors 
(N = 569) from five domains (clinical, psychological, socio-demographic, 
biological, lifestyle) were used to predict recovery from anxiety disorders 
and recovery from all common mental disorders (CMDs: anxiety disorders, 
major depressive disorder, dysthymia, or alcohol dependency) at 2-year 
follow-up using random forest classifiers (RFCs).
Results
At follow-up, 484 patients (54.6%) had recovered from anxiety disorders. 
RFCs achieved a cross-validated area-under-the-receiving-operator-
characteristic-curve (AUC) of 0.67 when using the combination of all 
predictor domains (sensitivity: 62.0%, specificity: 62.8%) for predicting 
recovery from anxiety disorders. Classification of recovery from CMDs 
yielded an AUC of 0.70 (sensitivity: 64.6%, specificity: 62.3%) when using 
all domains. In both cases, the clinical domain alone provided comparable 
performances. Feature analysis showed that prediction of recovery from 
anxiety disorders was primarily driven by anxiety features, whereas recovery 
from CMDs was primarily driven by depression features.
Conclusions
The current study showed moderate performance in predicting recovery 
from anxiety disorders over a 2-year follow-up for individual patients and 
indicates that anxiety features are most indicative for anxiety improvement 
and depression features for improvement in general.
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Introduction
Anxiety disorders are characterized by highly heterogeneous clinical 
course trajectories. After 2 years, the prognosis varies across disorders 
with remittance rates of 72.5% for panic disorder without agoraphobia, 
69.7% for generalized anxiety disorder, 53.5% for social phobia and 52.7% 
for panic disorder with agoraphobia (Hendriks, Spijker, Licht, Beekman, 
& Penninx, 2013). Remitted patients experience a relatively benign course 
with moderate remaining symptom severity, disability and a low subjective 
need for care (Batelaan, Rhebergen, Spinhoven, van Balkom, & Penninx, 
2014; Spinhoven et al., 2016; van Beljouw, Verhaak, Cuijpers, van Marwijk, & 
Penninx, 2010). However, around 60% of patients have persistent symptoms, 
relapses, or chronic disease up to 6 years after the diagnosis (Batelaan et 
al., 2014; Spinhoven et al., 2016). Disease course in these patients is often 
characterized by substantial levels of disability. Predicting long-term 
disease course can be seen as an important step towards personalized 
medicine (Steyerberg, 2009). This would make targeted treatment efforts 
viable, in which treatments are tailored towards the individual risk for a poor 
disease outcome (McGorry, Ratheesh, & O’Donoghue, 2018). However, in 
anxiety disorders, there is a lack of robust course predictors. For instance, 
different DSM anxiety disorder diagnoses were shown to be poorly predictive 
of subsequent course (Batelaan et al., 2014). In current clinical practice, in 
the absence of valid risk prediction models, course prediction relies solely on 
clinician’s opinions, which show poor accuracy (Randall, Sareen, Chateau, & 
Bolton, 2019).
Several clinical, psychological, biological, sociodemographic and 
lifestyle markers are related to the disease course. For instance, higher 
baseline severity of anxiety symptoms, presence of somatic or psychiatric 
comorbidity, and higher levels of disability are linked to worse outcomes at 
1-year (van Beljouw et al., 2010), 2-year (Batelaan et al., 2014; Hendriks 
et al., 2013; Scholten et al., 2013), 6-year (Spinhoven et al., 2016), and 12-
year follow-up (Bruce et al., 2005). Contrastingly, some authors suggest 
the same factors lead to better initial treatment results (Baldwin & Tiwari, 
2009; Rodriguez et al., 2006). Also, a chronic duration of anxiety was linked 
to worse outcomes in most studies (Batelaan et al., 2014; Hendriks et al., 
2013; Scholten et al., 2013; Spinhoven et al., 2016), while not showing any 
effect on disease course in another study (Nay, Brown, & Roberson-Nay, 
2013). Most studies showed that a younger age at onset was associated with 
a chronic course (Batelaan et al., 2014; Beesdo-Baum et al., 2012; Rodriguez 
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et al., 2006), while others showed no such age effect (Nay et al., 2013; 
Scholten et al., 2013). Inconsistent findings are likely due to methodological 
differences between studies. Other factors possibly related to worse disease 
course were duration of untreated illness (Baldwin & Tiwari, 2009), the 
use of anti-anxiety medication (Bruce et al., 2005; Scholten et al., 2013), 
and presence of childhood trauma (Asselmann & Beesdo-Baum, 2015; 
Batelaan et al., 2014; Scholten et al., 2013). Psychological factors that 
negatively impact anxiety disorder disease course up till 6-year follow-up 
included high neuroticism (Asselmann & Beesdo-Baum, 2015; Scholten et 
al., 2013; Spinhoven et al., 2016), low extraversion (Spinhoven et al., 2016), 
high anxiety sensitivity (Asselmann & Beesdo-Baum, 2015; Scholten et al., 
2013), high levels of worrying (Spinhoven et al., 2016), and low mastery 
(Asselmann & Beesdo-Baum, 2015; Scholten et al., 2013). Only a few 
studies linked biological parameters to disease course in anxiety disorders: 
C-reactive protein (CRP) levels were longitudinally associated with anxiety 
symptoms (Copeland, Shanahan, Worthman, Angold, & Costello, 2012), 
increasing cortisol levels were linked to higher 6-month anxiety severity in 
girls (Schiefelbein & Susman, 2006), and lower Brain-Derived Neurotropic 
Factor (BDNF) levels were found in patients with a poor response to 
treatment (Kobayashi et al., 2005). However, most research into biological 
parameters for anxiety disorders was done cross-sectionally, showing 
that anxiety disorder status is linked to higher CRP-levels (Copeland et al., 
2012; Pitsavos et al., 2006; Vogelzangs, Beekman, De Jonge, & Penninx, 
2013), higher metabolic syndrome markers (Carroll et al., 2009; Kahl et al., 
2015; Perez-Cornago, Ramírez, Zulet, & Martinez, 2014), higher tumour 
necrosis factor-α (TNF-α) levels (Hoge et al., 2009; Pitsavos et al., 2006), 
and lower BDNF levels (Molendijk et al., 2012). Inconsistently, anxiety 
symptoms were linked to both higher (Zoccola, Dickerson, & Yim, 2011) 
and lower (O ’Donovan et al., 2010) cortisol, as well as higher (Hoge et al. 
2009; O ’Donovan et al. 2010; Pitsavos et al. 2006) and lower (Vogelzangs 
et al. 2013) interleukin-6 (IL-6) measurements. Finally, sociodemographic 
and lifestyle factors such as education years (van Beljouw et al., 2010), age 
(Asselmann & Beesdo-Baum, 2015; Catarino et al., 2018), partner status 
(Asselmann & Beesdo-Baum, 2015; Batelaan et al., 2014), social support 
(van Beljouw et al., 2010), smoking status (Bruce et al., 2005), nicotine 
dependency (Nay et al., 2013), current financial problems (Nay et al., 2013), 
employment status (van Beljouw et al., 2010), and income (van Beljouw et 
al., 2010) were associated with anxiety disorder disease  course. In spite 
of  these many variables that predict disease course at the group level, it 
is not known whether this translates to accurate predictions for individual 
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patients. Currently, no encompassing model exists with sufficient sensitivity 
and specificity in disease course prediction to be feasible for use at the level 
of the individual patient.
A possible explanation for the lack of accuracy in course prediction in 
anxiety disorders is the complex, multicausal aetiology of anxiety disorders. 
Univariable and multivariable analyses of predictors of disease course 
showed low levels of explained variance (Bokma, Batelaan, Hoogendoorn, 
Penninx, & van Balkom, 2020). Furthermore, the inference is typically 
done on the group-level which does not allow for generalizable statements 
for the single individual. Multivariable machine learning (ML) methods 
provide a possible solution for this problem, as they are well-suited for 
solving problems with high numbers of predictors in complex, multicausal 
disorders (Iniesta, Stahl, & McGuffin, 2016). The use of ML in the field of 
psychiatry may have great potential for its application in the prediction 
of disease course trajectories (Hahn, Nierenberg, & Whitfield-Gabrieli, 
2017). Prediction of the disease course can be regarded as a ‘classification’ 
problem, which can be solved using supervised algorithms (Deo, 2015). In 
these, algorithms are trained on patients with known predictor and outcome 
variables to derive a function that can be applied to unseen patients to 
predict their outcome based on the values of their predictor variables. In 
anxiety disorders, supervised algorithms were applied a few times cross-
sectionally, to relate predictors from various domains to current disease 
status (Woo, Chang, Lindquist, & Wager, 2017) or to predict short-term 
treatment effects (Lueken & Hahn, 2016). To our best knowledge, however, 
no studies applied supervised ML algorithms to predict the disease course in 
anxiety disorders.
The aim of this study was to predict long-term anxiety disorder course, 
using an ML approach applied to clinical, psychological, biological, 
sociodemographic and lifestyle baseline data. Specifically, we investigated 
the utility of a random forest classifier (RFC) (Breiman, 2001) to predict 
clinical course in patients with any baseline anxiety disorder. Our main 
outcome was recovery from anxiety disorders at 2-year follow-up. As 
secondary outcome recovery from all common mental disorders (CMDs) 
at 2-year follow-up was used. CMDs include anxiety disorders, but also 
depressive disorders and substance use disorders as these disorders often 
co-occur, show diagnostic instability over time (Hovenkamp-Hermelink et 
al., 2016; Lamers et al., 2011; Scholten et al., 2016; Verduijn et al., 2017), 
and recovery from one but not the other does not index a major improvement 
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in health. Finally, we assessed which predictor domains contributed most to 
disease course predictions. We hypothesized that RFCs using a wide array of 
baseline data from different domains would yield adequate 2-year recovery 
predictions for both outcomes. Furthermore, we hypothesized that the 
combination of the five domains would yield the best predictions.
Methods
Study sample
The participants in this study were selected from the multi-site Netherlands 
Study of Depression and Anxiety (NESDA), an ongoing naturalistic cohort 
study into the course of depression and anxiety. The baseline sample 
consists of 2981 participants who were recruited from the community, 
primary care and specialized mental health care centres. All participants 
had a lifetime or current depressive disorder or anxiety disorder diagnosis 
(n = 2329, 78.1%) or were healthy controls (n = 652, 21.9%). NESDA allowed 
for the presence of comorbid psychiatric disorders, with the exception of 
psychotic disorders, obsessive compulsive disorder, post-traumatic stress 
disorder, bipolar disorders, or severe substance use disorders. Exclusion 
criterion consisted of insufficient proficiency of the Dutch language. 
Baseline data collection was performed in 2004–2007 and was followed by 
1-year, 2-year, 4-year, 6-year, and 9-year follow-up measurements. Full 
descriptions of the design of NESDA were published previously (Penninx et 
al., 2008). The study protocol was approved by the Ethical Review Board of 
all participating institutes and written informed consent was obtained from 
all participants.
For the purpose of this study, patients with current (6-month) panic 
disorder (PD, with or without agoraphobia), generalized anxiety disorder 
(GAD) or social anxiety disorder (SAD) diagnoses at baseline were 
selected (n = 1206). In our sample, psychiatric comorbidity was allowed. 
The diagnosis was established according to DSM-IV criteria with the 
Composite International Diagnostic Interview (CIDI, version 2.1) (American 
Psychiatric Association, 2000; Wittchen, 1994; World Health Organization, 
1998). From these patients, 212 were excluded due to missing diagnostic 
information at 2-years follow-up. A further 107 patients were removed due 
to having more than 20% missing variables across predictor variables at 
baseline. This yielded a final sample of 887 anxiety disorder patients with 
sufficient data available. Excluded patients showed comparable symptom 
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severity at baseline – mean anxiety severity (Beck’s Anxiety Inventory; 
BAI): 20.35 ± 11.74 v. 18.30 ± 10.48, t = 1.81, p = 0.07; mean depression 
severity (Inventory of Depressive Symptomatology-Self Report; IDS-
SR): 30.71 ± 12.65 v. 29.39 ± 12.65, t = 0.97, p = 0.33. Excluded patients 
were younger (mean age: 38.25 ± 12.05 v. 41.92 ± 12.20 years, t = 4.62, 
p < 0.001), and had a lower mean number of education years: 11.03 ± 3.15 
v. 11.88 ± 3.35, t = 3.97, p < 0.001, consistent with differences across the 
whole NESDA sample (Lamers et al., 2012). Gender did not differ between 
excluded and included patients (% female in excluded sample 68.2%, in 
included sample 66.8%, χ2 = 0.22, p = 0.64).
Investigated classifications
Two distinct classification tasks predicting outcomes at 2-year follow-
up were performed. Both were binary classification tasks predicting (1) 
recovery from anxiety disorders or (2) recovery from all CMDs. Anxiety 
disorders were defined as either PD, agoraphobia, GAD, or SAD. Recovery 
from anxiety disorders was deemed present if no anxiety disorder diagnoses 
persisted at follow-up. These diagnoses referred to all follow-up anxiety 
disorders, not only the index disorder(s). Anxiety disorders, dysthymia, 
major depressive disorder (MDD) and alcohol dependency are sometimes 
collectively referred to as CMDs (Ormel et al., 2013; Vollebergh et al., 
2001). For the purpose of this study, we defined recovery from all CMDs if 
at follow-up no anxiety disorders, MDD, dysthymia or alcohol dependency 
diagnoses were present. Assessment of CMDs is relevant as it is evident from 
population-based studies that depressive disorders and alcohol dependency 
are the most commonly occurring comorbidities in anxiety disorders (Alonso 
& Lépine, 2007; Judd et al., 1998; Wittchen, Kessler, Pfister, & Lieb, 2000), 
rates of diagnostic instability across anxiety disorders, depressive disorders 
and alcohol dependency are high (Gustavson et al., 2018; Hovenkamp-
Hermelink et al., 2016; Scholten et al., 2016) and recovery from one but 
not the other does not imply a major improvement in health. We assessed 
recovery from anxiety disorders as a primary outcome measure and recovery 
from all CMDs as a secondary outcome measure. These two outcome 




At baseline, a wide array of putative predictors from five domains (clinical, 
psychological, sociodemographic, biological and lifestyle) were selected, 
yielding a total of 651 variables. In our analyses, only information at the 
individual item level was used. Total summary scores for questionnaires 
were not calculated, as these would be correlated to the individual items. 
The exception was the NEO Five-Factor Inventory (NEO-FFI), as its domains 
(e.g. neuroticism) are of specific clinical relevance. Items were excluded 
if more than 20% of patients were missing the corresponding item. This 
resulted in the inclusion of 569 predictors at baseline (see Table 1). If a 
variable did not apply for a patient, it was re-coded as a new category for 
ordinal or nominal variables or as 0 for continuous variables (all continuous 
variables were positive). Such an encoding allowed to maintain the variable 
for classification and encoded it with a not naturally occurring value implying 
that this variable did not apply for this patient. All additional missing 
variables were imputed using median/mode imputation calculated on the 
training set (see below) to obtain a full data set. No variable had more than 
10% missing values before imputation was applied. Additional information 
about measurement instruments, variable scoring and collection can 
be found in the Supplementary Methods. We investigated the predictive 
capability of all domains individually and the combination of all five domains.
Machine learning algorithm
RFCs (Breiman, 2001) were used in all analyses. RFCs have been shown to 
perform well on many different machine learning problems (Fernández-
Delgado, Cernadas, Barro, & Amorim, 2014), specifically in biomedical 
sciences (Olson, Cava, Mustahsan, Varik, & Moore,  2018). An RFC is built as 
an ensemble of many decision trees (Breiman, Friedman, Olshen, & Stone, 
1984) which themselves are trained by considering random subsamples of 
variables and patients for each tree. Such a procedure leads to improved and 
robust prediction performance in comparison to individual trees (Breiman, 
2001). Details on hyperparameters used in the analysis can be found in the 
Supplementary Methods. All analyses were implemented using the scikit-
learn (version 0.20.2) (Pedregosa et al., 2011) and imbalanced-learn 
toolboxes (version 0.4.3) (Lemaître, Nogueira, & Aridas, 2017) in the Python 
programming language (version 3.7.2).
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Evaluation
To evaluate the performance of our classifiers 10-times-repeated-10-fold-
cross-validation was applied. In this procedure, the data set is repeatedly (n 
= 100) divided into disjoint training (90% of data) and test (10% of data) sets 
and the RFC is only fit on the training data and evaluated on the independent 
test data. The final performance is obtained as an average across all test 
set evaluations. We measured performance as area-under-the-receiver-
operator-curve (AUC). In addition, we calculated sensitivity, specificity, 
balanced accuracy – average between sensitivity and specificity – and 
positive/negative predictive values. To further validate our classification 
performance label-permutation tests (n = 1000) of average AUC values were 
performed (Ojala & Garriga, 2010). The obtained p values were Bonferroni-
corrected across five individual and one combination of all domains and 
alpha was set to 0.05.
To systematically compare the performance of different predictor 
domains patients were distributed in exactly the same way for each of the 
classifications, i.e. the train and test set of any cross-validation iteration 
included the same patients for each predictor domain. This allowed the 
calculation of normalized average differences in AUC scores across cross-
validation iterations for each pair of predictor domains (including the 
combination of all domains). Non-parametric sign-flipping tests (n = 10 000) 
were then employed to derive p values which were Bonferroni-corrected for 
30 comparisons with alpha set to 0.05.
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Table 1. Included baseline predictor variables across the five predictor domains
Domain Timespan Constructs (no of items) Measurement instruments
Clinical domain Current Common mental disorder diagnoses (25), 
pathological worrying (11), phobic concerns 
(15), disability (35), all psychotropic 
medication, by classes (13).
WHO-Composite International Diagnostic 
Interview (CIDI), Penn State Worry 
Questionnaire (PSWQ), Fear Questionnaire 
(FQ), WHO-Disability Assessment Schedule 
II (WHO-DAS), according to Anatomical 
Therapeutic Chemical (ATC) codes.
(311 variables)
Past week Depressive symptoms (28), general distress and 
somatization (32), mood and anxiety symptoms 
(30), suicidal ideation (5).
Inventory of Depressive Symptomatology-
SR (IDS-SR), Four-Dimensional Symptom 
Questionnaire (4DSQ), Mood and Anxiety 








Perceived need for care (14). Perceived Need for Care Questionnaire.
Past three
years
Previous psychotropic medication, by classes 
(6).
According to ATC codes.
Past four
years
Anxiety duration, months (1). Life Chart Interview (LCI).
Lifetime Anxiety and depressive disorders diagnoses 
(14), bipolar symptoms (13), number of negative
life-events (1), childhood trauma (3), 
convictions about the importance of care and 
past experiences with care (36).
CIDI, Mood Disorder Questionnaire (MDQ), 
Brugha questionnaire, NEMESIS questionnaire, 





Current Anxiety sensitivity (16), cognitive reactivity to 
sadness (34), mastery (5), personality structure 
according to the Five Factor (76).
Anxiety Sensitivity Index, Leiden Index of 





Current Demographic characteristics (6), employment 
status (5), marital status (2), sexual preference 
(1), housing status (5), family and household 
decomposition (6), income (11), religion (1),
leisure activities (20), loneliness (11), social
support (3).
Self-report questionnaires, de Jong-Gierveld 
loneliness scale, Close Person Inventory.
Biological domain 
(49 variables)
Current Number of chronic diseases (2), chronic pain 
(1), menstrual cycle status (4), Body Mass 
Index (1), hip/waist circumference ratio (2), 
blood pressure (7), handedness (1), hand-grip 
strength (2), current fever or cold (2), autonomic 
nervous system function (6), blood plasma 
measures, including CRP, TNF-α, BDNF, and IL-6 
(21).
Chronic graded pain scale, OMRON M4 
IntelliSense digital blood pressure monitor, 




Current Smoking status (1), psychoactive substances 
use (1), amount of alcohol consumption (1), 
levels of physical exercise (4).
Fagerström Test for Nicotine Dependence, 
Alcohol Use Disorders Identification Test, 
International physical activity questionnaire.
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Variable importance
In addition to its strong classification performance RFCs allow to quantify 
the importance of each variable towards the classification task (Breiman, 
2001). However, the standard calculation of variable importance has been 
shown to be biased (Strobl, Boulesteix, Zeileis, & Hothorn, 2007) and 
a permutation-based variable importance scheme has been suggested 
instead (Altmann, Toloşi, Sander, & Lengauer, 2010; Hapfelmeier & Ulm, 
2013; Strobl et al., 2007). Following this approach, we calculated p values 
for each variable by permuting (n = 1000) every variable separately. The 
computed p values were then corrected according to the false discovery rate 
(FDR) (Benjamini & Hochberg, 2000) and significance was set to 0.05. Given 
that variable importance was calculated every cross-validation iteration, 
important variables were defined as variables which were consistently 
significant under FDR for at least 50% of all cross-validation iterations. This 
very stringent procedure for identifying important variables was employed to 
calculate valid variable importance information specific to the classification 
task. Variable importance were only investigated for the classifications using 
the data from the combination of all domains. In addition, we investigated 
differences in the average rankings of important variables between the two 
classification tasks. A detailed description of this approach can be found in 
the Supplementary Methods.
Results
At 2-year follow-up, 484 patients (54.6%) recovered from anxiety 
disorders, and 362 patients (40.8%) did not have any CMD. Baseline 
clinical, psychological, sociodemographic, biological and lifestyle variables 
are provided for patients with and without anxiety disorders at follow-
up (Table 2) and for patients with and without CMD at follow-up (online 
Supplementary Table 1). Various clinical and psychological variables 
showed differences between the two groups. By contrast, biological and 
lifestyle status did not differ between the two groups.
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Recovery from anxiety disorders
Classification performance
Results of our evaluation of the RFC when predicting recovery from anxiety 
disorders are reported in Table 3 and Fig. 1A. AUC values for the predictor 
domains ranged from 0.49 to 0.67 with significant (pBonferroni < 0.05) AUC values 
obtained for the clinical (0.67), and psychological (0.65) domains, as well 
as for the combination of all domains (0.67). Classification accuracies were 
small to moderate with the highest accuracy achieved by the combination 
of all domains (62.4%) with a sensitivity of 62.0% and specificity of 62.8%. 
In addition, we investigated the performance of the RFC for subgroups of 
patients who had any comorbidity (MDD, dysthymia, or alcohol dependency, 
n = 252 recovered, n = 248 persistent) at baseline and for patients who did 
not (n = 232 recovered, n = 155 persistent). For that, the RFC trained on all 
data domains and all patients of the training set was evaluated within the 
two subgroups on the test set separately. The RFC obtained an average 
AUC of 0.64 within the no-comorbidity group and an AUC of 0.68 within the 
comorbidity group showing slightly increased performance for predictions 
within the comorbidity group.
Domain comparisons
When comparing different domains according to their AUC a clear ordering 
was observed: The clinical domain outperformed every other domain except 
for the combination of all domains (pBonferroni < 0.05), the psychological 
domain outperformed the sociodemographic, biological, and lifestyle 
domains (pBonferroni < 0.05), the sociodemographic domain outperformed the 
biological and lifestyle domains (pBonferroni < 0.05), and the biological domain 
outperformed the lifestyle domain (pBonferroni < 0.05). The combination of 
all domains was better than any domain except for the clinical domain 
(pBonferroni < 0.05).
Variable importance
Consistently selected significant variables (N = 17) identified through a 
permutation-based variable importance calculation of the RFC are reported 
in online Supplementary Table 2. Only variables from the clinical and 
psychological domain were selected. These variables were derived from 
different measurement instruments (BAI, IDS-SR, Fear Questionnaire (FQ), 
NEO-FFI, WHO-Disability Assessment (WHO-DAS), Four-Dimensional 
Symptom Questionnaire (4DSQ), Mastery scale) but all referred to 
characteristic anxiety symptoms, with an emphasis on anxious arousal items.
Table 2. Continued
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Recovery from all common mental disorders
Classification performance
Results of the second classification procedure predicting recovery from 
CMDs are reported in Table 4 and Fig. 1B. AUC values ranged from 0.53 to 
0.70 with significant ( pBonferroni < 0.05) AUC values obtained for the clinical 
(0.70), psychological (0.67), and sociodemographic domain (0.65) as well 
as the combination of all domains (0.70). The highest accuracy was achieved 
by the combination of all domains (63.4%) with a sensitivity of 64.6% and 
a specificity of 62.3%. As in the case of the prediction of the recovery from 
anxiety disorders, we investigated the performance of the RFC for subgroups 
of patients who had (n = 164 recovered, n = 336 persistent) or did not (n = 
198 recovered, n = 189 persistent) have any comorbidities at baseline. For 
that, the RFC trained on the combintation of all domains and all patients 
of the training set was evaluated within the two sub-groups on the test set 
separately. The RFC obtained an AUC of 0.62 within the no-comorbidity 
group and an AUC of 0.73 within the comorbidity group. As in the case of the 
prediction of recovery from anxiety disorders the RFC was showing better 
performance for patients with comorbidities at baseline.
Domain comparisons
The best performing domains for this classification were the same as in 
the recovery from anxiety disorders classification. The clinical domain 
and the combination of all domains did not differ in their performance but 
outperformed any other domain during the classification. The order for the 
performance of the other domains was the same as with the recovery from 
anxiety disorders classification.
Variable importance
48 variables were identified as being consistently selected significant 
variables contributing to the classification (online Supplementary Table 3). 
In this classification, selected variables included a larger set of measures 
related to mood disorders and not only anxiety symptomatology. With one 
exception (sociodemographic) all variables were again selected from the 
clinical or psychological domain.
Difference in important variables between prediction analyses
Variables which were more (or less) important in the prediction of recovery 
from anxiety disorders than the prediction of all CMDs are reported in 
online Supplementary Table 4. These results confirmed the importance of 
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anxiety-related variables for the prediction of recovery from anxiety, and the 
importance of depression-related variables for the prediction of recovery 
from all CMDs.
Table 2. Baseline characteristics of anxiety disorder sample, group comparisons between 
patients who had no anxiety disorder (n = 484) at 2-year follow-up and patients who did 
(n = 403)






 PD diagnosis 176 (36.4%) 192 (47.6%) Χ2 = 11.52 <0.001
 Agoraphobia diagnosis 141 (29.1%) 176 (43.7%) Χ2 = 20.24 <0.001
 SAD diagnosis 196 (40.5%) 212 (53.6%) Χ2 = 12.98 <0.001
 GAD diagnosis 141 (29.1%) 136 (33.7%) Χ2 = 2.18 0.14
 MDD diagnosis 174 (36.0%) 188 (46.7%) Χ2 = 10.42 0.001
 Dysthymia diagnosis 58 (12.0%) 88 (21.8%) Χ2 = 15.53 <0.001
 Use of psychotropic medication, current 345 (71.3%) 294 (73.0%) Χ2 = 0.31 0.58
 Avoidance behaviour severity, mean FQ, current 31.76 ± 18.21 40.90 ± 20.07 t = -6.98 <0.001
 Pathological worrying severity,  
 mean PSWQ, current
35.95 ± 9.91 39.56 ± 9.39 t = -5.52 <0.001
 Suicidal thoughts, SSI, past week 72 (14.9%) 111 (27.5%) Χ2 = 21.55 <0.001
 Level of distress, mean 4DSQ, past week 16.03 ± 8.94 19.85 ± 8.75 t = -6.39 <0.001
 Depressive symptoms severity,  
 mean IDS-SR, past week
26.58 ± 12.00 32.78 ± 12.59 t = -7.48 <0.001
 Sleep disturbances, mean ISR, past four weeks 9.39 ± 5.15 10.19 ± 5.24 t = -2.28 0.02
 Anxiety symptoms severity,  
 mean BAI, past month
15.97 ± 9.36 21.10 ± 11.05 t = -7.49 <0.001
 Percentage of time spent with anxiety symptoms,
 LCI, past four years
43.81% ± 33.20 54.04% ± 34.20 t = -4.37 <0.001
 History of childhood life events1 89 (18.4%) 74 (18.4%) Χ2 = 0.00 0.99
 History of childhood trauma2 258 (53.3%) 247 (61.4%) Χ2 = 5.93 0.02
 History of serious suicide attempts 66 (13.7%) 87 (21.6%) Χ2 = 9.57 0.002
Psychological domain
 Neuroticism, mean NEO-FF subscale 40.46 ± 6.89 43.66 ± 6.73 t = -6,95 <0.001
 Extraversion,  mean NEO-FFI subscale 34.70 ± 6.51 32.43 ± 6.82 t =  5.06 <0.001
 Conscientiousness,  mean NEO-FFI subscale 40.88 ± 6.45 39.23 ± 6.36 t =  3.82 <0.001
 Agreeableness, mean NEO-FFI subscale 43.38 ± 5.37 42.59 ± 5.27 t =  2.20 0.03
 Openness,  mean NEO-FFI subscale 38.25 ± 6.03 38.04 ± 6.32 t =  0.51 0.61
 Cognitive reactivity to sadness, mean LEIDS 40.80 ± 17.98 46.76 ± 17.98 t = -4.91 <0.001
 Anxiety sensitivity, mean ASI 33.63 ± 9.47 36.58 ± 10.43 t = -4.35 <0.001
 Mastery, mean Mastery scale 15.77 ± 4.02 13.89 ± 4.06 t =  6.90 <0.001
Sociodemographic domain
 Age in years 41.88 ± 12.09 41.97 ± 12.34 t = -0.11 0.91
 Education years 12.02 ± 3.29 11.70 ± 3.41 t =  1.43 0.15
 Female gender 329 (68.0%) 276 (68.5%) Χ2 = 0.03 0.87
 Currently employed 280 (57.9%) 206 (51.1%) Χ2 = 4.03 0.05
Table continues
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 Has children 268 (55.4%) 212 (52.6%) Χ2 = 0.68 0.41
 Current severe loneliness 47 (9.7%) 58 (14.4%) Χ2 = 4.57 0.03
Biological domain
 Number of chronic somatic diseases 0.67 ± 0.89 0.72 ± 0.95 t = -0.82 0.41
 Chronic pain with high disability 100 (20.7%) 121 (30.0%) Χ2 = 10.31 0.001
 BMI 25.46 ± 4.72 25.71 ± 5.52 t = -0.74 0.46
 Mean heart rate (bpm) 71.70 ± 9.59 72.05 ± 10.12 t = -0.52 0.60
 Systolic blood pressure (mmHg) 136.3 ± 20.63 135.9 ± 17.97 t = 0.31 0.76
 CRP (mg/L, n=876) 2.67 ± 4.05 3.12 ± 6.29 t = -1.26 0.21
 IL-6 (pg/ml, n=876) 1.28 ± 3.00 1.43 ± 3.15 t = -0.69 0.49
 TNF-α (pg/ml, n=871) 1.07 ± 1.28 1.04 ± 1.12 t = 0.41 0.69
 BDNF (ng/ml, n=865) 9.18 ± 3.64 9.20 ± 3.46 t = -0.08 0.94
Lifestyle domain
 Former smoker 153 (31.6%) 119 (29.5%)
Χ2 = 2.86 0.24
 Current smoker 174 (36.0%) 167 (41.4%)
 Low physical activity, past week 103 (22.7%) 98 (25.3%)
Χ2 = 1.84 0.40
 High physical activity, past week 156 (34.4%) 117 (30.2%)
 Any substance use, past week 33 (6.8%) 33 (8.2%) Χ2 = 0.60 0.44
 Hazardous drinking or alcohol dependency,3
 past year 
109 (22.6%) 87 (21.6%) Χ2 = 0.13 0.71
PD, panic disorder; SAD, social anxiety disorder; GAD, generalized anxiety disorder; MDD, major depressive disorder; FQ, 
Fear Questionnaire; PSWQ, Penn State Worry Questionnaire; SSI, Suicidal Ideation Scale; 4DSQ, Four-Dimensional Symptom 
Questionnaire; IDS-SR, Inventory of Depressive Symptomatology-SR; ISR, Insomnia Rating Scale; BAI, Beck’s Anxiety Inventory; 
LCI, life chart interview; NEO-FFI, NEO Five-Factor Inventory; LEIDS, Leiden Index of Depression Sensitivity; ASI, Anxiety 
Sensitivity Index; BMI, Body Mass Index; CRP, c-reactive protein; IL-6, interleukin-6; TNF-α, tumour necrosis factor-α; BDNF, 
Brain-Derived Neurotrophic Factor.
p values shown in bold are <0.05.
aChildhood life events (<16 years of age) were parental divorce, being placed in a juvenile prison, raised in a foster family, 
placed in a child home, death of a parent.
bChildhood trauma included emotional neglect, psychological abuse, physical abuse, and sexual abuse.
cAs measured with the AUDIT. Scores above 8 are reflective of hazardous drinking, scores at 13 or higher (females) and 15 or 
higher (males) are indicative of probable alcohol dependency.
Transfer analysis
We replicated the classification of recovery from anxiety disorders at 2-year 
follow-up in a transfer learning setting: in such an approach we utilized the 
labels indicating recovery of CMDs during the training of the RFC classifier 
(training set) but subsequently evaluated its performance on the test set 
using the recovery from anxiety disorder labels. The result of this analysis 
can be seen in online Supplementary Table 5. Utilizing the transfer learning 
approach led to improved performance in predicting anxiety disorder 
recovery (AUC = 0.71 v. AUC = 0.67 for both training and testing on anxiety 
disorder recovery labels using either only the clinical or the combination of 
all domains). The increased performance was observed due to an increase 
Table 2. Continued
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in sensitivity of the classification for correctly identifying recovered anxiety 
patients. For all individual domains and the combination of them, sensitivity 
increased by 7.6 ± 1.9 when training on the CMDs labels first. Specificity only 
decreased slightly (mean decrease: 2.7 ± 0.8) which led to the improved 
overall performance.
Discussion
One of the most important goals in personalized medicine is providing 
individual disease course predictions. Our results show that individual 
prediction of 2-year course in anxiety disorders is possible using various 
predictors but it is only moderately successful. The main outcome measure 
was recovery from anxiety disorders and our predictions reached a balanced 
accuracy of 62.4% with an AUC of 0.67. The current performance by itself 
does not warrant implementation of our models in routine psychiatric care 
as it would yield too many false positives/negatives. However, predictive 
properties of clinician opinion in predicting disease course in anxiety 
disorders are not available and therefore it remains unclear which predictive 
performance threshold is needed for a statistical model to surpass clinician 
opinion and become an improvement over current routine care.
Our study yielded two models with comparable accuracy for predicting 
2-year anxiety disorder course: one consisting of predictors from all five 
domains and one consisting of predictors only from the clinical domain. 
Biological, lifestyle, and sociodemographic predictors did not contribute 
significantly to course prediction. This is surprising as these domains were 
previously shown to be related to anxiety disorder aetiology. Our results 
thereby suggest that the underlying aetiology is of less importance to course 
prediction after the development of threshold disorders and that after 
anxiety disorders have developed, phenotypical characteristics have more 
impact on subsequent disease course. This is evident from the individual 
features that contributed most to the classification. All of these features 
reflected symptoms, psychological states or traits associated with the 
emotions of fear and anxiety, such as the presence of ‘phobic symptoms’, 
difficulty ‘walking alone in a busy street’ or ‘dealing with people you don’t 
know’, ‘feeling tense’, ‘not liking to be where the action is’, and ‘feeling faint 
or lightheaded’. A previous NESDA study that aimed to predict the naturalistic 
course in depression showed similar performance to the current study when 
2-year follow-up MDD diagnosis was correctly classified with an AUC of 
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0.66  and balanced accuracy of 62% (Dinga et al., 2018). In this study, clinical 
features were most important as well, though the nature of those items was 
related to depression.
Table 3. Evaluation of the 2-year recovery from anxiety disorders classification [mean 
(S.D.)]
Domains AUC Accuracy Sensitivity Specificity PPV NPV
Clinical 0.67 (0.05)* 61.7 (4.4) 61.5 (6.3) 61.9 (7.6) 0.66 (0.05) 0.57 (0.04)
Psychological 0.65 (0.05)* 61.0 (4.5) 60.0 (6.4) 61.9 (7.5) 0.66 (0.05) 0.56 (0.05)
Socio- 
demographic 0.56 (0.06) 53.1 (5.1) 49.7 (7.4) 56.5 (7.5) 0.58 (0.06) 0.48 (0.05)
Biological 0.53 (0.06) 52.7 (4.9) 50.3 (6.8) 55.0 (7.6) 0.57 (0.05) 0.48 (0.05)
Lifestyle  0.49 (0.05) 50.2 (4.3) 46.6 (5.5) 53.7 (7.6) 0.55 (0.05) 0.46 (0.04)
Combination 0.67 (0.05)* 62.4 (4.6) 62.0 (6.1) 62.8 (7.5) 0.67 (0.05) 0.58 (0.05)
AUC, area-under-receiver-operator-curve; PPV, positive predictive value; NPV, negative predictive value; * pBonferroni < 0.05.
 p values shown in bold are <0.05.
Table 4. Evaluation of the two-year recovery from all common mental disorders 
classification  [mean (SD)]
Domains AUC Accuracy Sensitivity Specificity PPV NPV
Clinical 0.70 (0.05)* 62.2 (4.6) 65.0 (7.1) 59.3 (5.6) 0.52 (0.05) 0.71 (0.05)
Psychological 0.67 (0.05)* 62.2 (4.8) 61.8 (8.4) 62.6 (6.4) 0.53 (0.05) 0.71 (0.05)
Socio- 
demographic 0.65 (0.05)* 60.8 (5.2) 65.2 (7.5) 56.5 (6.5) 0.51 (0.05) 0.70 (0.05)
Biological 0.57 (0.05) 56.0 (4.8) 57.5 (8.2) 54.6 (6.7) 0.47 (0.05) 0.65 (0.05)
Lifestyle  0.53 (0.05) 51.8 (4.7) 62.3 (7.9) 41.2 (6.5) 0.42 (0.04) 0.61 (0.06)
Combination 0.70 (0.05)* 63.4 (4.8) 64.6 (7.3) 62.3 (6.1) 0.54 (0.05) 0.72 (0.05)
AUC, area-under-receiver-operator-curve; PPV, positive predictive value; NPV, negative predictive value; * pBonferroni < 0.05.
p values shown in bold are <0.05.
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Figure 1. Classification performance of random forest classifiers. Performance is 
quantified by area-under-the-receiver-operator-curve (AUC) values calculated for 
each test set of all cross-validation iterations and is shown in box-and-whisker plots for 
all data domains. (a) Performance of the recovery from anxiety disorders prediction,(b) 
Performance of the recovery from all common mental disorders prediction. Asterisks 
mark a significant classification performance according to label-permutation tests 
(n = 1000) and Bonferroni-correction for six tests.The dashed line indicates chance-
level performance.
As anxiety disorders and other psychiatric disorders frequently co-occur and 
show diagnostic instability over time, a secondary outcome was assessed. 
This broad perspective model was trained on recovery from all CMDs and 
showed marginally higher accuracy (63.4%) and AUC (0.70) in comparison 
with the main narrow perspective outcome. Like in the narrow perspective, 
omitting all domains except the clinical domain did not lead to a significant 
loss of predictive power (accuracy = 62.2% and AUC = 0.70).
The individual features that were most consistently chosen during 
the classification again were almost exclusively from the clinical and 
psychological domains. Symptoms, psychological traits, and psychological 
states associated with depression and worrying contributed most to the 
classification. For instance: ‘feeling down’, ‘feeling sad’, having ‘a desire 
to die’, ‘suffering from worry’, ‘feeling tense’, and ‘having little control 
about the things that happen’. This suggests that predictions for recovery 
from all CMDs were largely driven by co-occurring depressive symptoms. 
Our decision to investigate the CMDs classification was also supported 
by the results of the additional transfer analysis which showed improved 
performance (accuracy = 63.3% and AUC = 0.71 for the combination of 
all domains data) when using the recovery from all CMDs labelling during 
training and the recovery from anxiety labels during model evaluation. This 
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analysis showed that patients suffering from any mental disorder at 2-year 
follow-up – anxiety or not – constituted a more homogenous group while 
patients who fully recovered were more easily identified than patients only 
recovering from anxiety disorders (but having an additional CMD instead). 
This suggests that applying a broad perspective in future attempts in clinical 
prediction is more feasible for anxiety disorders.
Previous ML studies in anxiety disorders were invariably small in sample 
size and most focused on predicting immediate treatment response using 
neuroimaging data (Ball, Stein, Ramsawh, Campbell-Sills, & Paulus, 2014; 
Doehrmann et al., 2013; Hahn et al., 2014; Pantazatos, Talati, Schneier, & 
Hirsch, 2014; Whitfield-Gabrieli et al., 2016). Some studies used clinical, 
biological and/or neuroimaging data to distinguish between different 
types of anxiety disorders and healthy controls (Carpenter, Sprechmann, 
Calderbank, Sapiro, & Egger, 2016; Frick et al., 2014; Hilbert, Lueken, 
Muehlhan, & Beesdo-Baum, 2017; Pantazatos et al., 2014). To the best 
of our knowledge, this is the first study into individual long-term course 
prediction in anxiety disorders. A strength of this study is the use of a large 
dataset with a high number of variables from a variety of predictor domains, 
most of which were previously related to disease course at the group level. 
In addition, using RFCs allowed for combining large numbers of predictors 
into an overall model and allowed the identification of the most contributing 
predictors, providing insight into the possible processes involved with 
recovery in anxiety disorders.
In spite of the wide array of predictors, the current study showed only 
moderate accuracy. This has a number of explanations. First, NESDA is a 
naturalistic cohort study in which the exposure to environmental stressors 
and treatment regimens varied across patients during the 2-year follow-up 
period. These different exposures will have impacted the 2-year outcomes. 
Furthermore, different data types might improve predictive accuracy. For 
instance, previous ML studies showed the strong potential of neuroimaging 
data to predict treatment response in anxiety disorders (Ball et al., 2014; 
Doehrmann et al., 2013; Hahn et al., 2014; Pantazatos et al., 2014; Whitfield-
Gabrieli et al., 2016), sometimes exceeding predictions made using 
clinical data (Ball et al., 2014; Doehrmann et al., 2013). Our study did not 
encompass neuroimaging data, as these were only available in a subset of 
NESDA participants (Janssen, Mourão-Miranda, & Schnack, 2018). Other 
examples include gait analysis (Zhao et al., 2019), actigraphy (Merikangas 
et al., 2019), or social media data (Reece & Danforth, 2017). Additionally, 
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more frequent data collection might improve predictive accuracy (Kubben, 
Dumontier, & Dekker, 2019), which has now been implemented in the most 
recent wave of NESDA (Difrancesco et al., 2019). However, it is worth noting 
that our analyses showed that using a large set of variables from various 
domains (either combined or independently) did not outperform the clinical 
domain alone. Finally, future studies could explore differences in predictive 
performance across different patient subgroups, by analyzing separate 
patient groups consisting of different anxiety disorders, or groups with 
different comorbidity patterns separately.
Clinical care for anxiety disorders would benefit greatly from improved 
course prediction as it would pave the way for targeted treatments. The 
current study showed moderate accuracy in predicting recovery from 
anxiety disorders over a 2-year follow-up for individual patients. Items 
from the clinical and psychological domain were the most contributing 
predictors, while biological, lifestyle, and sociodemographic predictors 
were contributing less. The limited performance while using a wide array 
of predictors does not justify application in routine clinical care. The 
results from our study can, however, be used as a benchmark for future 
studies, with future studies likely resulting in further enhancements of the 
predictive properties. It has long been argued that statistical modelling will 
exceed clinician opinion in prediction problems (Ayres, 2007; Meehl, 1954), 
with clinician interpretation of statistical models likely yielding the best 
predictive power (Kuhn & Johnson, 2013). As a result, statistical models will 
increasingly become an addition to clinician opinion. Eventually, targeted 
treatment regimens and secondary prevention strategies will become more 
feasible if predictive models further evolve. This study provides an important 
first step towards valid long-term ML-based predictions in anxiety disorders.
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Full descriptions of clinical domain measurement instruments
Lifetime history for Anxiety and Depressive Disorders and presence of 
DSM-IV Panic Disorder, Panic Disorder with Agoraphobia, Agoraphobia, 
Generalized Anxiety Disorder, Social Anxiety Disorder, MDD, Dysthymia and 
Alcohol Dependency (one month, six-month, one year recency) at baseline 
were assessed using the WHO-Composite International Diagnostic Interview 
(CIDI, version 2.1). The CIDI is a structured interview with good reliability 
and validity (World Health Organization 1998). 
Sleep quality during the past four weeks was assessed with the Women’s 
Health Initiative Insomnia Rating Scale (IRS) (Levine et al. 2003). This 
questionnaire consists of six items and a summary score. 
Mood and anxiety symptoms during the past week were assessed with the 
Mood and Anxiety Scoring Questionnaire (Watson et al. 1995). The MASQ 
consists of 30 individual items and three summary scores: positive affect, 
negative affect and levels of somatization. 
Presence of lifetime bipolar symptoms were assessed with the Mood 
Disorder Questionnaire (MDQ) (Hirschfeld et al. 2000). This questionnaire 
consists of 13 individual items and a summary score.
Levels of general distress and somatization during the past week were 
measured with the Four-Dimensional Symptom Questionnaire (4DSQ) 
(Terluin 1996). These two dimensions were measured in 32 items and two 
summary scores. 
Levels of pathological worrying tendencies were assessed using the 11-item 
self-report version of the Penn State Worry Questionnaire (PSWQ) (Drost et 
al. 2012).
Depressive symptoms during the past week were assessed with the 
Inventory of Depressive Symptomatology-SR (IDS-SR) (Rush et al. 1986, 
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Symptoms of anxiety during the past month were assessed with the Beck 
Anxiety Inventory (BAI), a 21-item self-report questionnaire (Beck et al. 
1988). 
Presence of avoidance behaviors was assessed with the Fear Questionnaire 
(FQ), a 15-item self-report questionnaire (Marks & Mathews 1979).
Presence of childhood trauma was assessed with a 3-item adaptation from 
the NEMESIS questionnaire (Wiersma et al. 2009).
Symptoms of suicidality during the past week were assessed with the 5 items 
from the Suicidal Ideation Scale (SSI) that refer to the current state (Beck et 
al. 1979).
The total number of negative life-events during the past year was assessed 
with the Brugha questionnaire (Brugha et al. 1985).
Duration of anxiety symptoms during the last four years prior to 
baseline were assessed with the Life Chart Interview (LCI), a structured 
retrospective interview using a calendar approach (Lyketsos et al. 1994). 
The LCI has adequate reliability and validity (Warshaw et al. 1994). Due to 
large proportions of missingness, time spent with depressive and avoidance 
symptoms were not included in analyses.
Subjects’ convictions about the importance of care and their past experiences 
with care in relation to mental health problems were assessed with the 36-
item QUality Of care Through the Eyes of the patient (QUOTE): Anxiety/
Depression version (Sixma et al. 1998).
Subjects’ perceived need for care at various domains during the past 
six months was assessed with the 20-item Perceived Need for Care 
Questionnaire (PNCQ) (Meadows et al. 2000). After missing data handling, 
14 items were included in analyses.
Levels of disability were measured with the WHO-Disability Assessment 
Schedule (WHO-DAS II), a 36-item self-report questionnaire measuring levels 
of disability (Chwastiak & Von Korff 2003). Four work-related items were 
omitted from further analyses due to large proportions of missing values. 
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All baseline pharmacotherapeutic use was assessed using inspection of 
medication containers and coded according to Anatomical Therapeutic 
Chemical (ATC) codes at baseline (WHO Collaborating Centre for Drug 
Statistics Methodology n.d.). Historic use of psychopharmacotherapeutics 
during the three-year period prior to baseline was reported retrospectively.
Full descriptions of psychological domain measurement 
instruments
Anxiety sensitivity was measured with the 16-item Anxiety Sensitivity Index 
(ASI) (Reiss et al. 1986).
Cognitive reactivity to sadness was measured with the 34-item Leiden Index 
of Depression Sensitivity (LEIDS) (Van der Does 2002).
Levels of mastery were assessed with an adapted version of the Pearlin 
Mastery Scale, consisting of 5 items (Pearlin & Schooler 1978; Kempen et al. 
1998).
Personality structure was assessed with the NEO Five-Factor Inventory, 
a shortened version of the Revised NEO Personality Inventory (McCrae 
& Costa 2004). In our analyses, all 60 individual items, as well as domain 
scores from the five domains were used.
In order to be able to assess relative levels of these psychological traits, 
summary scores were standardized at the level of the whole NESDA sample.
Full descriptions of sociodemographic domain measurement 
instruments
Information on sociodemographic information from subject was gathered 
in a structured manner by face-to-face interviews with trained research 
assistants. Information gained referred to demographic characteristics 
(6 items), employment status (6 items), marital status (2 items, of which 
one was omitted due to high number of missing values), sexual preference 
(2 items, of which one was omitted due to high number of missing values), 
housing status (5 items), sources and level of income (11 items), religion 
status (3 items of which two were omitted due to high number of missing 
values), family and household decomposition (23 items, of which seventeen 
were omitted due to high number of missing values), and participation in 
various leisure activities (23 items, of which three were omitted due missing 
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descriptive statistics table dichotomously. Categories that we presented 
as ‘currently employed’ included ‘now employed’, ‘self employed’ and ‘on 
pregnancy or maternity leave’. The remaining categories were ‘occupationally 
disabled’, ‘on sickness benefit’, ‘early retirement’, ‘unemployed’ and ‘other’. 
Current levels of loneliness were assessed with the de Jong-Gierveld 
loneliness scale, an 11 item self-report questionnaire (de Jong-Gierveld & 
Kamphuls 1985). Severe loneliness was defined as a maximum score of 11.
Levels of current social support were assessed with the 38-item Close 
Person Inventory (CPI)  (Stansfeld & Marmot 1992). However, due to large 
proportions of missing data, only 3 items were included in our analyses.
Full descriptions of biological domain measurement 
instruments
The number of chronic diseases with or without treatment were assessed 
using a 21-item face-to-face interview (Penninx et al. 2008). Subjects were 
asked for presence of 30 common chronic somatic diseases and were able to 
report any additional diseases they may have. This yielded 2 items that were 
both included.
Levels of chronic pain during the past 6 months were assessed with the 
chronic graded pain scale in which levels of chronic pain are summarized in a 
single ordinal item consisting of 5 grades of pain (Von Korff et al. 1992).
The current menstrual cycle status was assessed in five self-reported items, 
of which 4 were used in analyses.
Body Mass Index (BMI) and hip/waist circumference ratio were measured 
by a trained research assistant, in accordance to international standards.
(World Health Organisation 1989)
Autonomic nervous system function was reflected by measurements of 
mean heart rate, heart rate variability, inter-beat-interval, pre-ejection 
period, aggregated respiratory sinus arrhythmia, and aggregated 
respiration rate. These were measured during the baseline data collection 
interview with the Vrije Universiteit Ambulatory Measuring System (Vu-
AMS) (de Geus et al. 1995). 
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Systolic and diastolic blood pressure was measured with the OMRON M4 
IntelliSense digital blood pressure monitor (HEM-752A, Omron Healthcare, 
Inc., Bannockburn, Illinois, USA n.d.). In NESDA, the average of two 
measurements was used.
Handedness was assessed by self-report. Hand-grip strength, a proxy for 
overall muscle strength, was assessed twice with the Jamar dynamometer 
(Bellace et al. 2000; Ashton & Myers 2004). 
Whether subjects had a fever or a cold during the last week was assessed by 
self-report. 
Fasting blood samples of NESDA participants were obtained in the morning 
around 8 am and kept frozen at -80°C. Various laboratory tests were 
performed on these samples.
Brain-Derived Neurotropic Factor (BDNF), Triglycerides, High Density 
Cholesterol (HDL), glucose, tryptophan, kynurenine, 3-Hydroxykynurenine, 
Cystatin C, Urea, Uric acid, Creatinin, Cotinine, Parathyroid hormone (PTH), 
25-hydroxy vitamin D, Dehydroepiandrosterone, Dehydroepiandrosterone 
sulfate (DHEA-S), Sex hormone-binding globulin (SHBG), Estradiol 
(E2), and Testosterone (nmol/l) were assayed at the Clinical Chemistry 
department of the VU University Medical Center using standard laboratory 
procedures. Dehydroepiandrosterone measurements were omitted due to 
missings.
High-sensitivity plasma levels of C-reactive protein (CRP) were measured 
in duplicate by an in-house ELISA based on purified protein and polyclonal 
anti-CRP antibodies.(Dako, Glostrup, Denmark n.d.) The CRP assay was 
standardized against the CRM 470 reference agent. The lower detection limit 
of CRP was 0.1 mg/l and the sensitivity was 0.05 mg/l.
Plasma Interleukine-6 (IL-6) levels were measured in duplicate by a high 
sensitivity enzyme-linked immunosorbent assay.(PeliKine CompactTM 
ELISA, Sanquin, Amsterdam, The Netherlands n.d.) The IL-6 assay was 
standardized against a recombinant human IL-6 standard. The lower 
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Plasma Tumour necrosis factor-alpha (TNF-α) levels were assayed in 
duplicate at Good Biomarker Science, Leiden, The Netherlands, using a high-
sensitivity solid phase ELISA.(Quantikine® HS Human TNF- α Immunoassay, 
R&D systems Inc, Minneapolis, MN, United States n.d.) The TNF-α assay was 
calibrated against a highly purified E. coli-expressed recombinant human 
TNF-α. The lower detection limit of TNF-α was 0.10 pg/ml and the sensitivity 
0.11 pg/ml. 
Full descriptions of lifestyle domain measurement instruments
Smoking status was assessed with three items from the Fagerström Test 
for Nicotine Dependence (Heatherton et al. 1991). Subjects were divided 
into current smokers, former smokers and subjects who never smoked. Two 
items were omitted due to missings. 
Number of different psychoactive banned substances used by subjects was 
assessed by self-report.
The amount of alcohol consumption during the past year was assessed with 
the Alcohol Use Disorders Identification Test (AUDIT) (Saunders et al. 1993).
The levels of physical exercise, expressed in metabolic equivalent of task 
(MET)-minutes/week during the past week were assessed with the 4-item 
International physical activity questionnaire (Ainsworth et al. 2000).
Extended description random forest classifier
Each Random Forest classifier (RFC) was build using 1000 classification 
trees (Breiman et al. 1984) and the number of randomly selected variables 
per node was set at the square root of the number of variables (default 
value). Subsample aggregating (subagging) was used instead of bootstrap 
aggregating (bagging) to create new random subsets of data points per tree. 
Subagging allowed for balancing the data set (Chen et al. 2004) by sampling 
the same number of subjects for each class, and improving the validity of 
variable importance calculations (Strobl et al. 2007). The balancing of the 
classes can improve classification performance in data sets with imbalanced 
distribution of classes where a classifier might focus on only correctly 
predicting the majority class by assigning all data to this class. 63.2% of 
all subjects was used as the subsampling factor. This corresponds to the 
number of unique subjects in a bootstrap sample when using bagging and is 
recommended as a default (Boulesteix et al. 2012).
220
Variable importance calculation 
The standard calculation of variable importance for RFC has been shown to 
be biased towards continuous variables and categorical variables with many 
categories (Strobl et al. 2007). To ensure the validity of variable importance 
calculations it was suggested to use subagging and permutation-based 
variable importance calculations (Strobl et al. 2007; Altmann et al. 2010; 
Hapfelmeier & Ulm 2013). To implement permutation-based variable 
importance calculations we permuted each variable separately a 1000 times 
and assessed its variable importance under permutation (Ojala & Garriga 
2010). The computed null-distribution was then used to calculate a P-value 
of the actually observed variable importance for each variable. 
Difference in selected variables
To compare whether variable importance differed between the two 
classification tasks the following analysis was conducted: 1. based on 
the P-values calculated from permutation-based variable importance we 
computed a rank from most important (smallest P-value) to least important 
variable per cross-validation iteration, 2. we averaged this ranking across 
the cross-validation runs to obtain an average rank for each variable, 3. we 
calculated the absolute difference of ranks between the two classification 
tasks, 4. we explored each rank difference which was higher (lower) than 
the mean rank difference +(-) twice the standard deviation. In this way we 
could determine which variables average rank changed strongly between 
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Supplementary Table 1. Baseline characteristics of anxiety disorder sample, group 
comparisons between patients who had no common mental disorders (n = 362) at two-
year follow-up and patients who did have any common mental disorder at follow-up 
(n = 525)








PD diagnosis 135 (37.3%) 233 (44.4%) Χ2 = 4.34 0.035
Agoraphobia diagnosis 111 (30.7%) 206 (39.2%) Χ2 = 6.86 0.009
SAD diagnosis 147 (40.6%) 261 (49.7%) Χ2 = 7.15 0.007
GAD diagnosis 92 (25.4%) 185 (35.2%) Χ2 = 9.63 0.002
MDD diagnosis 103 (28.5%) 259 (49.3%) Χ2 = 38.7 <0.001
Dysthymia diagnosis 26 (7.2%) 120 (22.9%) Χ2 = 38.3 <0.001
Use of psychotropic medication, current 252 (69.6%) 387 (73.7%) Χ2 = 1.79 0.181
Avoidance behaviour severity, mean FQ, current 30.96 ± 18.64 39.33 ± 20.06 t = -6.37 <0.001
Pathological worrying severity,  
mean PSWQ, current
35.05 ± 9.81 39.35 ± 9.47 t = -6.49 <0.001
Suicidal thoughts, SSI, past week 38 (10.5%) 145 (27.6%) Χ2 = 38.6 <0.001
Level of distress, mean 4DSQ, past week 14.78 ± 8.79 19.83 ± 8.66 t = 8.47 <0.001
Depressive symptoms severity,  
mean IDS-SR, past week
24.96 ± 11.82 32.47 ± 12.92 t = -9.14 <0.001
Sleep disturbances, mean ISR, past four weeks 9.05 ± 4.94 10.23 ± 5.33 t = -3.38 0.001
Anxiety symptoms severity,  
mean BAI, past month
15.57 ± 9.40 20.19 ± 10.79 t = -6.77 <0.001
Percentage of time spent with anxiety symptoms, 
LCI, past four years
42.4% ± 32.9 52.7% ± 34.2 t = -4.36 <0.001
History of childhood life events1 68 (18.8%) 95 (18.1%) Χ2 = 0.07 0.79
History of childhood trauma2 182 (50.3%) 323 (61.6%) Χ2 = 11.3 0.001
History of serious suicide attempts 43 (11.9%) 110 (21.0%) Χ2 = 12.1 <0.001
Psychological domain
Neuroticism, mean NEO-FF subscale 39.77 ± 6.88 43.39 ± 6.69 t = -7.78 <0.001
Extraversion,  mean NEO-FFI subscale 35.40 ± 6.44 32.40 ± 6.67 t = 6.93 <0.001
Conscientiousness,  mean NEO-FFI subscale 41.54 ± 6.19 39.16 ± 6.46 t = 5.52 <0.001
Agreeableness, mean NEO-FFI subscale 43.84 ± 5.13 42.46 ± 5.41 t = 3.87 <0.001
Openness,  mean NEO-FFI subscale 38.13 ± 5.99 38.18 ± 6.28 t = -0.13 0.90
Cognitive reactivity to sadness, mean LEIDS 38.77 ± 17.91 46.77 ± 17.71 t = -6.55 <0.001
Anxiety sensitivity, mean ASI 33.45 ± 9.63 36.02 ± 10.16 t = -3.77 <0.001
Mastery, mean Mastery scale 16.49 ± 3.83 13.82 ± 4.00 t = 9.97 <0.001
Sociodemographic domain
Age in years 40.94 ± 12.25 42.59 ± 12.13 t = -1.97 0.047
Education years 12.16 ± 3.29 11.68 ± 3.37 t = 2.12 0.034
Female gender 252 (69.6%) 353 (67.2%) Χ2 = 0.56 0.45
Currently employed 218 (60.2%) 268 (51.0%) Χ2 = 7.28 0.007
Has children 168 (46.4%) 239 (45.5%) Χ2 = 0.07 0.80
Current severe loneliness 29 (8.0%) 76 (14.5%) Χ2 = 8.50 0.004
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Biological domain
Number of chronic somatic diseases 0.61 ± 0.84 0.75 ± 0.96 t = -2.25 0.025
Chronic pain with high disability 67 (18.5%) 154 (29.3%) Χ2 = 13.4 <0.001
BMI 25.28 ± 4.64 25.77 ± 5.38 t = -1.47 0.14
Mean heart rate (bpm) 72.03 ± 9.76 71.75 ± 9.89 t = 0.40 0.69
Systolic blood pressure (mmHg) 135.7 ± 20.91 136.5 ± 18.4 t = -0.62 0.53
CRP (mg/L, n=876) 2.70 ± 4.10 2.99 ± 5.83 t = -0.88 0.38
IL-6 (pg/ml, n=876) 1.23 ± 3.05 1.43 ± 3.08 t = -0.94 0.35
TNF-α (pg/ml, n=871) 1.09 ± 1.36 1.04 ± 1.09 t = 0.55 0.58
BDNF(ng/ml, n=865) 9.26 ± 3.57 9.14 ± 3.54 t = 0.48 0.63
Lifestyle domain
Former smoker 119 (32.9%) 153 (29.1%)
Χ2 = 3.99 0.14
Current smoker 125 (34.5%) 216 (41.1%)
Low physical activity, past week 64 (18.9%) 137 (27.3%)
Χ2 = 11.5 0.003
High physical activity, past week 129 (38.1%) 144 (28.7%)
Any substance use, past week 22 (6.1%) 44 (8.4%) Χ2 = 1.65 0.20
Hazardous drinking or alcohol dependency3 
past year 
76 (21.1%) 120 (22.9%) Χ2 = 0.38 0.54
PD: Panic Disorder; SAD: Social Anxiety Disorder; GAD: Generalized Anxiety Disorder; MDD: Major Depressive Disorder; FQ: 
Fear Questionnaire; PSWQ: Penn State Worry Questionnaire; SSI: Suicidal Ideation Scale; 4DSQ: Four Dimensional Symptom 
Questionnaire; IDS-SR: Inventory of Depressive Symptomatology-SR; ISR: Insomnia Rating Scale; BAI: Beck’s Anxiety Inventory; 
LCI: Life chart interview; NEO-FFI: NEO Five-Factor Inventory; LEIDS: Leiden Index of Depression Sensitivity; ASI: Anxiety 
Sensitivity Index; BMI: Body Mass Index; CRP: c-reactive protein; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α; BDNF: 
Brain Derived Neurotrophic Factor.
1 childhood life events (<16 years of age) were parental divorce, being placed in a juvenile prison, raised in a foster family, placed 
in a child home, death of a parent.
2 childhood trauma included emotional neglect, psychological abuse, physical abuse and sexual abuse 
3 as measured with the AUDIT. Scores above 8 are reflective of hazardous drinking, scores at 13 or higher (females) and 15 or 
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Supplementary Table 2: Consistently selected significant variables in the recovery 
from anxiety disorders classification
Item Description Selection Frequency 
[%]
NEO-FFI item 31 I rarely feel fearful or anxious 98
IDS-SR item 27 Panic/Phobic symptoms 98
WHO DAS item 38 How much embarrassment did you experience because of your health 
problems during the past 30 days?
97
FQ item 05 Walking alone in a busy street 95
CIDI PDA 1m Panic with agoraphobia - past month 94
Life chart item 01 percent of time with anxiety symptoms 87
WHO DAS item 16 Dealing with people you do not know? 83
NEO-FFI, neuroticism Anxiety alternative rationally derived decomposition of neuroticism domain 78
CIDI PDA 12m Panic with agoraphobia - past year 77
IDS-SR item 07 Feeling Anxious or Tense 74
4DSQ item 05 During the past week did you feel: tense? 70
NEO-FFI, item 22 I like to be where the action is 69
MASTERY item 04 I often feel helpless dealing with the problems of life 66
CIDI SAD l Social Anxiety Disorder - in lifetime 63
CIDI PDA 6m Panic with agorafobia - past 6 months 61
BAI item 19 Faint, lightheaded 59
4DSQ item 02 During the past week did you suffer from: worry? 54
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Supplementary Table 3: Consistently selected significant variables in the recovery 
from common mental disorders classification
Variable Name Description Selection Frequency [%]
MASQ item 03 Felt successful 100
4DSQ item 01 During the past week did you suffer from: feeling down or depressed? 100
CIDI dysthymia 1m Dysthymia  - past month 100
IDS-SR item 05 Feeling Sad 100
4DSQ item 11 During the past week did you feel: that you can’t enjoy anything anymore? 100
CIDI dysthymia 6m Dysthymia  - past 6 months 100
4DSQ item 09 During the past week did you feel: that you can’t cope anymore? 100
4DSQ item 08 During the past week did you feel: that you can no longer take interest in the people and things around you? 100
4DSQ item 02 During the past week did you suffer from: worry? 100
4DSQ item 10 During the past week did you feel: that you can’t face it anymore? 100
Mastery item 02 Some of my problems I cannot seem to solve at all 100
NEO-FFI, neuroticism Selfreproach 100
Mastery item 04 I often feel helpless dealing with the problems of life 98
Mastery item 05 Sometimes I feel like a play ball of life 98
4DSQ item 05 During the past week did you feel: tense? 97
CIDI MDD 12m Major Depression - past year 97
CIDI dysthymia 12m Dysthymia  - past year 96
SSI item 02 Desire to die 95
IDS-SR item 08 Response of Your Mood to Good or Desired Events 95
Mastery item 01 I have little control about the things that happen to me 95
IDS-SR item 07 Feeling Anxious or Tense 93
CIDI MDD 1m Major Depression - past month 93
MASQ item 25 Had trouble making decisions 91
IDS-SR item 21 Capacity for Pleasure or Enjoyment (excluding sex) 90
MASQ item 22 Felt really “up” or lively 88
Life chart anxiety percent of time with anxiety symptoms 87
BAI item 19 Faint, lightheaded 83
MASQ item 06 Felt really happy 82
MASQ item 13 Felt dissatisfied with everything 79
MASQ item 11 Felt like I was having a lot of fun 79
SSI item 01 Desire to live 76
Loneliness item 03 I experience a general sense of emptiness 73
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BAI item 08 Unsteady 70
NEO-FFI, neuroticism depression 69
IDS-SR item 15 Concentration/Decision Making 68
MASQ item 23 Felt inferior to others 66
MASTERY item 03 There is not much that I can do to change important things in my life 64
MASQ item 29 Felt really good about myself 62
MASQ item 28 Worried a lot about things 62
QUOTE item 10 Started feeling in control over my problems. 60
PSWQ item 02 Many situations make me worry 59
NEO-FFI, conscientiousness Orderliness 59
QUOTE item 16 The professional taught me how to deal with future symptoms. 54
QUOTE item 05 The general practicioner explained the pros and cons of different medications. 53
MASQ item 21 Was short of breath 53
IDS-SR item 30 Leaden Paralysis/Physical Energy 52
NEO-FFI, neuroticism Negative affect 51
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Supplementary Table 4: Variables which were more (or less) important in the broad 
perspective (recovery from anxiety and affective disorders) in comparison to the 
narrow perspective (recovery from anxiety disorders).
Variable Name Description
More important for narrow perspective 
WHO DAS item 16 Dealing with people you do not know
BAI item 21 Hot, cold sweats
FQ item 04 Traveling alone by train or bus
IDS-SR item 26 Other bodily symptoms
BAI item 05 Fear of worst happening
CIDI SAD l Social Anxiety Disorder - in lifetime
Blood plasma item 02 Kynurenine (µmol/l)
WHO DAS item 38 How much embarrassment did you experience because of your health problems during the past 30 days?
CIDI SAD 12m Social Anxiety Disorder - past year
More important for broad perspective
loneliness item 03 I experience a general sense of emptiness
QUOTE item 16 The professional taught me how to deal with future symptoms
4DSQ item 07 During the past week did you feel: that you just can’t do anything anymore?
CIDI MDD 1m Major Depression - past month
MASQ item 26 Felt like I had a lot of energy
CIDI MDD 6m Major Depression - past 6 months
MASQ item 10 Felt hopeless
QUOTE item 10 Started feeling in control over my problems. 
SSI item 03 Reasons for living or dying
CIDI dysthymia 12m Dysthymia  - past year
MASQ item 13 Felt dissatisfied with everything
CIDI MDD 12m Major Depression - past year
QUOTE item 17 The professional reduced my symptoms. 
4DSQ item 14 During the past week: tingling in the fingers
4DSQ item 06 During the past week did you feel: easily irritated
IDS-SR item 02 Sleep During the Night
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Supplementary Table 5: Evaluation of the two-year recovery from anxiety disorders 
classification using a transfer learning approach [mean (SD)]
Domains AUC Accuracy Sensitivity Specificity PPV NPV
Clinical 0.71 (0.05) 62.5 (5.3) 65.4 (8.7) 59.7 (7.3) 0.53 (0.06) 0.72 (0.06)
Psychological 0.67 (0.05) 62.0 (5.0) 61.6 (8.6) 62.4 (6.6) 0.53 (0.05) 0.70 (0.05)
Socio-demographic 0.65 (0.06) 60.6 (5.7) 64.4 (8.7) 56.7 (7.3) 0.51 (0.06) 0.70 (0.06)
Biological 0.57 (0.05) 55.4 (4.7) 57.3 (7.8) 53.6 (6.4) 0.46 (0.04) 0.65 (0.05)
Lifestyle  0.53 (0.06) 51.7 (4.5) 62.0 (7.2) 41.5 (6.9) 0.42 (0.04) 0.61 (0.06)
Combination 0.71 (0.05) 63.3 (4.8) 65.0 (8.5) 61.7 (6.0) 0.54 (0.05) 0.72 (0.05)
AUC, area-under-receiver-operator-curve; PPV, positive predictive value; NPV, negative predictive value
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General summary and discussion
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The main aims for this thesis were twofold. The first aim was to increase 
knowledge on factors that negatively impact the clinical course in anxiety 
disorders. The second aim was to develop and test statistical models for 
predicting poor clinical course in anxiety disorders over time. Chapters 2, 3, 
and 4 focussed on the first aim, whereas chapters 5, 6, and 7 focussed on the 
second aim. 
General summary 
In chapter 2 the aim was to implement a screening programme for anxiety 
disorders in patients who visited the cardiac emergency department (CED) 
with acute chest pain. ‘Non-cardiac chest pain’ (NCCP) is diagnosed in 
patients presenting with acute chest pain when a cardiac cause for the 
chest pain can be ruled out. From the literature it is clear that over 50% 
of patients with acute chest pain are diagnosed with NCCP. A substantial 
proportion (12-41%) of NCCP have a panic disorder (PD). In light of these 
high prevalence numbers, the aim of this paper was to screen for PD and 
other psychiatric disorders in NCCP patients. A sample of 252 adult patients 
who presented with acute chest pain and were diagnosed with NCCP at the 
CED in the VU-University Medical Center between 2012 and 2013 were 
included and eligible for screening. The screening programme consisted 
of two phases: the first phase was performed at the CED by trained 
CED nurses and consisted of administration of the Hospital Anxiety and 
Depression Scale (HADS) after the diagnosis of NCCP was made. Patients 
who scored above a predefined cut-off score were eligible for the second 
phase of screening. This second phase was scheduled on a later timepoint 
at the psychiatry department and consisted of a structured interview 
into different psychiatric diagnoses using the Composite International 
Diagnostic Interview (CIDI). 
Unfortunately, the first phase of screening was initiated in only 60 out of 
252 (23.8%) eligible NCCP patients. This was largely due to low staff 
adherence, who prioritized other tasks over initiating the screening 
programme. Patient adherence was a lot better in the first phase of 
screening: 51 out of 60 patients (85.0%) who were offered screening 
adhered to the administration of the HADS. Nearly half of screened NCCP 
patients (24/51 or 47.1%) scored above the HADS cut-off and were eligible 
for the second phase of screening. Out of these, 12 patients (50%) refused 
further participation and 8 NCCP patients were diagnosed with a psychiatric 
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disorder, of which two were diagnosed with PD. Eventually, the screening 
programme was not deemed feasible. The main barrier for implementation 
was low staff adherence. 
In chapter 3 the aim was to assess relative impact of anxiety-and depressive 
disorders (ADDs) and chronic somatic diseases (CSDs) on levels of 
disability and work impairment. Patients with ADDs are burdened with high 
levels of disability and work impairment. The same goes for patients with 
CSDs, such as low back pain, migraine, diabetes and obesity. Furthermore, 
ADDs often co-occur with CSDs. This physical-mental (PM) comorbidity 
further reduces levels of functioning and is thought to hamper treatment 
effects for somatic diseases. Likewise, PM-comorbidity likely negatively 
impacts the course of ADDs. The aim of this study was to cross-sectionally 
investigate the effects of ADDs, different categories of CSDs, and PM-
comorbidity on functional outcomes in adult patients. The sample was 
derived from the Netherlands Study of Anxiety and Depression (NESDA) 
and included patients with ADDs and controls (total n=2,371). Anxiety 
disorders included generalized anxiety disorder (GAD), social anxiety 
disorder (SAD), agoraphobia and PD. Depressive disorders included major 
depressive disorder and dysthymia. Presence of 30 different CSDs was 
assessed. Only somatic diseases for which patients received treatment or 
medication were counted. In the sample, patients with ADDs more often 
had any CSD. From adjusted logistic regression analyses an odds ratio of 
1.34 (95% confidence interval (CI) 1.09-1.64) was derived for patients 
with ADDs for having any of the CSDs. The different CSDs were divided 
into seven categories: respiratory, cardio-metabolic, musculoskeletal, 
gastrointestinal, neurological, endocrine and cancers. Out of these, only 
gastrointestinal diseases were significantly more present in patients with 
ADDs (OR=3.29, 95% CI 2.15-5.05). 
From descriptive statistics it was evident that ADDs were associated with 
worse functional status: the total standardized disability score, measured 
with the World Health Organisation Disability Assessment Schedule 
(WHO-DAS II) was 29.0 ± 16.4 whereas the total disability score in controls 
was 7.8 ± 9.3 (t=-30.7, p<0.001). Multivariate linear regression analyses 
showed that ADDs were related to the highest levels of disability (main 
effect β= 20.1). CSDs were also associated with disability (main effect 
β= 3.88). Interestingly, there was an interaction effect present for CSDs 
and ADDs on levels of disability. In the interaction model, the regression 
formula was disability = c + β1*ADDs + β2* CSDs + β3*ADDs*CSDs. In 
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this formula, c was 13.1, β1 was 18.6, β2 was 0.80 (not significant) and β3 
was 4.06. This implicates that the effects of CSDs on disability are mostly 
present in patients who also have ADDs. In this interaction model, having 
a CSD without having an ADD does not increase the levels of disability. It 
also implies that the effect of comorbid CSDs and ADDs on disability scores 
is larger than the sum of separate effects for CSDs and ADDs, i.e., there is 
synergistic effect modification. 
Work impairment analyses were performed in a subset of 1,462 employed 
respondents. From descriptive statistics, it seemed that work impairment 
was higher in patients with ADDs: 67.6% of patients had at least some 
absence from work due to health related reasons (absenteeism), whereas 
only 32.7% of controls had absence from work (Χ2 = 163.9, p<0.001). 
Likewise, ADD patients were more likely to have reduced work performance 
(presenteeism) in comparison with controls: 60.5% of patients had any 
form of presenteeism, whereas only 32.5% of controls had any form of 
presenteeism (Χ2 = 132.2, p<0.001). To assess the individual and combined 
effect of ADDs and CSDs on work impairment outcomes multinomial 
regression analyses were performed. The work impairment outcomes 
were categorized and comparisons were made against the ‘healthy’ 
categories of no absenteeism and no presenteeism. It seemed that CSDs 
were only associated with the most critical work impairment outcomes: 
extended absenteeism OR= 1.42 (95% CI 1.07-1.88) and impaired work 
performance OR= 1.42 (95% CI 1.08-1.87). ADDs were associated with all 
work impairment outcomes: short absenteeism OR= 2.88 (95% CI 2.16-
3.84), extended absenteeism OR= 6.64 (95% CI 4.69-9.40), reduced work 
performance OR= 1.83 (95% CI 1.38-2.43) and impaired work performance 
OR= 7.51 (95% CI 5.11-11.1). These regression coefficients were adjusted 
for sociodemographics and show a clear difference between ADDs and 
CSDs on work impairment outcomes with ADDs effects being much more 
impactful. Additionally, main effect models were made using four predictor 
categories for combinations of ADDs and CSDs exposure: controls (no 
ADDs, no CSDs), pure physical (CSDs without ADDs), pure mental (ADDs 
without CSDs), and PM- comorbidity (ADDs and CSDs). The pure physical 
group was not associated with absenteeism but was associated with 
impaired work performance. The pure mental subgroup was significantly 
associated with all work impairment outcomes. Finally, PM- comorbidity 
was consequently associated with the worst work impairment outcomes. 
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These findings highlight the importance of recognizing and treating 
psychiatric comorbidity in patients with CSDs and likewise to recognizing 
and treating somatic comorbidity in patients with ADDs in order to counter 
long-term disability and reduced (work) functioning. 
In chapter 4 the aim was to evaluate different definitions and diagnostic 
criteria for treatment resistance in anxiety disorders (TR-AD). Currently, 
no clear criteria for TR-AD exist. This is problematic, as a large proportion 
of anxiety disorder patients experience suboptimal treatment results. 
Various different terms are used in the literature, for instance “treatment 
resistance”, “remaining symptomatic”, “refractory”, and “nonresponse”. 
These terms are used quite freely and interchangeably but often seemingly 
without taking regard to the actual definitions for these terms. In order to 
align these different terms a systematic literature review was performed. All 
scientific works that included some definition or operationalization for TR-
AD were included. From these sources, definitions were gathered and were 
systematically described with regard to different aspects or criteria that 
comprised each definition. The aim was to collect and integrate all criteria 
and aspects for TR-AD that are currently used. A secondary aim was to 
integrate these criteria into a consensus definition for TR-AD. 
The search strategy yielded 13,042 unique records. These were assessed 
first by two researchers on title and abstract. This resulted in 388 records 
eligible for full-text screening. From these, 62 studies were included into 
the data synthesis. The included studies all provided a specific definition 
for TR-AD, or they provided inclusion criteria for TR-AD patients. The 
selection of studies consisted of reviews, guidelines, book chapters, trials 
and cohort studies. The anxiety disorders studied included PD (n=33), GAD 
(n=34), SAD (n=21), specific phobia (n=5) and anxiety disorders in general 
(n=5). In order to meet criteria for TR-AD, most studies (85.5%) included 
a specified minimal number of failed treatments, ranging from one to five 
failed treatments. Further criteria included failed pharmacologic treatments 
(93.5%), failed psychotherapy treatments (29.0%), a specified minimal 
treatment duration (54.8%), a specific response criterium (41.9%), e.g. 
a greater than 50% reduction in anxiety severity should be present to no 
longer meet criteria for TR-AD. Moreover, a threshold for anxiety severity 
was used in nearly half (46.8%) of studies. Finally, some criteria were used 
sparingly (less than 10%) in TR-AD definitions: minimal duration of anxiety 
disorder, presence of functional impairments, presence of comorbidity. 
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From quantitative analyses, it appeared that study quality did not impact 
the criteria provided: the same criteria were reported among low and high 
quality studies. 
Finally, the criteria from this systematic review were integrated into a new 
consensus definition for TR-AD using the most prevalent criteria and aspects 
identified in this review. According to the consensus definition TR-AD is 
present if there is at least one failed pharmacological treatment using a first-
line antidepressant (SSRI/ SNRI). Treatment failure should be defined as a 
reduction in symptom severity less than 50% after a treatment period of at 
least 8 weeks. Second, patients should also have a failed psychotherapy trial, 
using a first-line psychotherapeutic approach (CBT). This psychotherapy 
failure should also be defined by a symptom severity reduction that does not 
exceed 50% and the psychotherapy should be provided according to local 
protocol and should span a duration of at least 8 weeks. Finally, the symptom 
severity at assessment of TR-AD should be above a specified threshold. 
The thresholds described differed across anxiety disorders diagnoses and 
the cut-off values were based on the most frequently used cut-off values. 
Consistently using this new consensus definition in studies into TR-AD 
will increase the homogeneity of the studied population and increase 
generalizability of findings, thereby bolstering knowledge on TR-AD. 
In chapter 5 the aim was to evaluate a generic staging model for psychiatric 
disorders for use in anxiety disorders. The main goals were to assess the 
construct- and predictive validity of the staging model. In the paradigm 
of clinical staging, different stages can be distinguished that reflect 
increasing levels of disease progression. Each subsequent disease stage 
will be associated with a less favourable disease course. Theoretically, the 
different stages in a staging model should also reflect different underlying 
pathophysiological processes. However, in psychiatry the underlying 
pathophysiologic characteristics are multifactorial and thereby less 
adequate for this purpose. Therefore, currently staging models in psychiatry 
are mainly based on clinical features.
For the purpose of this study, a heuristic staging model, proposed by a 
highly regarded Australian research group, was adapted for use in anxiety 
disorders. All 1,305 NESDA subjects with an anxiety disorder at baseline 
were included in the analyses. A further 1,115 subjects without current 
anxiety disorder or depressive disorder, but with presence of risk factors 
for development of an anxiety disorder were included. At baseline, all 2,420 
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subjects were assigned to a clinical stage. The stages ranged from stage 
0 (asymptomatic, at risk subjects) to stage 4B (chronic symptoms with 
comorbidity). Stage assignment was based on life chart interviews with 
regard to anxiety disorder duration as well as on severity of symptoms and 
on presence of psychiatric comorbidity. From descriptive statistics it was 
apparent that higher stages showed higher proportions of diagnoses at 
follow-up timepoints. For instance, at two-year follow-up 2.7% of subjects 
originally in stage 0 had an anxiety disorder versus 68.0% of subjects 
originally in stage 4B.
Construct validity was assessed by comparing several baseline clinical 
characteristics that were not used in stage assignment. It was hypothesized 
that higher clinical stages would be associated with worse clinical 
parameters at baseline and that these associations would follow a linear 
trend along each of the stages. This was indeed the case: patients in higher 
stages had more childhood trauma, a lower age of onset, more current 
psychiatric treatments, higher anxiety severity, more social and agoraphobic 
avoidance and higher levels of worrying. Furthermore, patients in higher 
stages had more depressive symptoms and higher levels of disability. 
Nonparametric tests for trends across ordered groups were significant 
for all predefined validators after Bonferroni correction for repeated 
statistical testing. This implicates that on average, higher clinical stages 
were associated with worse clinical characteristics at baseline, indicating 
adequate construct validity. 
To evaluate the predictive validity of the model, a number of analyses were 
performed. First, the clinical staging model was related to presence of DSM-
IV diagnoses over time. Two sets of generalized estimating equations (GEE) 
were performed to evaluate odds for each baseline clinical stage to have 
either an anxiety disorder or any psychiatric disorder at three subsequent 
timepoints (2-year, 4-year and 6-year follow-up). It was hypothesized 
that higher clinical stages showed higher odds for having anxiety disorder 
diagnoses and psychiatric disorder diagnoses at each follow-up timepoint. 
It appeared that this was indeed the case: odds ratio (OR) for having any 
anxiety disorder at 6-year follow-up for stage 4B was 11.8 (95% CI 8.39-
16.6) in comparison with stages 0-1B. Likewise, OR for stage 4B for having 
any psychiatric disorder at 6-year follow-up was 10.7 (95% CI 7.70–15.0) 
in comparison with stages 0-1B. For all stages, 6-year proportions of 
psychiatric diagnoses were lower in comparison to 2-year proportions. For 
the first outcome, presence of anxiety disorders, a more linear trend across 
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baseline stages became apparent. For presence of any psychiatric disorders, 
the B stages were at highest risk. Overall the model showed a significant 
linear trend across all stages. This implicates that risks of having any anxiety 
disorder at follow-up are higher in each subsequent stage, but changes of 
having any psychiatric disorder are highest among B stages who already 
had psychiatric comorbidity at baseline. Subsequently, predictive validity 
was assessed using a dimensional approach. The baseline clinical stages 
were related to follow-up measurements of anxiety severity, depression 
severity and disability using linear mixed models (LMM), thereby allowing to 
estimate missing data points. This yielded estimated means for each stage at 
follow-up timepoints. LMM analyses showed that anxiety severity gradually 
decreased over time for most stages while retaining the ordering between 
stages. Stages 2B, 3A and 4A showed comparable anxiety severity over time 
whereas stages 3B and 4B were burdened with the highest levels of anxiety 
severity, depression severity and disability. 
To summarize, this chapter showed the first successful empirical attempt 
of applying a staging model to a cohort of anxiety disorder patients and 
controls. The results show that the studied model has adequate predictive 
and construct validity, thereby providing an evidence-based staging model 
for use in clinical care in anxiety disorders.
In chapter 6 the aim was to assess whether each of the aspects of TR-AD 
derived in a systematic review (chapter 4 in this thesis) were associated with 
poor outcomes. As chapter 4 yielded a number of criteria for the definition 
of TR-AD, the hypothesis was that each of these criteria were individually 
associated with poor outcomes after treatment. A secondary aim in this study 
was to develop a dimensional measurement instrument using combined 
information from each of the individual TR-AD criteria. This dimensional 
instrument reflects the degree of TR-AD, which could be a relevant addition 
to the dichotomous approach to TR-AD that was applied in chapter 4. 
For the purpose of this study, out of a total of 1,305 NESDA subjects with 
anxiety disorders at baseline, a sample of 679 subjects that reported having 
received psychiatric treatments between baseline and 2-year follow-up were 
included. In this sample, each of the criteria for TR-AD that were derived in 
the systematic review (chapter 4) were assessed at baseline. These baseline 
TR-AD criteria included number of first-line pharmacologic treatments 
previous to inclusion, number of second-line pharmacologic treatments 
previous to inclusion, number of adequate psychotherapeutic treatments 
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previous to inclusion, levels of anxiety severity, presence of functional 
impairments, presence of psychiatric comorbidity, and previous duration of 
anxiety symptoms. From these literature-derived criteria a measurement 
tool was developed. In order to do this, each of the TR-AD criteria were 
scored in accordance with the Dutch Measure for quantification of Treatment 
Resistance in Depression (DM-TRD). The DM-TRD is a dimensional 
measurement tool that measures the degree of treatment resistance in 
depression. This way a measurement tool with a potential range of scoring 
from 2-23 was made. 
At baseline, the average score on the measurement tool was 10.8 ± 2.3. 
Bivariate logistic regression analyses were used to relate individual 
baseline TR-AD criteria to treatment outcome after two-years by assessing 
persistence of anxiety disorder diagnoses at two-year follow-up. High 
symptom severity at baseline was clearly associated with poor outcomes at 
two-year: OR for persistence of anxiety disorders was 6.48 (95% CI 3.29-
12.8) in comparison with subjects with low symptom severity at baseline. 
High levels of functional impairments were also associated with poor 
outcomes at two-year follow up: OR=2.90 (95% CI 1.51-5.63). The same 
positive associations were found for presence of psychiatric comorbidity 
(OR=1.73, 95% CI 1.25-2.39) and extended duration of anxiety symptoms 
(OR = 2.79, 95% CI 1.94-4.03 versus short duration). The previous number 
of first-line pharmacotherapeutic treatments were not associated with 
outcomes after two year (OR=1.10, 95% CI 0.87-1.39). Nor were the number 
of previous second-line pharmacotherapeutics (OR= 1.39, 95% CI 0.91-
2.12) or the number of previous psychotherapy trials (OR=1.11, 95% CI 
0.73-1.69). The dimensional measurement instrument that was developed 
using these TR-AD criteria was positively associated with poor outcomes at 
two-year follow-up: OR= 1.29, 95% CI 1.20-1.39, indicating that the odds for 
persistence of anxiety disorders after two-years are increased with 1.29 for 
each point increment in the measurement instrument. 
Finally, the psychometric properties for this measurement instrument were 
assessed. Using the Youden-index the most efficient cut-off value for the 
measurement instrument was calculated at 11 points or higher. Using this 
cut-off value, the sensitivity for predicting persistence of anxiety disorders 
during treatment was 0.70, while the specificity was 0.57. From this, the 
positive predictive value was calculated at 0.68 and the negative predictive 
value at 0.60. The area under the curve (AUC) was calculated to be 0.66. 
This performance can be regarded as moderate. However, in the absence 
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of a gold-standard test for predicting outcomes after treatment in anxiety 
disorders, it represents the best performance currently available. Therefore, 
it seems that the newly developed measurement tool for assessing the 
degree of TR-AD could be beneficial in assessing the level of TR-AD in 
individual patients. This could have implications for choosing adequate 
treatment regimens in individual patients. However, this study should be 
replicated in a different sample to evaluate the generalizability of these 
findings. 
In chapter 7 the aim was to develop a machine learning prediction model 
for the longitudinal course in anxiety disorders based on a wide variety of 
data. Many risk factors were previously linked to anxiety disorders or to the 
longitudinal course in anxiety disorders. None, however, have predictive 
properties that warrant using them for risk prediction in clinical care. 
Previously, these predictors were mainly studied in isolation instead of as 
a part of a large scale model. Possibly, combining many putative predictors 
into a single model could result in a model with adequate predictive 
properties. Machine learning algorithms are especially suited for problems 
with many different putative factors, as they are able to use data-driven 
methods for selecting the most relevant factors.
For the purpose of this study, various putative predictors from five predictor 
domains were selected. These domains included clinical variables, 
psychological variables, biological variables, sociodemographic variables 
and lifestyle variables. The hypothesis was that combining many predictors 
into a single large scale model would result into a model with adequate 
predictive properties for longitudinal course in anxiety disorders. The 
current study was performed in a total of 887 anxiety disorder patients from 
NESDA. The investigated classifications were twofold: first, recovery from 
anxiety disorders at two-year follow-up. Second, recovery from all common 
mental disorders (CMDs) at two-year follow-up. Anxiety disorders included 
GAD, PD, agoraphobia and SAD. CMDs were defined as either an anxiety 
disorder, major depressive disorder, dysthymia or alcohol dependency. 
So, for the purpose of the second classification, recovery is present when 
no disorder from these disorders groups was diagnosed at follow-up. To 
build the model, Random Forest Classifiers (RFCs) were used. A RFC is 
built as an ensemble of many different decision trees, which are trained by 
considering random subsets of variables and patients for each tree. In this 
study, each RFC consisted of 1,000 decision trees. At baseline 651 individual 
item level predictors were selected from the five predictor domains (clinical, 
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psychological, biological, sociodemographics, lifestyle). After removal of 
items with too many missing values, 569 items remained. RFCs were built 
using these items and by using a 10x10 cross validation approach on training 
sets (90% of the subjects) and test sets (the remaining 10% of the subjects). 
The algorithm was trained on the combination of all predictor domains, but 
also on each different predictor domain separately.
At two-year follow-up, 484 patients (54.6%) recovered from anxiety 
disorders and 362 patients (40.8%) did not have any CMD. The performance 
of RFCs in predicting recovery of anxiety disorders at two-year follow-up 
was moderate: the area under the receiver operator curve (AUC) ranged 
from 0.49 (lifestyle) to 0.67 (clinical) in individual predictor domains. The 
only domains with statistically significant two-year predictions were the 
clinical domain (AUC=0.67) and the psychological domain (AUC=0.65). When 
combining predictors from all domains, the AUC was 0.67. With regard to the 
second outcome measure (recovery from CMDs) it seemed that predictions 
were somewhat more precise. The AUC for recovery from CMDs ranged from 
0.53 (lifestyle) to 0.70 (clinical) in individual domains. In this analysis the 
clinical domain (AUC=0.70), the psychological domain (AUC=0.67) and the 
sociodemographic domain (AUC=0.65) yielded significant predictions. The 
combination of all domains yielded an AUC of 0.70. 
Additional analyses were performed to identify individual items that highly 
contributed to the predictions. This was done to gain more insight into the 
relative importance of each of the predictors in the longitudinal course in 
anxiety disorders. In predicting recovery from anxiety disorders, 17 items 
were selected in over 50% of the RFCs, thereby fulfilling the criterium 
for consistent selection. These predictors derived from the clinical and 
psychological domains and were related to anxiety responses, mostly to 
anxious arousal. In predicting recovery from CMDs, 48 variables were 
consistently selected. One consistently selected predictor was from the 
sociodemographic domain, all others from the clinical and psychological 
domains. In addition to anxiety items, for this classification many mood-
related items were consistently selected. When compared to the variables 
that were consistently selected in predicting recovery from anxiety 




Methodological strengths and limitations
Several strengths and limitations need to be addressed in order to appraise 
the findings reported in this thesis. First, some general strengths and 
limitations on the NESDA cohort will be discussed. After that, the most 
relevant strengths and limitations of each of the separate chapters will be 
addressed. 
Four of the chapters presented in this paper used data from the Netherlands 
Study on Depression and Anxiety (NESDA) for data analyses. As described 
in the general introduction, NESDA is a prospective cohort study designed to 
evaluate the longitudinal course in depression and anxiety. A major strength 
of this study is the large sample size (n=2,981 at baseline). Furthermore, 
a very extensive approach to data collection was chosen. This enabled the 
operationalization of different models from literature within NESDA. For 
instance, this allowed the operationalization and validation of the generic 
staging model presented in chapter 5 for use in anxiety disorders without 
having to omit major criteria that are used in the model. Also, it allowed for 
using a wide array of putative predictors (N=651) to build the data-driven 
prediction model presented in chapter 7. 
However, using NESDA also had some limitations. First, repeatedly using the 
same dataset for data analysis has the downside of reduced generalizability 
across the reported findings. Repeating some of the analyses in an 
independent sample would be beneficial to increase the generalizability. Still, 
previous analyses showed that the longitudinal clinical course of subjects in 
NESDA is comparable with that in other cohort studies.1 This bolsters the 
confidence that the findings in this thesis are in fact generalizable beyond 
NESDA and beyond the Netherlands. Furthermore, by design NESDA has a 
large time gap between each wave of measurements. The shortest follow-
up period between two full waves of data collection used in these papers 
was two years. From a practical and economical perspective this decision is 
very understandable. However, this comes at the cost of having a long period 
of time in which no data on disease status or on environmental stressors is 
available. At each subsequent wave of data collection, information on the 
intervals between waves were retrospectively assessed to make up for this 
loss. These retrospective assessments are suboptimal and this approach 
hampered some of the analyses presented in this paper. Finally, for the 
purpose of course prediction, periods of two years represent a very extensive 
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timespan. Many other studies into course prediction use shorter follow-
up periods as predictions are thereby less vulnerable to unknown outside 
variables affecting the accuracy of predictions. Therefore, the chances of 
highly accurate course predictions using NESDA data and a minimal follow-
up period of two-years were by design reduced. 
An important strength of the screening programme presented in chapter 
2 was its implementation in routine clinical care as provided at the CED. 
If proven successful, this would implicate a high applicability for this 
programme across CEDs. Currently, the large group of NCCP patients 
leave the CED with a diagnosis per exclusionem (NCCP). This screening 
programme could improve the diagnostics for this large group of patients 
without major alterations to the workflow at the CED. The major limitation 
in this study was the lack of systematic gathering of data on reasons for low 
adherence across CED staff and patients. For instance, a qualitative study 
phase as addition to the current study could have shed more insight into 
the low adherence and might have yielded useful input for future screening 
programs. 
The major strength of the study presented in chapter 3 is the rigorous 
assessments of both chronic somatic diseases (CSDs) and anxiety- and 
depressive disorders (ADDs). This made the current study the largest study 
of its kind in which a wide variety of CSDs were assessed, as well as a wide 
range of ADDs. This enabled us to link these to the functional outcomes of 
disability and work impairment and assess the presence of interaction 
effects. Furthermore, the large sample size made it possible to evaluate 
separate groups of CSDs. A limitation in this study was the reliance on self-
report evaluation for assessments of CSDs. This is accompanied by the risk 
of a self-report bias. In order to reduce risks for self-report bias a sensitivity 
analysis was performed in which more stringent criteria for CSD diagnoses 
were applied. Applying these stringent criteria did not change the main 
outcomes, which bolstered the confidence that the initial analyses were 
accurate. 
The main strength of chapter 4 was the rigorous approach to delineate the 
concept of treatment resistant anxiety disorders (TR-AD). Although various 
authors pinpointed the lack of a consensus definition for TR-AD, no one 
previously performed a systematic review of the available literature. This 
approach made it possible to derive a consensus definition thereby removing 
the necessity of authors and scholars of having to choose one definition over 
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the other. A major limitation of this study was that the process of integrating 
the literature-based definitions for TR-AD could not be done without some 
arbitrary choices by the authors. For instance, the decision of basing the 
consensus definition on the statistical mode for each criterium within 
the definition was made by the researchers. Furthermore, some criteria 
that were only sporadically mentioned were removed. These choices are 
defendable, but still arbitrary to some extent and this could have introduced 
a small bias. 
The main strength of chapter 5 in which a staging model was adapted for use 
in anxiety disorders is the use of an validation approach. In this approach, 
construct validity was assessed by comparing each of the clinical stages to 
construct validators. After using a number of anxiety-related questionnaires 
to assign subjects to clinical stages it was still possible to use other baseline 
questionnaires as construct validators. A limitation in chapter 5 was the 
transgression that was made away from the original transdiagnostic 
framework for the staging model. In the original model, less emphasis 
is laid on different psychiatric disorders but more on the longitudinal 
course without taking into account which disorder is present. In adopting 
this model, the aim was to incorporate the transdiagnostic approach by 
evaluating presence of comorbidity as a profiler and by choosing general 
psychopathology validators that reflect that longitudinal course in anxiety 
disorder should indeed be seen in a transdiagnostic framework. 
A major strength in chapter 6 is the use of literature-based criteria for TR-AD 
as predictors for subsequent course during treatment. This is an improvement 
over other measurement instruments that assess the degree of treatment 
resistance in other psychiatric disorders as these measurement instruments 
were not based on findings from a systematic review. A limitation in this 
chapter is the retrospective assessment of treatment exposure during the 
follow-up and using this assessment as an inclusion criterion. This inclusion 
criterion was necessary in order to be able to study treatment resistance in 
a subset of patients that received treatments. But by using a retrospective 
selection criterion this study cannot be seen as fully prospective. This might 
have introduced a selection bias or a self-report bias. Additionally, some 
underreporting of certain types of treatments could have occurred as data 
on treatments were not gathered via care providers but via subjects. This 
could have introduced some bias towards the null hypothesis with regard to 
effect of previous treatments.
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The main strength of chapter 7 in which machine learning algorithms were 
used for course prediction in anxiety disorders was the use of a data driven 
approach. The aetiology of anxiety disorders is multifactorial and the precise 
relationship between different aetiologic factors remains largely unknown. 
Data driven machine learning methods are especially adept in unravelling 
these kind of scientific problems. Another strength is the use of cross 
validation methods to improve the external validity and reduce the risk of 
overfitting the model to the data. Moreover, using features at an individual 
item level increased the internal validity for building the model as it enabled 
previously unrecognized associations between individual variables to be 
used in the predictions. By contrast, if summary scores would have been 
used, a lot of information and individual variation would have been lost. A 
limitation in this chapter was that the levels of evidence for including each 
of the different putative predictors varied substantially. Theoretically, all 
predictors should be previously related to anxiety disorder longitudinal 
course in order to be used validly. In reality, all putative predictors were at 
least related in some way to anxiety disorders, but for a large proportion this 
was limited to cross-sectional associations. Although the Random Forest 
classifier is adept in excluding features without any link to the investigated 
outcome the accuracy of the prediction model could ultimately suffer 
from inclusion of many unrelated features as in each iteration a number of 
unrelated features have to be discarded, leaving less choice for adding useful 
features. Therefore, including a smaller number of features at baseline could 
have resulted in improved accuracy in the final models.
Factors that impact the clinical course in anxiety disorders. 
As is apparent from the introduction from this thesis, the most prominent 
factors that impact the clinical course in anxiety disorders are clinical 
factors like anxiety severity, anxiety duration, presence of comorbidity 
and other clinical aspects. The first aim in this thesis was to expand on the 
knowledge about factors that impact the clinical course in anxiety disorders. 
To describe these factors in the remainder of this discussion an ordering 
across susceptibility markers, diagnostic markers, prognostic markers and 
predictive markers will be used. This ordering is often used in research 
into biological markers for psychiatric disorders and can also be used for 
markers from different domains.2,3 These marker categories are helpful as 
they point towards the mechanism of action of each marker. Currently, most 
research in anxiety disorders focussed on diagnostic markers. For instance, 
in PD structural changes to certain brain areas and altered serotonin and 
noradrenergic network activation in patients were found. These biomarkers 
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are present in patients but less so in controls, thereby constituting a 
diagnostic marker. More knowledge on each of the markers types could 
lead to better understanding of the clinical course in anxiety disorders. All 
findings from this thesis will be discussed in accordance to this ordering of 
markers.
Susceptibility markers
Susceptibility markers are present in persons who later develop a particular 
disorder.3 Perfect susceptibility markers are always present in individuals 
who later develop a disorder but never in individuals who do not develop this 
disorder. From previous research it is apparent that several sociodemographic 
characteristics are overrepresented in anxiety disorder samples. Well 
established risk factors for development of anxiety disorders include low 
socio-economic status, female gender, lifetime history and family history 
of psychiatric disorders and exposure to childhood adversity such as abuse, 
neglect and parental problems.4–6 Furthermore, young age could be seen as 
a risk factor for development of anxiety disorders due to the young average 
age of onset. The findings in this thesis underscore the previous findings 
that low socio-economic status, female gender and younger age are related 
to subsequent development of anxiety disorders. Lifetime history of anxiety 
disorders and family history of psychiatric disorders were used in chapter 5 
to assign subjects to at-risk stages. These risk factors can be regarded as 
susceptibility markers for future development of anxiety disorders. 
Diagnostic markers
Diagnostic markers are markers that distinguish between patients with 
a particular disorder and those who do not have the disorder.2 Perfect 
diagnostic markers are always present in patients but never in controls. In 
chapter 2 it was investigated whether non-cardiac chest pain (NCCP) can 
be used as a diagnostic marker for PD. NCCP often presents with squeezing, 
pressure-like, or burning sensations in the chest and although cardiologists 
see it as a diagnosis per exclusionem, the presence of NCCP should instigate 
a further diagnostic work-up. The list of differential diagnoses for NCCP is 
extensive and includes both somatic illnesses as well as psychological and 
psychiatric disorders.7 Even in absence of psychiatric disorders, symptoms of 
NCCP can be treated effectively with cognitive behavioural therapy.8 Due to 
the overlap in symptomatology between NCCP and panic attacks and due to 
the high prevalence of PD in cohorts of NCCP patients the symptoms of NCCP 
could be due to PD. A diagnosis of NCCP could thereby constitute a diagnostic 
marker for PD. Unfortunately, the study presented in chapter 2 suffered from 
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implementation problems that led to insufficient adherence in CED staff 
as well as in patients. Therefore it does not seem feasible to improve the 
diagnostic process of PD (and other psychiatric disorders) by providing this 
screening program in the CED. Possibly, the presence of NCCP in PD patients 
might be a susceptibility marker for PD instead of a diagnostic marker. This 
could be the case if chest pain is the first symptom in the development of 
a repeating pattern of panic attacks and avoidance behaviours. Another 
possibility is that chest pain is a prognostic or predictive marker in PD. This 
could be the case if the presence of chest pain in PD patients was found 
to be related to the subsequent course in these patients or is predictive of 
subsequent treatment effects. Unfortunately, these hypotheses could not be 
tested using the present study and could be the focus for future research. 
Subthreshold anxiety symptoms are a likely diagnostic marker for preclinical 
high risk stages of anxiety disorders as subjects without anxiety disorders 
who suffer from subthreshold anxiety symptoms are at high risk for 
development of subsequent anxiety disorders. This group usually contains 
many individuals who have some of the aforementioned susceptibility 
markers. In chapter 5, subjects were assigned to at-risk stage 0 if they 
had any of the susceptibility markers (previous anxiety disorders, family 
history for psychiatric disorders or childhood trauma) but did not have any 
current anxiety symptoms. Prodromal stages 1A and 1B were assigned 
to subjects with these susceptibility markers who also had subthreshold 
anxiety symptoms. Longitudinal analyses of these groups showed an 
incremental increased odds for incident anxiety disorders at various follow-
up timepoints. At-risk subjects (stage 0) had 2.7% incidence of anxiety 
disorders at 2-year follow-up, 3.0% incidence of anxiety disorders at 
4-year follow-up and 3.1% incidence of anxiety disorders at 6-year follow-
up. Incidence levels were markedly higher in stages 1A and 1B: 14.9% and 
21.1% at 2-year follow-up, 11.2% and 15.6% at 4-year follow-up and 7.6% 
and 15.7% at 6-year follow-up respectively. It seemed that a large subset of 
subjects in prodromal stages subsequently developed an anxiety disorder. 
The presence of subthreshold anxiety symptoms along with the presence of 
susceptibility markers therefore seems an adequate diagnostic marker for 
the prodromal stage. Possibly, targeting groups of children or adolescents 
who have susceptibility markers and subthreshold anxiety symptoms could 
result in preventing development of anxiety disorders.9,10
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The aim in chapter 4 was delineating a useful definition for treatment 
resistance in anxiety disorders (TR-AD). By analysing and integrating the 
available literature on this topic a new consensus definition was created for 
TR-AD. The full definition was provided earlier. As TR-AD refers to chronic 
and difficult to treat pathology, this new definition for TR-AD could be used 
as a diagnostic marker for the more advanced stages of anxiety disorders. 
In chapter 5 several criteria were used to assign subjects to different stages 
of anxiety disorders. The main defining criterium used was duration of 
anxiety and avoidance symptoms. This is in line with the rationale behind 
staging models in psychiatry in which disease progression is mainly defined 
by the previous disease course.11 Using adjusted logistic regression models 
is was apparent that anxiety/avoidance duration categories (<30% of the 
previous months; 30<80% of the previous months; >80% of the previous 
months) were indeed linked to two-year outcomes. This remained true when 
adjusting for sociodemographics and other predictor variables. Duration 
of anxiety disorders could therefore be seen as a diagnostic marker for the 
different stages of anxiety disorders. 
Prognostic markers
Prognostic markers provide information about the clinical course in a 
particular disorder without taking treatment effects into account.2 Perfect 
prognostic markers are present in patients who have the highest probabilities 
for adverse disease-related events or a faster rate of decline but never in 
patients who are at low risk for these events or this decline. From analyses 
in chapter 3 it became apparent that an interaction effect on disability and 
work impairment outcomes is present between ADDs and CSDs. WHO-DAS 
II disability scores were 4-5 points higher in ADD patients who also have a 
CSD. Likewise, work impairment outcomes were the least favourable in ADD 
patients who also had CSDs. These findings point towards using CSDs as 
a prognostic marker for worse overall course – in terms of functioning - in 
anxiety disorders.
From the analysis in chapter 5 it became apparent that a younger age of onset 
was present in the most severe anxiety disorder patients. The average age of 
onset in stage 4B (severe, persisting, comorbid anxiety disorders) was 19.2 
± 12.4 years whereas the average age of onset in stage 2A (non-comorbid 
anxiety disorders with a short duration) was 23.9 ± 13.1 years. There was a 
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statistical significant trend across increasing stages. Younger age of onset 
can thereby be regarded a prognostic marker for development of chronic, 
severe anxiety disorders.
In all stages of anxiety disorders, presence of psychiatric comorbidity was 
clearly associated with markedly worse outcomes at follow-up, for instance 
adjusted OR for presence of two-year anxiety disorders were 1.49 (95% 
CI: 1.16-1.92). Presence of comorbidity should be seen as a prognostic 
marker. This is in line with a large field of research that consistently showed 
the course of disorders to be worse if comorbid psychiatric disorders are 
present.12,13
Further prognostic markers were identified in chapter 7 in which a machine 
learning algorithm was used to predict the naturalistic course over a two-
year period in anxiety disorder patients. Using a random forest classifier 
allowed for identification of different important predictor variables by 
assessing the frequency with which each of the predictors were selected in 
each iteration of the algorithm. This was done by permuting each variable 
separately a 1,000 times and assessing its variable importance under 
permutation.14 Features that were selected consistently can be considered 
prognostic markers for the naturalistic course in anxiety disorder patients. 
This approach led to 17 out of the available 569 items to be consistently 
selected (>50%) in the random forest classifier on the main outcome 
measure. These items included statements on traits on anxious arousal and 
avoidance behaviours (e.g. “I rarely feel fearful or anxious”, of generally 
avoiding “walking alone in a busy street”). Furthermore, items on personality 
traits neuroticism and extraversion were consistently selected. Moreover, 
psychological traits of mastery and anxiety sensitivity were often selected 
in the random forests. Other poor prognostic markers from descriptive 
statistics were presence of chronic pain, unemployment and low physical 
activity. These markers were more prevalent in the sample that subsequently 
did not recover from anxiety disorders, they were, however, not consistently 
selected (>50%) in the random forest classifiers. The benefit of prognostic 
markers could lie in risk stratification. Patients with poor prognostic markers 
should be identified and allocated targeted treatments that could prevent 
further disorder progression. It should be noted that in the setting of a 
naturalistic cohort study, a number of subjects received treatments, which 
makes it more difficult to identify prognostic markers. 
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Predictive markers
Predictive markers refer to markers that are linked to treatment results in 
patients with a particular disorder.2 Perfect predictive markers are present 
in all patients who show a specific response to treatments or interventions 
(for instance remission after psychotherapy) but never in patients who 
do not show this response. In chapter 6 the aim was to unravel predictive 
markers for anxiety disorder patients who underwent treatments over the 
course of a two-year period. A dimensional measurement for the degree of 
TR-AD predicted treatment results after two-years: the odds for persistence 
of anxiety disorders were increased by 1.29 for each point increment in the 
measurement instrument. When assessing the separate variables it appeared 
that treatment outcomes were less beneficial in anxiety disorder patients 
with a low educational status (OR for persistence of anxiety disorders = 0.95 
(95% CI: 0.90-0.99) per education year. Furthermore, higher anxiety severity 
predicted persistence of anxiety disorders (OR for severe symptoms= 6.48 
(95% CI: 3.29-12.8). Moreover, psychiatric comorbidities were more present 
in the subset of patients that persisted after treatment (OR=1.73, 95% CI: 
1.25-5.63). Finally, a longer duration of anxiety and avoidance symptoms 
predicted persistence of anxiety disorders after treatment, OR for extended 
previous duration= 2.79 (95% CI: 1.94-4.03). It should be noted that in 
chapter 6, only clinical variables were assessed as predictive markers. 
Integrated stage-specific model
One of the current challenges in scientific research in psychiatry is forming 
bridges between fundamental research into psychopathology and clinical 
research. The DSM- classification system remains dominant in the scientific 
psychiatric debate even as leading authorities acknowledge the need to 
reconstruct these constructs and start rebuilding a classification system 
from the bottom up. This approach is advocated in the Research Domain 
Criteria as proposed by the National Institute of Mental Health.15 One of 
the main goals for which the RDoC criteria were called into life is to work 
towards translation of biological findings from fundamental research into 
clinical practice. As DSM-classification systems proved inadequate for this 
goal, staging models might provide a solution. Staging models in psychiatry 
were developed to describe the progression of psychiatric disorders across 
the lifespan. In lower stages a-specific symptoms are present, in later stages 
psychiatric syndromes have developed or even refractory disorders have 
formed. In staging models, different stages can be linked to susceptibility 
markers, diagnostic markers, prognostic markers and predictive markers. 
This approach will likely yield different markers across clinical stages in a 
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way that could not be captured within the framework of DSM-classifications. 
In this way, staging models could be an important bridge between 
fundamental research findings and clinical practice. To integrate the main 
findings of the research in this thesis an integrated stage-specific model 
was developed. This integrated model for anxiety disorders was modelled 
to the recent putative biomarker stage-specific model for PD by Cosci and 
Mansueto.3 This stage-specific approach has the benefit that biomarkers 
and clinical markers might be more sensitive, specific and predictive when 
applied to a specific stage of anxiety disorders instead of to a dichotomous 
classification.3 In addition to the model by Cosci, the putative markers were 
Figure 1. Integrated stage-specific model for anxiety disorders.
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divided into susceptibility markers, diagnostic markers, prognostic markers 
and predictive markers as these distinctions are clinically relevant and are 
vital for development of personalized psychiatry. This model is thereby also 
in line with the RDoC criteria for future finetuning of classification systems.15 
See figure 1 for the integrated stage-specific model. 
Staging in psychiatry
Over the last decade, using clinical staging in psychiatry has become 
increasingly widespread. The first staging models for psychiatric disorders 
used an approach for a single disorder or psychiatric syndrome, e.g. for 
schizophrenia,16 bipolar disorder,16 PD16 and alcohol use disorder.17 An 
important benefit of these staging models is expanding the possibilities 
clinicians have to formalize their individualized assessment of the relative 
severity of the index disorder.16 Due to this syndromal approach, use 
of these models is restricted to health care settings who specialize in 
providing treatment for certain disorders. More recent studies increasingly 
advocate using a transdiagnostic approach, e.g. for severe psychotic and 
mood disorders18 or for overall psychopathology in adolescents.19 In these 
transdiagnostic staging paradigms, prodromal stages of psychiatric disorders 
are characterized by a-specific clinical features and are not yet distinguishable 
as specific disorders, while later stages develop into well-defined syndromal 
psychiatric classifications. In this transdiagnostic approach staging models 
are described as a “departure from silo-based diagnostic concepts that 
populate the current international classification systems”.19 Comorbidity 
can be accounted for in transdiagnostic staging models by assessment of all 
relevant forms of psychopathology. 
Anxiety disorders are a group of disorders that seem particularly suitable for 
assessment via a staging model. Many anxiety disorder patients refrain from 
seeking treatments for years after development of the first symptoms.20 As 
a result, the first episodes likely develop into chronicity.21,22 Furthermore, 
anxiety disorders are burdened with high levels of comorbidity with other 
anxiety disorders or with depressive disorders.23 Finally, there seems to 
be substantial diagnostic instability. A little over 30% of persons with an 
anxiety disorder have a transition to another anxiety disorder within a six-
year follow-up period. This proportion increases to 73% in case of a chronic 
course during follow-up.24 In this thesis four anxiety disorders were studied 
in unison. This was done to account for this diagnostic instability but also due 
to the likelihood of shared aetiology in these disorders. For instance, GWAS 
findings suggest these anxiety disorders share some genetic aetiology.25 
255




Moreover, some debate as to whether staging models should be ‘bidirectional’ 
or ‘unidirectional’ exists. The staging model by McGorry et al applied a 
unidirectional approach in which clinicians are advised to “note” whether 
subjects remit spontaneously, or recover after treatment and afterwards, 
these persons maintain their highest stage they were ever assigned to.19 A 
clear rationale for this decision was not provided and their approach has some 
important limitations. For instance, it leads to a conflation of higher stages, 
as remitted subjects have lower risks of poor outcomes, not comparable to 
subjects with current disorders or high symptom severity.24 Bidirectional 
models on the other hand are characterized by a design in which subjects can 
not only progress, but also mitigate across stages. Subjects with remitted 
disorders are especially crucial in this discussion, as they are the largest group 
of subjects that would either mitigate (in a bidirectional model) or remain at 
a higher stage (in a unidirectional model). The model presented in chapter 5 
was bidirectional: those with remitted disorders were assigned to stage 0, 1A 
or 1B, instead of remaining in stages 2, 3, or 4. The clinical course of anxiety 
disorders can be described as “waxing and waning” disorders.24,26,27 Therefore, 
for anxiety disorders, bidirectional staging models might fit best.
However, in contrast to the staging model tailored for use in anxiety disorders 
presented in chapter 5, some authors argue that staging models should be fully 
transdiagnostic.19 Instead, the staging model presented in chapter 5 could be 
termed half transdiagnostic as it did incorporate psychiatric comorbidity but 
did not assess the severity of the comorbidities. Instead, patients with different 
types of comorbidities were all assigned to the same ‘B’ substage. This was 
likely an oversimplification of the impact of psychiatric comorbidity on anxiety 
disorder course. However, the model presented in chapter 5 was validated in 
a transdiagnostic way by assessing general psychopathology validators. In 
this way it became apparent that higher clinical stages showed not only poorer 
anxiety outcomes but also poorer transdiagnostic outcomes. It could be argued 
that a fully transdiagnostic approach is likely most beneficial in certain clinical 
settings. Fully transdiagnostic staging models could be particularly relevant 
if the goal is early intervention.28 Fully transdiagnostic models can however 
suffer from loss of information with regard to certain endophenotypes related 
to end-stage disorders. Fully transdiagnostic models will also be less easily 
augmented with stage-specific prognostic or predictive markers as these 
markers are usually assessed in relation to a specific disorder. Therefore, in 
the context of multidisciplinary treatment settings aimed at anxiety disorders 
a half transdiagnostic staging model could be optimal.
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Finally, a few other aspects of staging models remain unelucidated. Some 
authors argue that stage 0 should be used to demarcate at-risk persons,19 
while others argue that the current state of research does not warrant the 
use of a stage 0.11 Stage 0 refers to persons without current psychopathology 
and could prove relevant if these persons have certain susceptibility markers 
that increase their risks of developing a psychiatric disorder. It is clear that 
many of such susceptibility markers exist. In addition to the clinical and 
sociodemographic susceptibility markers that were already mentioned 
and incorporated into the staging model presented in chapter 5 it is highly 
likely that genetic factors underly a certain susceptibility for development of 
anxiety disorders.29 Due to the presence of susceptibility markers for anxiety 
disorders the inclusion of stage 0 for at-risk persons seems empirically 
sound. Whether inclusion of persons in stage 0 should always warrant 
further evaluation or treatment is however very debatable. From a primary 
prevention perspective it might be beneficial to apply cost-effective early 
interventions which could lead to reduced overall burden of mental health in 
the long term.28 
Just like the debate revolving stage 0, the operationalization for stage 4 is 
not fully elucidated. Stage 4 should refer to the patients who exhibited the 
least favourable clinical course and are subsequently least likely to benefit 
from prolonged treatments. Stage 4 in the staging model should therefore 
overlap with the concept of treatment resistance. As was showed in chapter 
4, however, the concept of treatment resistance in anxiety disorders is not 
clearly defined. Possibly, applying the consensus definition for TR-AD that 
was presented in chapter 4 to stage 4 of the clinical staging model leads to a 
more clear description of stage 4 in the anxiety disorder staging model. 
Ultimately, using clinical staging models has the potential to improve the 
treatment decision processes in clinical care as different stages could 
benefit from different treatments. There is evidence for the assumption that 
interventions in early stages will be both more effective and less harmful 
than treatments delivered later in the course.30 These early interventions 
don’t have to be disorder-specific. For instance, many transdiagnostic 
cognitive processing errors can be treated with cognitive behavioural 
therapy, thereby reducing the severity and maintenance of symptoms 
across a range of clinical presentations.30 Early treatments in prodromal 
stages of anxiety disorders are likewise effective: cognitive behavioural and 
psychosocial interventions in high risk groups led to lower anxiety symptoms 
and lower subsequent incidence of anxiety disorders.31 Besides the use in 
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clinical practice, clinical staging may also be useful in research, especially 
research at the aetiology of anxiety disorders. Possibly, subgroups of anxiety 
disorders based on the staging model can provide a better basis for research 
at the aetiology in comparison with using DSM classifications. 
Prediction models in anxiety disorders
The second main aim for this thesis was to improve predictions for the 
clinical course of anxiety disorders by assessing predictive properties of 
different prediction models. Prediction models are statistical models based 
on various predictor variables and they provide diagnostic, prognostic 
or predictive probabilities for certain outcomes.32 In three of the papers 
presented in this thesis prediction models were designed. The first model 
presented is the clinical staging model (chapter 5). This prognostic model 
is based on a clinician-opinion model for disease progression in anxiety 
disorders. The second model presented (chapter 6) is a predictive model 
in which a dimensional measurement instrument was developed based on 
literature-derived criteria for advanced progression in anxiety disorders. 
The final prognostic model presented is a data-driven model (chapter 7) 
for naturalistic course in anxiety disorders. Different statistical metrics 
are used to evaluate the validity of predictions. The most used metrics are 
sensitivity and specificity, indicating the proportion of correct predictions 
among groups that have a certain outcome (sensitivity) versus correct 
predictions in the group that does not have that outcome (specificity). These 
can be summarized in either an overall accuracy measure or in an Area Under 
the Receiving Operator Curve (AUC).33 To calculate the AUC, all possible 
predicted probabilities from the prediction model are used as separate 
thresholds. For each threshold, the predicted probabilities are dichotomized 
into those above and those below the threshold. Subjects with a predicted 
probability above the threshold are classified as high risk, while those with 
predicted probabilities below the threshold are classified as low risk. Using 
these risk predictions it is possible to calculate sensitivity and specificity 
for each of these thresholds. The ROC curve is the plot of sensitivity vs. one 
minus specificity calculated for all possible thresholds. When sensitivity and 
specificity are high, the AUC is high as well, indicating adequate predictive 
properties.34 When predicting binary outcomes, the concordance-statistic 
(c-statistic) refers to the probability that a randomly selected subject who 
experienced this outcome will have a higher predicted risk based on the 
prediction model compared to a randomly selected subject who did not have 
the outcome.34 The c-statistic is equal to the AUC. For all prediction models 
in this thesis, AUCs were calculated to assess accuracy of predictions.
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In order to use the clinical staging model as a prediction tool the clinical 
stages were assessed at baseline according to the adopted model presented 
in chapter 5. In these analyses, the staging model was coded as a ordinal 
variable with a range of 0 (stage 0) to 8 (stage 4B). When using this staging 
model as a prediction tool for 2-year presence of anxiety disorder diagnoses 
the AUC across all stages was calculated at 0.81 (95% CI: 0.80-0.83). This 
level of accuracy is substantial. It should be noted, however, that this AUC 
was calculated when including subjects from preclinical stage 0, 1A and 1B. 
By including preclinical subjects the accuracy of predictions was inflated at 
the cost of clinical utility as this comparison is less clinically relevant. A more 
clinically relevant comparison would be across clinical stages as this could 
inform clinicians and patients of individualized risks in patients in comparison 
to other patients. As a post-hoc analysis, the AUC for comparisons across 
clinical stages 2A to 4B was calculated. This clinical comparison yielded a 
moderate AUC of 0.64. Therefore, the clinical staging model is moderately 
able to predict poor outcomes at follow-up. On average, the probabilities are 
0.64 that a random anxiety disorder patient who did not remit at two-year 
follow-up was originally in a higher clinical stage when compared with a 
random anxiety disorder patient who did remit at two-year follow-up. 
The second prediction model assessed is the dimensional measurement 
instrument based on literature-derived criteria for treatment resistance 
in anxiety disorders presented in chapter 6. This measurement instrument 
is based on various clinical characteristics and assessment of these 
characteristics yields a potential score between 2 and 23, with an observed 
range in the studied sample of patients with an anxiety disorder who 
subsequently received treatments from 2 to 16. For each observed score 
the sensitivity and specificity were calculated for persistence of two-year 
anxiety disorders and the optimal cut-off value was calculated at 11 or 
above. This cut-off value was accompanied with a sensitivity of 0.70 and 
a specificity of 0.57. The AUC for all cut-off values was calculated at 0.66, 
marginally higher in comparison with the AUC using the staging model. The 
use of a dimensional measurement instrument for TR-AD was therefore 
not clearly associated with improved predictive properties for persistence 
of anxiety disorders at two-year follow-up in comparison with the ordinal 
staging model. 
The final prediction model was the random forests classifier trained in 
anxiety disorder patients to classify persistence of anxiety disorders at 
two-year follow-up. This model was trained on a wide array of clinical, 
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psychological, biological, sociodemographic and lifestyle variables and 
yielded individual predictions based on decision trees. These predictions 
were dichotomous: based on the combination of predictor variables a patient 
was predicted to either be remitted or have a persisting anxiety disorders. 
Using these individual predictions it was possible to calculate AUCs for the 
whole model as well as for individual predictor domains. For the whole model 
the AUC was calculated at 0.67 for persistence of anxiety disorder diagnoses 
at two-year follow-up. This model thereby provides the highest accuracy of 
predictions across all three models presented. However, the improvement in 
predictive properties that was achieved from using a wide array of predictor 
variables was marginal in comparison with the more straightforward models 
of clinical staging and the degree of TR-AD measurement tool. 
Overall, the accuracy of the predictions in the models presented were 
consistently moderate. Comparison with earlier prediction models in anxiety 
disorders are difficult as previous attempts are scarce. One prognostic study 
into the recurrence of PD in a large sample of remitted PD patients was 
identified. This study developed a prediction model for recurrence of PD in a 
sample of 949 remitted PD patients and validated its performance in a sample 
of 732 remitted PD patients. The prognostic model included eleven predictor 
variables and the validated predictive properties were adequate with an AUC 
of 0.73.35 In a different approach, an European study developed a prediction 
model for 6-month incidence of GAD and PD in healthy subjects (n=4,905) 
who visited their general practitioner.36 The predictive properties for this 
model were estimated to be substantial with an AUC of 0.78. However, a 
replication study in a U.S. sample showed poor predictive properties with an 
AUC of 0.62.37 A few small machine learning studies focussed on predicting 
immediate treatment response using neuroimaging data.38–43 Although 
some of these studies provided substantially higher AUCs these are not 
comparable due to the small sample sizes and the cross-sectional design.
There is no guideline for what levels of accuracy in prognostic tests should 
be deemed adequate. The performance of prognostic tests will depend on 
different factors. First, the population in which a prediction is tested is highly 
relevant. If the population consists of a very homogenous group of patients 
it will become increasingly difficult to adequately predict differences in 
outcomes among this homogenous group. Alternatively, it is much easier to 
predict an outcome across a very heterogenous population, as is illustrated 
by the high predictive performance of the staging model when asymptomatic 
at-risk subjects were included alongside chronic anxiety disorder patients. 
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Likewise, it might be easier to predict recurrences in remitted patients as this 
sample could be more heterogenous in comparison to predicting persistence 
in current patients. This might explain the somewhat higher AUC in the study 
into remitted PD patients.35 Second, the prevalence of outcomes is relevant. 
For instance, psychiatrists are reasonably well-equipped to predict future 
suicidal behaviour but their assessments of future suicides are much less 
precise, partly as this is an outcome with a much lower incidence.44 This will 
especially reduce the sensitivity of the prediction as predictions will more 
likely turn out to be false negative than true positive. Alternatively, in some of 
the analyses presented in this thesis it appeared more feasible and relevant 
to predict a broad outcome measure that included all CMDs, so either anxiety 
disorders, depressive disorders or alcohol dependency as combined outcome 
measure. By choosing this broad outcome measure the contrast between the 
two possible outcomes is increased (healthy versus affected). The predictive 
properties for the ML model were significantly better for this broad outcome 
measure (AUC increased from 0.67 to 0.70). This increase was largely due 
to an increase of 7.6 points in sensitivity. The work presented in this thesis 
thereby highlights the potential benefits of using broad outcome measures in 
anxiety disorders when studying the longitudinal course. Finally, the amount 
of time the prognostic test covers is highly relevant. If the amount of time for 
a prediction increases, the uncertainty in predictions also increases. In all of 
the models presented, the follow-up periods were extended. This explains 
the lower predictive performance in the models presented in comparison to 
the studies assessing immediate treatment response or longitudinal studies 
with shorter follow-up periods.
Currently diagnostic, prognostic and predictive models are not yet widely 
implemented. Likely, continued application of machine learning methods 
to prediction problems in psychiatry will result in development of adequate 
prediction models. It is shown in other fields of psychiatry that predictions 
using ML algorithms outperform those using logistic regression analyses.45 
ML prediction models may assist clinical decision making without telling 
clinicians what to do precisely. 
Clinical implications
A number of clinical implications could follow from the results of this thesis. 
The main implications are diagnostic. First, the results and integration of 
this thesis warrant applying the staging paradigm in anxiety disorders. As is 
clear from the studies presented in this thesis, in anxiety disorders, much of 
the clinical course is defined by the current clinical characteristics. Anxiety 
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disorder clinical care should therefore at least consist of a combined clinical 
assessment of previous duration, anxiety severity, presence and severity of 
functional impairments and presence and severity of somatic and psychiatric 
comorbidity. After assessing these core clinical characteristics it is possible 
for the clinician to assess the current clinical stage. The adapted staging 
model presented in this thesis provides a method for translating these 
assessments into the appropriate clinical stage. 
Second, when assessing anxiety disorder patients, previous treatments 
and its effects should be assessed. As was clear from the systematic 
review presented in chapter 4 many authors disregard psychotherapeutic 
treatments in their assessments of TR-AD. This is not in line with treatment 
guidelines in which psychotherapeutic treatments play a central role. 
Currently, stepped-care treatment algorithms for anxiety disorders are 
based on providing subsequent treatments after treatment failures indicate 
the need for applying a next step treatment. The definition for TR-AD should 
therefore be aligned with the current clinical practice. The definition for TR-
AD provided in this paper could be used to align diagnostic criteria in this 
group and provide alignment with treatment guidelines. 
Finally, applying prediction models to improve clinical decision-making 
will become feasible when accuracy of predictions is sufficient. Moreover, 
prediction models based on predictive markers might be most clinically 
relevant as they could have direct implications for treatment decisions. For 
instance, the degree of TR-AD measurement tool could be used to assess 
likelihood of prospective treatment failures. The findings in this thesis 
should be seen as encouraging for clinicians interested in personalized 
medicine. 
Future research
Expanding upon the current state of knowledge on prognosis and prediction 
in anxiety disorders is still needed. In this thesis it was argued that identifying 
different susceptibility, diagnostic, prognostic and predictive markers across 
clinical stages of anxiety disorders leads to improvement of evidence-based 
prognosis and precision psychiatry. Even though stage-specific models are 
a good method to summarize and visualize the current state of research in 
anxiety disorders, few studies so far used this stage-specific approach. 
Future studies could focus on this approach more as it advances evidence-
based prognosis and personalized psychiatry in different stages of disease 
progression. The stage-specific model could still be much more refined by 
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incorporating research from the wide array of psychiatric research. Many 
possibly susceptibility, diagnostic, prognostic and predictive markers for 
anxiety disorder fell outside the scope of the current thesis. For instance, 
polygenetic risk scores might be linked to increased susceptibility for anxiety 
disorders, thereby constituting a susceptibility marker.29 Additionally, certain 
neuroimaging findings might be useful as diagnostic markers for anxiety 
disorders. For instance, diagnostic neuroimaging findings in GAD include 
lower availability of dopamine transporters (DAT) in the striatum, lower 
number of fronto-cortical GABA-A receptors,46 larger dorsomedial prefrontal 
cortical volume in women,47 and larger amygdala volumes.48,49 Diagnostic 
findings in PD include volumetric differences across the basal ganglia and 
the anterior cingulate cortex.46 Possible diagnostic markers in SAD include a 
hyperresponsive emotion network, a diminished cognitive control network, 
an overactive default-mode network and an active motivational system.50 
Currently, pooled mega-analysis of neuroimaging data is performed 
worldwide, using data from various sites in the ENIGMA study.48 Results for 
anxiety disorders neuroimaging mega-analyses are to be expected shortly. 
These results could lead to pruning of previous neuroimaging findings and 
the stage-specific model should be aligned with results from ENIGMA in 
the future. Other putative diagnostic markers for anxiety disorders that 
warrant a closer investigation include increased hair cortisol levels in GAD,51 
lower oxytocin and testosterone levels in SAD.52–54 Behavioural inhibition 
might be seen as an additional diagnostic marker for at-risk stages of SAD. 
Behavioural inhibition refers to a particular temperamental trait defined by 
an inhibited pattern of emotional and behavioural responses to unfamiliar 
people or unusual situations and incidence of SAD is increased two- to 
sevenfold in children who show behavioural inhibition in comparison to non-
inhibited children.55,56 Additional possible prognostic markers that were not 
investigated in this thesis include hypersensitivity to carbon dioxide (CO2), 
aberrant levels of tetranectin, creatine kinase MB, ghrelin and lipids in PD.57–59 
Assessing CO2 reactivity in PD patients after treatment with antidepressants 
could possibly be a predictive marker and further investigation is warranted 
as preliminary results suggest that decreased CO2 reactivity after one week 
of treatment predicted treatment results after 1 month.60 Other possible 
predictive markers include phosphate and BDNF levels for outcomes 
after CBT in PD,61,62 as well as altered heart rate variability after treatment 
with mirtazapine or exposure therapy in PD,63,64 reversible MAOA gene 
hypomethylation in PD after CBT,65 and higher reactivity to fearful faces in 
the rostral ACC, lesser reactivity in the amygdala and increased activation 
in the pregenual ACC in PD patients with beneficial treatment effects with 
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venlafaxine.66,67 In SAD, right frontal electroencephalography asymmetry 
might be a predictive markers as it predicted CBT effects without being 
linked to pre-treatment SAD severity.68 Furthremore, pharmacogenetic 
differences might be used as predictive markers as better treatment results 
with venlafaxine were found in GAD patients with at least one G-allele of 
the Serotonin receptor 2A.70 All of these putative predictive markers should 
be investigated further to assess their merits as expansions to the stage-
specific model for anxiety disorders. Novel research modalities might derive 
further additions to the stage-specific model. Some promising examples 
include experience sampling methods, 71 gait analysis,72 actigraphy data,73 or 
social media data.74 
Additionally, in order to fully use the stage-specific model, further 
investigations in different populations are warranted. For instance, 
investigating populations of at-risk or subthreshold adolescents might 
lead to further knowledge on stage 1 markers. Also, studies into treatment 
resistant samples are needed to further elucidate markers for stage 4 anxiety 
disorders. From a methodological perspective, the design of the studies 
presented in this thesis was not adequate to study next-step strategies 
after applying the prediction models. Future studies could use a prospective 
longitudinal approach to assess susceptibility and prognostic markers and 
could use randomized controlled trials to validly assess predictive markers. 
In addition, integration of findings from various studies is also much needed. 
In the second part of this thesis a number of prognostic and predictive 
markers were integrated into statistical models. The development of 
such multi-modal models is much needed as it is abundantly clear that no 
one single factor is sufficiently related to the clinical course in anxiety 
disorders. However, many iterations are likely needed in order to optimize 
the statistical layout of these models. Also, frequent updates to these 
models are warranted as a response to ongoing advances in the scientific 
field. Clinical utility for prediction models could be increased by performing 
test reclassification analyses in addition to calculating accuracy and AUCs. 
In these analyses, the degree to which the use of a prognostic test results 
in reclassifying a patient into a different risk category is assessed. If high 
numbers of reclassification occur, the prognostic test adds something to 
routine clinical care and makes implementation more warranted.33 Moreover, 
implementation studies for statistical models should be performed. Also, 
when studying anxiety disorders the investigated outcomes should include 
symptoms of other CMDs. The longitudinal analyses in this thesis clearly 
264
showed that the predictive properties for statistical models that included a 
broad outcome perspective were superior to those that were modelled on 
a narrow outcome perspective. The aim of evolving statistical prediction 
models that is mentioned in this thesis is an example of the expanding 
reliability on advanced computational science. The field of medicine is on 
the verge of large-scale application of machine learning models.75 However, 
some methodological and ethical considerations should be addressed. 
Currently, only 10.4% of the total models developed in the field of 
psychiatry are internally validated, and only 4.6% are externally validated.76 
Furthermore, issues regarding patient privacy and confidentiality, informed 
consent, and patient autonomy were raised.77 These ethical questions should 
be continuously asked in order for translation of machine learning models to 
be implemented effectively and ethically. 
Overall, the findings from this thesis point towards the importance of a clear 
and rigorous diagnostic work-up when assessing a patient with an anxiety 
disorder. Many different clinical aspects of anxiety disorders are related to 
the subsequent clinical course. Furthermore, the stage-specific approach 
in identifying diagnostic, prognostic and predictive risk factors is a valuable 
addition to the diagnostic framework. And although the predictive properties 
should still be refined, this thesis provides different easy to use diagnostic, 
prognostic and predictive models for clinicians. This focus on diagnostic, 
prognostic and predictive aspects of anxiety disorders is an important step 
toward precision psychiatry and could lead to improvements in the treatment 
decision process, leading to providing patients with the right treatment at 
the right time.
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Het doel van hoofdstuk 2 was  om een  screeningsprogramma voor 
angststoornissen te implementeren bij patiënten die met acute pijn op de 
borst de eerste harthulp bezochten.  ‘Niet-cardiale pijn op de borst’ wordt 
gediagnosticeerd bij patiënten met acute pijn op de borst nadat een cardiale 
oorzaak van de pijn is uitgesloten.  Meer dan de helft van alle patiënten 
met pijn op de borst krijgt de diagnose niet-cardiale pijn op de borst. 
Onderzoek wijst uit dat een aanzienlijk deel (12-41%) van deze patiënten 
een paniekstoornis heeft.  In de praktijk wordt tot nu toe niet gescreend 
op paniekstoornissen en andere psychiatrische stoornissen bij patiënten 
met niet-cardiale pijn op de borst. Vanwege de hoge prevalentiecijfers van 
deze stoornissen is screening belangrijk. Het doel van deze studie was om 
te screenen op  paniekstoornissen en andere psychiatrische stoornissen 
bij patiënten met niet-cardiale pijn op de borst.  Het onderzoek werd 
tussen 2012 en 2013 uitgevoerd op de eerste harthulp van het VU Medisch 
Centrum. Een groep van 252 volwassen patiënten met niet-cardiale pijn 
op de borst kwam in aanmerking voor screening naar psychiatrische 
stoornissen. Het screeningsprogramma bestond uit twee fasen: de eerste 
fase werd uitgevoerd op de eerste harthulp door getrainde cardiologie 
verpleegkundigen en bestond uit het afnemen van de Hospital Anxiety 
and Depression Scale (HADS) nadat de diagnose niet-cardiale pijn op de 
borst was gesteld.  Alle patiënten die angstige of depressieve symptomen 
vertoonden boven een afkapwaarde op de HADS kwamen in aanmerking voor 
de tweede fase van de screening. Deze tweede fase werd ingepland op een 
later tijdstip en vond plaats op de afdeling psychiatrie in hetzelfde ziekenhuis. 
De tweede screeningsfase bestond uit een gestructureerd interview waarbij 
verschillende psychiatrische diagnoses werden onderzocht met behulp van 
het Composite International Diagnostic Interview (CIDI).
Helaas werd de eerste fase van screening bij slechts 60 van de 252 (23,8%) 
patiënten met niet-cardiale pijn op de borst uitgevoerd. Dit lage aantal was 
grotendeels te wijten aan een lage  bereidheid van verpleegkundigen om 
het screeningsprogramma op te starten. Zij gaven aan dat andere taken 
een hogere prioriteit hadden dan het screeningsprogramma.  Van de 60 
patiënten die screening kregen aangeboden op de eerste harthulp waren 
51 patiënten (85,0%) bereid hieraan deel te nemen.  Bijna de helft van de 
gescreende patiënten met niet-cardiale pijn op de borst (24/51; 47,1%) 
scoorde boven de afkapwaarde op de HADS en kwam in aanmerking voor de 






zagen 12 patiënten (50%) af van verdere deelname. Van de overige 12 
patiënten werden 8 patiënten gediagnosticeerd met een psychiatrische 
stoornis, waaronder twee met de diagnose paniekstoornis.  Gezien deze 
lage aantallen werd verdere implementatie van het screeningsprogramma 
niet haalbaar geacht. De belangrijkste barrière voor implementatie was een 
onmogelijkheid van de verpleegkundigen om het uitvoeren van de screening 
te combineren met de andere taken in hun takenpakket. 
Het doel van hoofdstuk 3 was  om de impact van  angst- en depressieve 
stoornissen  en chronische somatische ziektes op beperkingen en 
beroepsmatig functioneren te beoordelen.  Patiënten met angst- en 
depressieve stoornissen  hebben vaak functionele beperkingen en 
beperkingen in het arbeidsmatige functioneren.  Hetzelfde geldt voor 
patiënten met chronische somatische ziektes,  zoals lage rugpijn, migraine, 
diabetes en obesitas.  Bovendien komen  angst- en depressieve stoornissen 
vaak samen voor met chronische somatische ziektes.  De comorbiditeit 
tussen deze psychiatrische aandoeningen met somatische aandoeningen 
vermindert het algehele functioneren nog verder en er wordt aangenomen 
dat het de behandelresultaten voor somatische ziekten vermindert.  Verder 
hebben chronische somatische ziektes waarschijnlijk een negatieve 
invloed op het beloop van  angst- en depressieve stoornissen.  Het doel van 
deze studie was om de effecten van  angst- en depressieve stoornissen, 
chronische somatische ziektes en comorbiditeit hiertussen op functionele 
beperkingen bij volwassen patiënten te onderzoeken.  We gebruikten de 
gegevens van de Nederlandse Studie naar Depressie en Angst (NESDA) 
om patiënten te includeren voor dit onderzoek. De steekproef omvatte 
2371 personen, bestaande uit patienten met  angst- en depressieve 
stoornissen en controles.  De onderzochte angststoornissen waren de 
gegeneraliseerde angststoornis, de sociale angststoornis, agorafobie 
en de paniekstoornis. De depressieve stoornissen omvatten de depressieve 
stoornis (major depressive disorder) en dysthymie. De aanwezigheid van 30 
verschillende chronische somatische ziektes werd onderzocht.  Somatische 
ziekten werden alleen meegeteld wanneer patiënten hiervoor een 
behandeling of medicatie nodig hadden.  In de steekproef hadden patiënten 
met  angst- en depressieve stoornissen vaker een chronische somatische 
ziekte.  Uit gecorrigeerde logistische regressieanalyses werd een odds-ratio 
(OR) van 1,34 (95% betrouwbaarheidsinterval (BI) = 1,09-1,64) afgeleid voor 
patiënten met angst- en depressieve stoornissen voor het hebben van een van 
de chronische somatische ziektes.  De verschillende chronische somatische 
ziektes werden onderverdeeld in zeven categorieën: respiratoire, cardio-
276
metabole, musculoskeletale, gastro-intestinale, neurologische, endocriene 
en kankers.  Van deze categorieën bleek de categorie gastro-intestinale 
aandoeningen de enige die significant vaker aanwezig was bij patiënten 
met angst- en depressieve stoornissen (OR=3.29, 2.15-5.05).
Uit de beschrijvende statistiek werd duidelijk dat  angst- en depressieve 
stoornissen samenhingen met een lagere functionele status: de totale 
gestandaardiseerde score voor beperkingen, gemeten met het World Health 
Organization Disability Assessment Schedule (WHO-DAS II) was 29,0 ± 
16,4 terwijl de totale score voor beperkingen in de controlegroep 7,8 ± 9,3 
was. Multivariate lineaire regressieanalyses toonden aan dat  angst- en 
depressieve stoornissen gerelateerd waren aan de hoogste niveaus van 
beperkingen (β = 20,1).  Chronische somatische ziektes waren in mindere 
mate ook geassocieerd met beperkingen (β = 3,88).  Bovendien was er een 
interactie-effect aanwezig tussen angst- en depressieve stoornissen en 
chronische somatische ziektes op de mate van beperkingen (β = 4,06).  Uit 
dit interactiemodel bleek dat de effecten van chronische somatische 
ziektes op beperkingen vooral aanwezig waren bij patiënten die ook angst- 
en depressieve stoornissen hebben.  Er bleek sprake van synergistische 
effectmodulatie, waarbij het effect van comorbide chronische somatische 
ziektes en  angst- en depressieve stoornissen op scores voor beperkingen 
groter is dan de som van de afzonderlijke effecten voor angst- en depressieve 
stoornissen en chronische somatische ziektes. 
Analyses van arbeidsbeperkingen werden uitgevoerd in een subset van 1462 
respondenten die aangaven te werken. Uit beschrijvende statistiek bleek dat 
de arbeidsbeperkingen groter waren bij patiënten met angst- en depressieve 
stoornissen: 67,6% van de  patiënten had op zijn minst enig ziekteverzuim, 
terwijl slechts 32,7% van de controles ziekteverzuim had (Χ2  = 163,9, 
p<0,001).  Evenzo hadden  patiënten met angst- en depressieve stoornissen 
in vergelijking met controles meer kans op verminderde werkprestaties: 
60,5% van de patiënten had enige vorm van verminderde werkprestatie 
terwijl slechts 32,5% van de controles verminderde werkprestaties had (Χ2 = 
132,2, p<0,001).  Er werden multinomiale regressieanalyses uitgevoerd om 
interactie effecten te kunnen beoordelen.  Hierbij werden de metingen ten 
aanzien van ziekteverzuim en verminderde werkprestaties gecategoriseerd 
en werden vergelijkingen gemaakt met de ‘gezonde’ categorieën van geen 
verzuim en geen verminderde werkprestaties. Het leek erop dat chronische 
somatische ziektes alleen geassocieerd waren met de meest ernstige 






1,07-1,88) en ernstig verminderde werkprestaties OR= 1,42 (95% BI 1,08-
1,87).  Angst- en depressieve stoornissen waren geassocieerd met alle 
uitkomsten van werkbeperkingen: kort verzuim OR= 2,88 (95% BI 2,16-
3,84), langdurig verzuim OR= 6,64 (95% BI 4,69-9,40), licht verminderde 
werkprestaties OR= 1,83 (95% BI 1,38- 2,43) en ernstig verminderde 
werkprestaties OR= 7,51 (95% BI 5,11-11,1).  Deze regressiecoëfficiënten 
werden gecorrigeerd voor  sociodemografische gegevens  en laten een 
duidelijk verschil zien tussen  angst- en depressieve stoornissen en 
chronische somatische ziektes op de uitkomsten van arbeidsbeperkingen, 
waarbij  de effecten  van  angst- en depressieve stoornissen veel groter 
waren.  Daarnaast werden modellen gemaakt met behulp van vier 
categorieën voor combinaties van  blootstelling  aan  angst- en depressieve 
stoornissen en chronische somatische ziektes: controles (geen angst- en 
depressieve stoornissen, geen chronische somatische ziektes), uitsluitend 
fysiek (chronische somatische ziektes zonder  angst- en depressieve 
stoornissen), uitsluitend mentaal (angst- en depressieve stoornissen zonder 
chronische somatische ziektes) en comorbiditeit (angst- en depressieve 
stoornissen en chronische somatische ziektes).  Er was geen relatie tussen 
chronische somatische ziekte en werkverzuim, maar wel met verminderde 
werkprestaties. De groep met angst- en depressieve stoornissen bleek 
te maken te hebben met hogere maten van werkverzuim en verminderde 
werkprestaties. Ten slotte bleek de groep met comorbiditeit geassocieerd 
met de slechtste uitkomsten voor alle maten van arbeidsbeperkingen.
Deze bevindingen benadrukken het belang van het herkennen en behandelen 
van psychiatrische comorbiditeit bij patiënten met chronische somatische 
ziektes en eveneens van het herkennen en behandelen van somatische 
comorbiditeit bij patiënten met  angst- en depressieve stoornissen om 
langdurige beperkingen en verminderd beroepsmatig functioneren bij deze 
patiënten tegen te gaan.
Het doel van hoofdstuk 4 was  om verschillende definities en diagnostische 
criteria voor therapieresistentie bij angststoornissen (TR-AD) in kaart te 
brengen.  Op dit moment zijn er geen eenduidige criteria voor TR-AD.  Het 
is belangrijk dat er duidelijke criteria komen, omdat de behandeling 
voor veel patiënten met een angststoornis een beperkt resultaat 
heeft.  In de literatuur worden verschillende termen gebruikt voor het 
optreden van een suboptimaal behandeleffect. Voorbeelden hiervan 
zijn ‘therapieresistentie’,  ‘symptomatisch blijven’, ‘refractair’ en ‘non-
respons’. Deze termen worden min of meer inwisselbaar gebruikt. Hoofdstuk 
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4 beschrijft een systematisch review waarin deze termen in kaart werden 
gebracht. Alle publicaties die een duidelijke beschrijving van het fenomeen 
TR-AD bevatten werden meegenomen in het review.  De verzamelde 
beschrijvingen werden systematisch beschreven met betrekking tot 
verschillende aspecten waar deze uit bestonden.  Het doel was om alle 
verschillende criteria en aspecten van definities van TR-AD te verzamelen 
en weer te geven. Een secundair doel was om deze criteria te integreren tot 
een nieuwe en eenduidige consensusdefinitie voor TR-AD.
De zoekstrategie leverde 13.042 unieke records op.  Deze publicaties 
zijn eerst onafhankelijk op titel en abstract beoordeeld door twee 
onderzoekers.  Dit resulteerde in 388 records die in aanmerking kwamen 
voor full-text screening en daarvan werden 62 studies opgenomen in de 
datasynthese. De geïncludeerde onderzoeken gaven allemaal een specifieke 
definitie voor TR-AD, of ze gaven inclusiecriteria voor patiënten die 
werden beschreven als TR-AD-patiënten.  De selectie van studies bestond 
uit reviews, richtlijnen, boekhoofdstukken, trials en cohortstudies.  De 
bestudeerde angststoornissen waren de paniekstoornis  (n=33),  de 
gegeneraliseerde angststoornis (n=34), de sociale angststoornis (n=21), de 
specifieke fobie (n=5) en angststoornissen in het algemeen (n=5).  Voordat 
een patiënt aan de criteria voor TR-AD voldoet, zijn er volgens de meeste 
onderzoeken (85,5%) een minimaal aantal behandelingen zonder resultaat 
nodig. Het minimale aantal behandelingen met onvoldoende resultaat 
varieerde van één tot vijf. Verdere criteria waren onder meer de voorwaarde 
dat er farmacologische behandelingen zonder resultaat moesten zijn 
(93,5%), de voorwaarde dat er psychotherapieën met onvoldoende 
resultaat moeten zijn (29,0%), de voorwaarde dat deze behandelingen 
een minimale duur moesten omvatten (54,8%), de voorwaarde dat een 
behandeling pas mocht worden beschouwd als één met onvoldoende 
resultaat wanneer er niet werd voldaan aan een specifiek responscriterium 
(41,9%), bijv. een vermindering van de ernst van de angstklachten van meer 
dan 50%. Bovendien werd in bijna de helft (46,8%) van de onderzoeken een 
drempel voor de ernst van angstklachten gebruikt vóór behandeling.  Ten 
slotte werden enkele voorwaarden in een kleine minderheid (minder dan 
10%) gebruikt in TR-AD-definities: minimale duur van de angststoornis, 
de aanwezigheid van functionele beperkingen en de aanwezigheid van 
psychiatrische comorbiditeit.  Uit kwaliteitsanalyses bleek dat de kwaliteit 
van het onderzoek geen invloed had op de door de auteurs gebruikte criteria 
voor TR-AD: dezelfde criteria werden gerapporteerd bij onderzoeken van 






Ten slotte werden de gevonden criteria uit deze systematische review 
geïntegreerd in een nieuwe consensusdefinitie voor TR-AD. Hiervoor werden 
de meest gebruikte criteria en aspecten voor TR-AD geselecteerd.  Volgens 
deze consensusdefinitie is TR-AD aanwezig als patiënten ten minste één 
farmacologische  behandeling  met een eerstelijns  antidepressivum  (SSRI/
SNRI) hadden.  Daarnaast moeten patiënten ook minimaal één eerstelijns 
protocollaire psychotherapeutische behandeling (CGT) gericht op de 
angststoornis hebben gehad. Deze behandelingen tellen alleen mee wanneer 
de behandeling er niet in slaagde om een angstreductie van minimaal 50% te 
bereiken na een behandelingsduur van minimaal 8 weken.  Ten slotte moet 
de ernst van de symptomen boven een gespecificeerde drempel liggen 
om aan de voorwaarden voor TR-AD te kunnen voldoen.  De afkapwaarden 
waren per angststoornis verschillend en voor de consensusdefinitie kozen 
wij de meest gebruikte afkapwaarden.  Het consequent gebruiken van deze 
nieuwe consensusdefinitie in onderzoeken naar TR-AD zal de homogeniteit 
van de bestudeerde populaties vergroten en de generaliseerbaarheid van 
bevindingen vergroten, waardoor er effectiever onderzoek kan worden 
gedaan naar vervolgstappen bij TR-AD.
Het doel van  hoofdstuk 5 was  om een  bestaand generiek stadiëringsmodel 
voor psychiatrische stoornissen te vertalen voor gebruik bij patiënten met 
angststoornissen.  De belangrijkste doelen waren het beoordelen van de 
construct validiteit en de voorspellende validiteit van deze aangepaste versie 
van dit stadiëringsmodel.  In het paradigma van klinische stadiëring kunnen 
verschillende stadia worden onderscheiden die de toenemende mate van 
ziekteprogressie weerspiegelen.  Elk hoger stadium gaat gepaard met een 
minder gunstig verder ziekteverloop.  Theoretisch zouden de verschillende 
stadia in een stadiëringsmodel ook verschillende onderliggende 
pathofysiologische processen moeten weerspiegelen.  In de psychiatrie 
zijn de onderliggende pathofysiologische kenmerken multifactorieel en 
hierdoor minder geschikt voor deze benadering. Om die reden zijn de huidige 
stadiëringsmodellen in de psychiatrie voornamelijk gebaseerd op klinische 
kenmerken.
Voor deze studie werd een stadiëringsmodel van een  hoog 
aangeschreven  Australische onderzoeksgroep aangepast voor gebruik 
bij angststoornissen.  Dit leverde een stadiëringsmodel op met stadia 
die variëren van stadium 0 (asymptomatisch, hoog risico) tot stadium 4B 
(chronische symptomen met comorbiditeit). Op de baselinemeting van 
NESDA werden proefpersonen geïncludeerd in dit onderzoek. Alle 1305 
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NESDA-proefpersonen met een angststoornis en 1115 proefpersonen zonder 
huidige angststoornis of depressieve stoornis maar met aanwezigheid 
van risicofactoren voor het ontwikkelen van een angststoornis werden 
geïncludeerd.  Alle 2420 geïncludeerde proefpersonen werden toegewezen 
aan een klinisch stadium.  De toewijzing aan stadia werd gebaseerd op life 
chart interviews die betrekking hadden op de duur van de angststoornis. 
Verder werd de ernst van de symptomen gemeten met vragenlijsten en 
werd de aanwezigheid van psychiatrische comorbiditeit onderzocht met 
gestructureerde interviews. Uit beschrijvende statistiek bleek dat hogere 
stadia samengingen met het vaker hebben van angststoornissen twee jaar, 
vier jaar of zes jaar later. Het percentage aanwezigheid van angststoornissen 
bij een follow-up na twee jaar was bijvoorbeeld 2,7% voor de proefpersonen 
die oorspronkelijk in stadium 0 werden ingedeeld terwijl dit percentage 
68,0% betrof voor de proefpersonen die oorspronkelijk in stadium 4B zaten.
De construct validiteit werd beoordeeld door verschillende klinische 
kenmerken op de baselinemeting te vergelijken tussen de verschillende 
stadia. Hierbij was van belang dat deze kenmerken niet waren gebruikt bij 
het toekennen van proefpersonen tot de verschillende stadia. De hypothese 
was dat hogere klinische stadia geassocieerd zijn met minder gunstige 
klinische parameters op baseline en dat deze associaties een lineaire 
trend zouden volgen langs  elk van de stadia.  Dit was inderdaad het geval: 
patiënten in hogere stadia hadden meer aanwezigheid van traumatische 
jeugdervaringen, een lagere leeftijd bij het optreden van de angststoornis, 
meer actuele psychiatrische behandelingen, een hogere ernst van de 
angstklachten, meer sociale en agorafobische vermijding en hogere mate van 
piekeren.  Bovendien hadden patiënten in hogere stadia meer depressieve 
symptomen en een hogere mate van beperkingen.  Niet-parametrische 
tests voor lineaire trends waren significant voor alle vooraf gedefinieerde 
validatoren na Bonferroni-correctie.  Dit impliceert dat hogere klinische 
stadia geassocieerd waren met minder gunstige klinische kenmerken bij 
aanvang, wat wijst op een adequate constructvaliditeit. 
Om de voorspellende validiteit van het model te evalueren, werden 
verschillende analyses uitgevoerd.  Ten eerste werd het klinische 
stadiëringsmodel gerelateerd aan de aanwezigheid van DSM-IV-diagnoses 
na verloop van tijd.  Er werden twee sets van generalized estimating 
equations (GEE) uitgevoerd om voor elk stadium te berekenen wat de 
kans was om ofwel een angststoornis of enigerlei psychiatrische stoornis 






en 6 jaar follow-up).  De hypothese was dat hogere klinische stadia een 
grotere kans hadden op het hebben van angststoornis diagnoses en 
overige psychiatrische diagnoses op elke follow-up meting.  Het bleek dat 
dit inderdaad het geval was: odds-ratios (OR) voor het hebben van een 
angststoornis bij de follow-up meting na 6 jaar was 11,8 (95% BI 8,39-16,6) 
voor stadium 4B afgezet tegen stadia 0-1B.  De OR voor het hebben van 
enigerlei psychiatrische stoornis na 6 jaar follow-up was 10,7 (95% BI 7,70-
15,0) voor stadium 4B afgezet tegen stadia 0-1B. Voor alle stadia waren de 
6-jaars proporties van aanwezigheid van psychiatrische diagnosen lager 
in vergelijking tot de 2-jaars proporties.  Voor de primaire uitkomstmaat, 
de aanwezigheid van angststoornissen, werd een lineaire trend  over de 
baseline-stadia  gevonden.  De B-stadia bleken de grootste kans te hebben 
voor de aanwezigheid van enigerlei psychiatrische stoornis bij follow-
up.  Over het algemeen vertoonde ook dit model een significante lineaire 
trend over alle stadia.  Deze bevindingen impliceren dat het risico op het 
hebben van een angststoornis bij de follow-up hoger is voor elke volgende 
fase, maar risico’s op het hebben van enigerlei psychiatrische stoornis zijn 
het grootst bij B-stadia waarbij al psychiatrische comorbiditeit aanwezig was 
bij de baselinemeting. Als aanvulling op deze dichotome benadering werd de 
voorspellende validiteit ook beoordeeld met behulp van een dimensionele 
benadering.  De klinische stadia bij de eerste meting werden gerelateerd 
aan follow-up metingen van de ernst van de angstklachten, de ernst van de 
depressieve klachten en de ernst van eventuele beperkingen door gebruik 
te maken van linear mixed models (LMM), waarmee ontbrekende gegevens 
nauwkeurig konden worden geschat.  Dit leverde geschatte gemiddelden 
op voor elk stadium op alle follow-up metingen.  Uit LMM-analyses bleek 
dat de ernst van de angst in de loop van de tijd geleidelijk afnam voor de 
meeste stadia, terwijl de rangorde die op de baseline meting aanwezig was 
tussen de verschillende stadia grotendeels behouden bleef.  Stadia 2B, 3A 
en 4A vertoonden vergelijkbare maten van ernst van angstklachten over de 
tijd, terwijl stadia 3B en 4B de hoogste angstniveaus, de hoogste ernst van 
depressieve klachten en de hoogste mate van beperkingen lieten zien.
Samenvattend toonde dit hoofdstuk de eerste succesvolle poging 
om een  stadiëringsmodel empirisch toe te passen op een cohort van 
angststoornispatiënten en controle personen.  De resultaten laten zien dat 
het bestudeerde model voldoende construct- en voorspellende validiteit 
heeft, en daarmee een evidence-based stadiëringsmodel biedt voor gebruik 
in de klinische zorg bij patiënten met angststoornissen.
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Het doel van hoofdstuk 6 was om de bevindingen uit hoofdstuk 4 empirisch 
te toetsen. Hoofdstuk 4 leverde een aantal criteria op die gezamenlijk de 
definitie voor therapieresistentie bij angststoornissen (TR-AD) vormen. Het 
doel in dit hoofdstuk was om te toetsen of de aanwezigheid van deze criteria 
ook daadwerkelijk samengaat met slechte resultaten na behandeling.  De 
hypothese hierbij was dat de aanwezigheid van de verschillende aspecten 
voor TR-AD inderdaad samenhangt met minder gunstige latere therapie-
effecten. Een tweede doel van deze studie was om een  dimensioneel 
meetinstrument te ontwikkelen door de verschillende TR-AD-criteria te 
integreren tot één maat.  Dit dimensionele instrument zou dan de mate van 
TR-AD weergeven, wat een relevante aanvulling zou kunnen zijn op de 
dichotome benadering van TR-AD die in hoofdstuk 4 werd toegepast.
Voor deze studie werd uit 1305 NESDA-patiënten met angststoornissen 
op de baseline meting een steekproef van 679 patiënten genomen die 
aangaven psychiatrische behandelingen te hebben gehad tussen de 
baselinemeting en de meting tijdens de follow-up na 2 jaar.  Alle criteria 
voor TR-AD die werden afgeleid uit het systematische review (hoofdstuk 4) 
werden op de baselinemeting beoordeeld.  Deze TR-AD-criteria betroffen 
het aantal eerstelijns farmacologische behandelingen, aantal tweedelijns 
farmacologische behandelingen, aantal adequate psychotherapeutische 
behandelingen, ernst van angstklachten, aanwezigheid van functionele 
beperkingen, aanwezigheid van psychiatrische comorbiditeit en eerdere 
duur van angstklachten. Op basis van deze criteria werd een meetinstrument 
ontwikkeld.  Om dit te doen, werd elk van de TR-AD-criteria gescoord in 
overeenstemming met de Dutch Measure for quantification of Treatment 
Resistant Depression (DM-TRD), wat een dimensioneel meetinstrument 
voor de mate van therapieresistentie bij depressies is. Op deze manier werd 
een meetinstrument gemaakt met een theoretische range van 2-23.
Op baseline was de gemiddelde score op het meetinstrument 10,8 ± 
2,3. Bivariate logistische regressieanalyses werden gebruikt om individuele 
baseline TR-AD-criteria te relateren aan het behandelresultaat na twee jaar 
door te beoordelen in welke mate na twee jaar nog angststoornisdiagnoses 
aanwezig waren.  Een hogere ernst van angstklachten op baseline was 
duidelijk geassocieerd met slechtere resultaten na twee jaar: de OR voor 
het hebben van een angststoornis na twee jaar was 6,48 (95% BI 3,29-
12,8) in vergelijking met proefpersonen met lage ernst van angstklachten 
bij baseline.  Hoge niveaus van functionele beperkingen waren ook 






BI 1,51-5,63).  Dezelfde positieve associaties werden gevonden voor de 
aanwezigheid van psychiatrische comorbiditeit (OR=1,73, 95% CI 1,25-2,39) 
en lange duur van angstsymptomen (OR=2,79, 95% CI 1,94-4,03 versus korte 
duur). Het eerdere aantal eerstelijns farmacotherapeutische behandelingen 
was niet geassocieerd met uitkomsten na twee jaar (OR=1,10, 95% BI 0,87-
1,39).  Evenmin was het aantal eerdere tweedelijns farmacotherapeutische 
behandelingen (OR=1,39, 95% BI 0,91-2,12), noch het aantal eerdere 
psychotherapeutische behandelingen (OR=1,11, 95% BI 0,73-1,69) 
geassocieerd met slechtere uitkomsten na 2 jaar.  Hogere scores op het 
dimensionele meetinstrument in zijn geheel waren duidelijk geassocieerd 
met slechtere behandelresultaten na twee jaar follow-up: OR=1,29, 
95% BI 1,20-1,39, wat aangeeft dat de kans op het aanwezig blijven van 
angststoornissen na twee jaar met 1,29 hoger uitvalt voor elk punt verschil 
op het meetinstrument.
Tot slot werden de klinimetrische eigenschappen van dit meetinstrument 
beoordeeld.  Met behulp van de Youden-index werd de meest efficiënte 
afkapwaarde voor het meetinstrument vastgesteld op 11 punten of 
hoger.  Met deze afkapwaarde was de sensitiviteit voor het voorspellen 
van aanwezig blijven van angststoornissen na een periode van 2 jaar 
waarin patiënten behandeld werden 0,70, terwijl de specificiteit 0,57 
was.  Hieruit werd de positief voorspellende waarde berekend op 0,68 en 
de negatief voorspellende waarde op 0,60.  De oppervlakte onder de curve 
(AUC) was 0,66.  De kracht van deze voorspellingen kan als matig worden 
beschouwd. Echter, vanwege het gebrek aan een gouden standaard waarmee 
de behandelresultaten bij angststoornissen nauwkeurig kunnen worden 
voorspeld geeft het hier gepresenteerde meetinstrument momenteel de 
beste nauwkeurigheid.  Het gebruik van dit meetinstrument kan bijdragen 
aan het effectief selecteren van behandelstrategieën bij individuele 
patiënten.  Voordat dit in de praktijk kan worden toegepast zou deze studie 
echter eerst moeten worden gerepliceerd in een andere steekproef om de 
generaliseerbaarheid van deze bevindingen te beoordelen.
Het doel van hoofdstuk 7 was  om met behulp van  machine learning 
methodes op basis van een grote verscheidenheid aan data  een 
voorspellingsmodel te ontwikkelen voor het longitudinale beloop bij 
patiënten met angststoornissen. Van veel risicofactoren is eerder al 
aangetoond dat ze samenhangen met het optreden van angststoornissen 
of met het longitudinale beloop van angststoornissen.  Geen enkele 
risicofactor heeft echter zodanige adequate voorspellende eigenschappen 
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dat ze in de klinische praktijk gebruikt kunnen worden voor het geven van 
een betrouwbare prognose.  Voorheen werden deze voorspellers veelal 
afzonderlijk onderzocht, in plaats van als onderdeel van één geïntegreerd 
model. Mogelijk kan het combineren van een veelheid van deze voorspellers 
in één model resulteren in betere voorspellende waarde.  Machine learning 
methodes zijn bij uitstek geschikt voor het maken van voorspellingen op 
basis van een grote verscheidenheid aan factoren, omdat ze een data-
gestuurde aanpak kunnen gebruiken om de meest relevante factoren te 
identificeren en te selecteren. De hypothese was dat het combineren van 
veel voorspellers in één grootschalig model zou resulteren in een model 
met goede voorspellende waarde wat betreft het longitudinale beloop bij 
angststoornissen. 
De huidige studie werd uitgevoerd bij 887 patiënten met een angststoornis 
uit de NESDA. Voor dit onderzoek zijn verschillende potentiële voorspellers 
uit vijf domeinen gebruikt.  De vijf domeinen zijn klinische variabelen, 
psychologische variabelen, biologische variabelen, sociodemografische 
variabelen en leefstijlvariabelen. De onderzochte classificaties waren 
tweeledig: ten eerste herstel van angststoornissen na twee jaar follow-
up.  Ten tweede, herstel van alle  veelvoorkomende psychiatrische 
stoornissen  (common mental disorders, CMD’s) na een follow-up 
van twee jaar.  De angststoornissen die onderzocht werden waren 
de gegeneraliseerde angststoornis,  de paniekstoornis, agorafobie 
en  de sociale angststoornis.  CMD’s werden gedefinieerd als ofwel een 
angststoornis, ofwel een depressieve stoornis, ofwel dysthymie, ofwel 
alcoholafhankelijkheid.  Voor de tweede classificatie is er dus sprake van 
herstel wanneer bij follow-up geen van deze stoornissen kon worden 
gediagnosticeerd.  Om de modellen te bouwen, werden Random Forest 
Classifiers (RFC’s) gebruikt. Een RFC is opgebouwd als een combinatie van 
meerdere beslisbomen, die worden getraind door willekeurige subsets van 
variabelen en patiënten te gebruiken voor elke beslisboom. In dit onderzoek 
bestond elke RFC uit 1.000 beslisbomen. Op baseline werden 651 individuele 
voorspellers op itemniveau geselecteerd uit de vijf domeinen (klinisch, 
psychologisch, biologisch,  sociodemografisch, leefstijl).  Er bleven 569 
items over nadat de items met te veel missing data waren verwijderd. De 
RFC’s werden gebouwd met behulp van deze 569 items en met behulp van 
een 10x10 cross-validatie op trainingssets (90% van de proefpersonen) en 






getraind op de combinatie van alle predictordomeinen, maar ook op elk 
verschillend domein afzonderlijk, om te zien in welke mate de afzonderlijke 
domeinen bijdragend zijn aan de betrouwbaarheid van de voorspellingen.
Na twee jaar follow-up herstelden 484 patiënten (54,6%) van hun 
angststoornis en hadden 362 patiënten (40,8%) geen CMD. De prestatie van 
de RFC’s bij het voorspellen van herstel van angststoornissen na twee jaar 
follow-up was matig: de area under the receiver-operator curve (AUC) voor 
het volledige model bedroeg 0,67.  Wanneer we de individuele domeinen 
onderzochten varieerde de AUC van 0,49 (leefstijl domein) tot 0,67 (klinische 
domein). De enige domeinen met statistisch significante voorspellingen over 
twee jaar waren het klinische domein (AUC=0.67) en het psychologische 
domein (AUC=0.65).  Met betrekking tot de tweede uitkomstmaat (herstel 
van CMD’s) leken de voorspellingen iets nauwkeuriger te zijn. De combinatie 
van alle domeinen leverde een AUC van 0,70 op. Bij de individuele domeinen 
varieerde de AUC voor herstel van CMD’s van 0,53 (leefstijl domein) tot 0,70 
(klinische domein). In deze analyse leverde het klinische domein (AUC=0,70), 
het psychologische domein (AUC=0,67) en het sociodemografische domein 
(AUC=0,65) significante voorspellingen op. 
Post-hoc analyses werden uitgevoerd om de individuele items te 
identificeren die in hoge mate hebben bijgedragen aan de voorspellingen. Dit 
werd gedaan om meer inzicht te krijgen in het relatieve belang van elk 
van de voorspellers voor het longitudinaal beloop bij angststoornissen, 
in samenhang met de andere variabelen.  Bij het voorspellen van herstel 
van angststoornissen werden 17 items geselecteerd in meer dan 50% 
van de RFC’s, waarmee werd voldaan aan het criterium voor consistente 
selectie.  Deze voorspellers waren afkomstig uit het klinische en 
psychologische domein en waren gerelateerd aan angstreacties, meestal 
aan angstige lichamelijke reacties. Bij het voorspellen van herstel van CMD’s 
werden 48 variabelen consistent (>50% van de RFCs) geselecteerd.  Eén 
geselecteerde voorspeller was afkomstig uit het sociodemografische 
domein, alle andere uit de klinische en psychologische domeinen.  Behalve 
items die betrekking hadden op uitingen van angst werden bij deze 
classificatie consequent veel stemmingsgerelateerde items geselecteerd. In 
vergelijking met de variabelen die consequent werden geselecteerd bij het 
voorspellen van herstel van angststoornissen, leek het herstel van CMD’s 
meer afhankelijk te zijn van variabelen die gerelateerd zijn aan uitingen van 
depressie. De prestaties van de voorspellingsmodellen in dit hoofdstuk zijn 
nog onvoldoende om deze routinematig in de klinische praktijk te gebruiken. 
286
Bovendien zou implementatie hiervan in de klinische praktijk door het grote 
aantal metingen dat nodig is om dit model toe te passen onhaalbaar zijn. 
Dat de huidige redelijke voorspellende waardes gehaald werden ondanks 
de lange termijn van follow-up van twee jaar is echter veelbelovend. Dit 
onderzoek toont duidelijk het potentieel van machine learning methodes 
voor het verbeteren van voorspellingsmodellen in een complex vakgebied 








Na vele analyses, woorden, zinnen, paragrafen en overpeinzingen wil 
ik u welkom heten bij mijn laatste woorden, zinnen en paragrafen in dit 
dankwoord. Het voelt gek om dit te schrijven en me te realiseren dat dit echt 
de allerlaatste woorden van dit proefschrift zijn. En feitelijk ligt de druk er 
flink op aangezien het dankwoord toch meestal het meest-gelezen stuk van 
een thesis blijkt te zijn. Dus daar gaan we. Dit lange en bij vlagen moeilijke 
traject had ik niet kunnen afronden zonder veel hulp. Bedankt!  
Allereerst Ton. Naast mijn opleider was je ook mijn promotor en vanuit beide 
rollen heb je me altijd alle mogelijkheden gegund om me te ontwikkelen 
op een manier die bij mij paste. Je maakte deze promotie mogelijk door 
de inmiddels eigenlijk al doodverklaarde AGIKO-constructie met kunst- 
en vliegwerk levend te houden. Je bezit een Obama-achtige positivisme 
met een onweerstaanbare ‘yes we can’ mentaliteit. Bij meerdere van mijn 
papers ontstonden er momenten waarop het hele proces wat dreigde 
vast te lopen en dan was één afspraak bij jou telkens voldoende om weer 
met een hernieuwd optimisme (en een hernieuwde to do lijst) terug te 
keren. Je didactische kwaliteiten staan buiten kijf en ik ben blij dat ik mijn 
voordrachten bij je kon oefenen en dat ik je feedback kon gebruiken. 
Regelmatig adviseerde je mij om mijn publiek niet te overschatten, wat bij 
mij een soort onbestemd maar zelfverzekerd gevoel opriep waarmee mijn 
voordrachten steeds leuker werden om te geven. Als laatste ben je een 
gangmaker met je humor en aanstekelijke lach en heb je menig lunch op de 
Oldenaller en menig opleidingsuitje op een manier positief gekleurd zoals 
alleen jij dat kan. Bedankt dat je met verve meerdere petten droeg!
Vervolgens Brenda. Ik weet nog goed dat ik aan het begin van mijn tijd als 
onderzoeker eens googlede naar jouw publicaties en dat ik steil achterover 
sloeg van wat ik tegenkwam. Het werd me direct duidelijk dat je één van de 
belangrijkste onderzoekers binnen de psychiatrie wereldwijd bent en het 
maakte me trots dat ik je mijn promotor mag noemen. Het was soms hard 
werken om het tempo van jouw feedback en het tempo van je argumentatie 
te volgen en te integreren. Ik leerde van je om niet voor de makkelijke weg 
te kiezen maar om telkens ambitieus en kritisch te blijven ten aanzien van 
mijn eigen werk. Je tilde mijn papers daarmee keer op keer naar een hoger 







Dan Neeltje. Als copromotor stond je het meest dicht bij mij en mijn 
projecten. Ik vond jou het perfecte verbindingsstuk tussen Ton, Brenda en 
mijzelf. Als voormalig protégé van hen beide is het niet vreemd dat ik in jou 
kwaliteiten van zowel Ton als Brenda herken. Je was de schakel die jullie 
tot een erg prettig en efficiënt team maakte. Je was altijd beschikbaar voor 
overleg over grote en kleine onderwerpen. Daarnaast heb je onmiskenbaar 
je eigen stijl: positief, kritisch, benaderbaar en respectvol. Je bent een 
held in het strategisch formuleren van tegenwerpingen richting onredelijke 
reviewers die je ontdeed van de Hollandse directheid waar ik me in het 
begin nog regelmatig schuldig aan maakte. Jouw mailtjes naar mij begonnen 
steevast met zinnen als “Heel goed! Het paper begint al richting de laatste 
fase te gaan”, waarvan ik na verloop van tijd steeds beter begon te begrijpen 
dat je eigenlijk bedoelde “heel leuk begin, maar er moet nog wel een hele 
boel gebeuren”. Ik denk dat je de allerlaatste persoon op aarde was om de 
overstap naar digitaal feedback geven te maken. Potloodfabrikanten over de 
hele wereld hebben met jou een gouden tijd achter de rug want je feedback 
kwam steevast in redelijk leesbare krabbels in de kantlijn van mijn printjes 
te staan. Bedankt voor al je krabbels en wijze raad!
Verder wil ik de overige medeauteurs bedanken voor hun bijdrages aan onze 
gezamenlijk papers. Aernout Beek, Annette Boenink en Jan Smit bedankt voor 
jullie bijdrage aan het eerste harthulp paper. Adriaan Hoogendoorn, bedankt 
voor je hulp en creativiteit bij de lastige statistiek van het stadiërings paper 
en je auteurloze hulp bij meerdere andere papers. Guido Wetzer en Jurriaan 
Gehrels, bedankt voor jullie inzet bij het doorploegen van de immense berg 
papers bij het systematische review. Erik Giltay, Robert Schoevers en Guido 
van Wingen, bedankt voor jullie bijdrage aan het machine learning paper. 
And thanks Paul Zhutovsky for a very pleasant cooperation as shared first 
authors on the machine learning paper. We were a pretty effective team if 
you ask me. 
Vervolgens wil ik graag de vele respondenten die hebben deelgenomen 
aan de NESDA studie bedanken. Ik realiseer me dat het deelnemen aan een 
studie zoals NESDA veel vergt van respondenten, zeker wanneer er sprake is 
van een actuele depressie of angststoornis. En dan ook nog eens een studie 
als NESDA met zijn zeer uitgebreide dataverzameling. Bedankt voor jullie 
inzet! Ik ben er van overtuigd dat jullie deelname voor veel andere huidige en 
toekomstige patiënten belangrijke winst oplevert. 
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Dan kan het niet anders dan dat kamer D2.05 als volgende aan de beurt is. 
Ilja, Ruth, Sjors en Lucas, in wisselende samenstellingen vormden wij over 
de jaren gezamenlijk een gerenommeerde GGZ/politieke denktank. Later 
ook nog aangevuld met AMC spion Angela. Eerst in de penthouse onder de 
naam D2.05, later in een meer bescheiden en donker hoekje van het gebouw. 
Ilja, ontzettend bedankt voor al jouw hulp bij mijn project en de projecten 
van iedereen, en dat je dan zelf ondertussen ook nog gepromoveerd bent, 
onvoorstelbaar. Sjors bedankt dat ik mocht meedelen in al je crackers, 
pindakaas, gemengde noten en je verhalen. Je eigen uitspraak “neem 
ruim” typeert je perfect. Ruth, bedankt voor je inspirerende voorbeeld 
in het bijhouden van email, ongeëvenaard. Angela, deed jij eigenlijk wel 
aan onderzoek, of zat je alleen maar aan zee? Lucas, bedankt voor de 
inspirerende gesprekken en gezellig dat je altijd even mee lunchte. 
Ook de andere junior onderzoekers op de Oldenaller hebben de 
onderzoeksjaren een heel stuk gezelliger gemaakt met veel lunches, 
meetings, borrels en een feestje hier en daar. Als groentje met Dóra, Josine 
en de rest pull-ups doen in het park. Later onder andere met Trees, Esther, 
Laura, Richard et al. Bedankt allemaal! Hopelijk komen we elkaar nog tegen 
op toekomstige werkvloeren of dansvloeren. 
Verder waren de opleidingsjaren voor mij een welkome afwisseling van de 
onderzoeksjaren, en andersom. Doordat het combineren van de opleiding 
met het onderzoek voor een lekker lang traject heeft gezorgd heb ik extra 
veel mede aiossen mogen ontmoeten. Bedankt voor vele vrijdagmiddag 
borrels, prachtige weekenden weg, leuke voorjaarscongressen en gewoon 
een gouden tijd. Bedankt Noach, Linda, Saskia, Afra, Ruud, Hans, Ellemijn, 
Esther, Peter, Marc en Frits en nog vele anderen, en bedankt AGIKO-
voorgangers en voorbeelden Sonja, Hans, Wouter en Flora.
Ook bedankt aan onze intervisiegroep “Duur & Delicious” voor alweer acht 
jaar levensintervisie, Thais eten, sterke verhalen, vermijdende input en 
confronterende adviezen! Stella, Laura, Kathelijne, Lidwien, Larissa, Doeke 
en Martijn; dat er nog maar vele mooie avonden mogen volgen. 
Omdat de boog niet altijd gespannen kan zijn ook een shout-out naar alle 
belangrijke vrienden. Ruud, Erik, Erik, Siert, Jorrit, SyMa, Johan, Con, 








Bedankt Martin van den Berg voor de illustraties in dit proefschrift. Mijn 
eerste en jouw laatste jaar als psychiater vielen samen in Sneek. Bedankt 
voor je raad en relativeringsvermogen!
Een extra bedankje voor Peter en Erik, bedankt dat jullie me als mijn 
paranimfen willen vergezellen naar de grote, intimiderende aula. Peblo, 
we begonnen samen in de Valeriuskliniek, jij als semi-arts, ik als aios. 
Later troffen we elkaar telkens weer, zelfs op het voetbalveld en in de 
derde helft. De vriendschap groeide als vanzelfsprekend. Bedankt voor je 
openheid, droge humor, warmte en bescheidenheid. En mocht ik omvallen 
in de aula verwacht ik veel van je als plaatsvervanger. Erik, bedankt dat jij de 
Amsterdamse groep wil vertegenwoordigen! We gaan inmiddels zo’n achttien 
jaar terug. In de beginjaren waren we een roemrucht DJ-duo. We delen een 
prachtige kerstdiner traditie met de rest van de eerder genoemde mannen. 
Het is mooi om te zien hoe je in die jaren altijd precies jezelf bent gebleven 
ondanks heel uiteenlopende paden die je insloeg. Je maakte uitstapjes naar 
andere werelddelen en andere carrièrepaden en je kwam telkens terug. Een 
vriendschap voor het leven.
Aukje, Liesbeth, Lydia. Het is toch wat, drie schoonmoeders... gelukkig is het 
in het echt lang niet zo erg als op papier. Fijn dat TWARLL bestaat! Dat is niet 
vanzelfsprekend maar voelt wel zo. Bedankt dat ik bij jullie kan lachen en 
dat we veel kunnen delen. En Liesbeth, je zal wel trots zijn op je schoonzoon 
psycholoog, of was het nou psychiater? Rosan, bedankt voor je no nonsense 
houding en je eerlijkheid! Leuk om je te mogen zien groeien de laatste jaren. 
Bedankt JAF, jullie zijn al mijn hele leven een stabiele twee-eenheid 
waardoor wij kinders alle ruimte hebben voor onze ontwikkeling. Allebaas, 
ondanks dat je je werk niet mee naar huis nam was je altijd een grote 
inspiratie voor me om ook het doktersvak te kiezen. Je was je tijd ver vooruit 
als mannelijke arts met een part-time dienstverband en een privéleven. 
Je was vast de enige medisch specialist die in die jaren nachtbraakte met 
Age of Empires. “Haa-yee-yoo-haa-hoo, homme-nahhh!” Je bent van alle 
markten thuis en ik kan je dus nu ook bedanken voor je steun op vele fronten. 
Dr. Moekes, bedankt voor de vele kleine zetjes de goede richting op die ik 
zelf pas achteraf opmerkte. Je bent een echte problemenoplosser. En soms 
zelfs een problemenvoorkómer. Je hebt bovendien toch een beetje de weg 
geplaveid voor Jouke en mij in de wetenschappelijke wereld. Het waren een 
paar spannende jaren qua gezondheid, gelukkig kunnen we die nu achter 
ons laten en heel knap hoe je die jaren optimistisch hebt volgebracht. 
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Bedankt voor al je zichtbare en onzichtbare acties! Jouke, mooi om onze 
geneeskunde studententijd te kunnen delen en tof dat we altijd welkom zijn 
bij elkaar en elkaars vrienden. Jammer dat mijn knieën niet meer in staat 
zijn voor één-tweetjes op het voetbalveld maar Pok en Tok weten elkaar 
daarbuiten gelukkig ook uitstekend te vinden. Mijke, Kippie, bedankt voor je 
scherpzinnigheid en je loyaliteit! Je hebt een heerlijk gezin waar ik me erg 
mee verbonden voel. Bij jullie kleintjes is de stress van werk opeens heel 
ver weg. Ik voel me gezegend met jullie allemaal als gezin. Daarbij mogen 
natuurlijk ook Magic Wierc en die Karo niet ontbreken. Wierc, bedankt voor 
je rust en humor. Je bent een stille kracht op vele manieren. 
Als laatste, bedankt liefste Tamar, TEA. Je bent altijd geduldig, begripvol 
en geïnteresseerd wanneer er werk gerelateerde obstakels waren. Bedankt 
voor je creativiteit en je vermogen om altijd een oplossing te vinden 
waarmee de gezamenlijkheid en gelijkwaardigheid voorop staat. Je maakte 
met je aanwezigheid van de weekendjes dienst in Sneek een feestje. Het 
samen aan onze papers werken in het ‘prachtige’ Amicitia hotel voelde als 
een enorme life-hack. Je liet me mijn presentaties bij je oefenen en was mijn 
grootste fan en gaf ook op subtiele wijze kritische feedback. Bedankt voor 
het herontdekken van je lievelingslied Ademnood en van het woord ‘fijn’. We 
kunnen elkaar in meerdere versnellingen goed vinden en ik kijk er naar uit 
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Amsterdam UMC (locatie VUmc) in which he focussed on geriatric internal 
medicine and dementias under supervision of Gooke Lagaay. Finally, he 
worked as a last year psychiatry resident at the crisis psychiatric department 
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